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ABSTRACT 
Activated receptor tyrosine kinase (RTK), such as the epidermal growth factor (EGF) 
receptor (EGFR) and the platelet-derived growth factor (PDGF) receptor (PDGFR), recruit 
downstream signalling proteins, including phosphatidylinositol 3-kinase (PI3K).  PI3K, 
composed of a regulatory p85 subunit and a catalytic p110 subunit, phosphorylates 
phosphatidylinositol 4,5-bisphosphate at the 3 position to generate phosphatidylinositol 3,4,5-
trisphosphate.  This lipid second messenger activates Akt, which promotes cell growth, cell 
cycle entry and progression, as well as cell survival and cellular migration.  PTEN, a tumor 
suppressor protein, dephosphorylates phosphatidylinositol 3,4,5-trisphosphate at the 3 position, 
turning off Akt signalling.  PTEN contains a C-terminal PDZ binding motif that binds to the 
PDZ2 domain of MAGI-2, a scaffolding protein that localizes signalling molecules to the 
plasma membrane.  MAGI-2 has ten domains that potentially mediate multiple protein-protein 
interactions simultaneously.  A PTEN associated-complex (PAC) has been described and may 
contain MAGI-2, PTEN and p85.  The PAC is hypothesized to form at the plasma membrane at 
appropriate sites for PTEN to gain access to its lipid substrates, since the binding of PTEN to 
MAGI-2 has been shown to enhance the suppression of PI3K-mediated Akt signalling.  In order 
to better understand the role of the PAC in attenuation of the Akt signalling pathway, regions of 
the MAGI-2 scaffolding protein were mapped to identify the interactions taking place in the 
PAC.  MAGI-2, and its individual domains, were expressed as GST fusion proteins.  These 
were immobilized onto beads and allowed to bind to cellular proteins including PTEN, p85, 
PDGFR and EGFR using a GST pull-down experiment.  The proteins bound to GST-MAGI-2 
were identified using an immunoblot analysis.  In vitro pull-down experiments revealed that 
MAGI-2 PDZ2 and PDZ5 domains bind to PTEN, and both MAGI-2 WW domains were shown 
to bind to p85.  EGFR and PDGFR did not bind to the PDZ domains of MAGI-2 under the 
conditions studied.  In order to study protein-protein interactions in cells, immunoprecipitation 
assays were also performed.  Full length MAGI-2 was expressed tagged to a Myc epitope.  This 
was used in immunoprecipitation assays to determine if MAGI-2 could co-immunoprecipitate 
with proteins involved in the Akt signalling pathway, such as PTEN, p85, PDGFR and EGFR.  
MAGI-2 can co-immunoprecipitate with PTEN upon 5 min EGF stimulation however, this 
result was inconclusive because replicate experiments did not verify this initial observation.  
MAGI-2 does not co-immunoprecipitate with the EGFR nor p85, under the conditions tested.  
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We examined for these interactions after 5 min of growth factor stimulation and more 
experiments that test different time points after growth factor stimulation would reveal if these 
interactions are present at shorter time points.  MAGI-2 has been shown to bind to PTEN and 
p85 in vitro and therefore has the potential to regulate the attenuation of the PI3K/Akt 
signalling pathway in response to activated EGFR and/or PDGFR.   
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1.0 INTRODUCTION 
 
1.1 Receptor tyrosine kinase activated PI3K/Akt signalling pathway  
Receptor tyrosine kinases (RTKs) are cell surface receptors that are capable of receiving 
signals from outside the cell and transmitting these signals intracellularly to generate an 
appropriate, transient cellular response.  RTKs are unique from other cell surface receptors in 
that they have intrinsic protein tyrosine kinase activity.  RTKs share a similar domain structure 
composed of an extracellular ligand binding domain, a single α-helical trans-membrane domain 
and a cytoplasmic domain containing the intrinsic tyrosine kinase activity with 
autophosphorylation sites (reviewed in Ogiso et al., 2002; Schlessinger, 2002).  Upon binding 
of the ligand to its respective receptor, a conformational change occurs that promotes receptor 
dimerization (Garrett et al., 1998, 2002; Ogiso et al., 2002).  Dimerization of the receptor 
induces a trans autophosphorylation event of the cytosolic domain (reviewed in Ferguson, 
2008).  The phosphorylated Tyr residues in the cytoplasmic domain of RTKs are docking sites 
for downstream signalling molecules that are recruited to the newly phosphorylated receptor, 
which are then activated and allows for further downstream signalling.   
Two main families of RTKs are the epidermal growth factor receptor (EGFR) and the 
platelet-derived growth factor receptor (PDGFR).  One of the many pathways that are activated 
by these receptors is the PI3K/Akt signalling pathway, which promotes cell cycle entry and 
progression, cellular survival, cellular migration and cell growth (Figure 1.1).  Upon epidermal 
growth factor (EGF) stimulation, EGFR subunits dimerize and autophosphorylation occurs on 
the Tyr residues of the cytosolic domain (reviewed in Pawson and Scott, 2005).  
Phosphorylated receptor recruits the phosphatidylinositol 3-kinase (PI3K) complex to the 
plasma membrane through binding of an adaptor protein, growth factor receptor-binding 
protein 2 associated binder 1 (reviewed in Hirano and Nishida, 2003; Schlessinger, 2002).  The 
PI3K complex is made up of the p85 regulatory subunit, bound to the p110 catalytic subunit 
(Ueki et al., 2002).  Binding of p110 to the p85 subunit of PI3K is required for p110 stability 
and proper PI3K function (reviewed in Geering et al., 2007).  Upon binding of the PI3K to 
EGFR, p85 inhibitory effects on p110 are relieved and p110 phosphorylates 
phosphatidylinositol (4,5) bisphosphate (PI4,5P2) on the 3 position to generate  
 
GAB1
Figure 1.1:  EGFR activates the PI3K/Akt signalling pathway that promotes cell cycle
entry and progression, as well as cell survival.  Upon EGF stimulation, EGFR subunits
dimerize and autophosphorylation occurs on Tyr residues.  Phosphorylated receptor recruits
the PI3K complex to the plasma membrane by association to the (growth factor receptor-
binding protein 2 associated binder 1) GAB1 adaptor protein.  The PI3K complex
phosphorylates PI4,5P2 to PI3,4,5P3.  The lipid second messenger PI3,4,5P3 is involved in the
recruitment and activation of the Ser/Thr  kinase Akt.  Akt signalling regulates the
phosphorylation of many downstream proteins, such as those that promote cell cycle entry, cell
growth, cellular survival and cellular migration.  In quiescent cells, PTEN is hypothesized to
be in its closed, inactive conformation.  Inactive PTEN is constitutively phosphorylated in the
regulatory domain by casein kinase II.  This closed conformation is hypothesized to mask the
positively charged residues of the C2 domain and the PDZ binding motif.  Upon growth factor
stimulation, PTEN is dephosphorylated and in its open conformation.  Positively charged
residues and the PDZ binding motif are exposed and PTEN is localized to the plasma
membrane, where its lipid phosphatase activity is turned on.  At the plasma membrane, PTEN
dephosphorylates PI3,4,5P3 back to PI4,5P2, counteracting PI3K activity, blocking cell growth
and survival effects of the activated PI3K/Akt pathway.
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phosphatidylinositol (3,4,5) trisphosphate (PI3,4,5P3) (Ueki et al.,2002).  The lipid second 
messenger PI3,4,5P3 recruits and activates phosphoinositide-dependent protein kinase-1, which 
is responsible for the activation of the Ser/Thr kinase Akt (Ueki et al., 2002).  The Akt 
signalling pathway initiates the phosphorylation of many downstream proteins that promote 
anti-apoptotic signalling.  Activation of EGFR results in the the phosphorylation and activation 
of the PI3K/Akt signalling pathway that leads to cellular survival, cell cycle entry and 
progression and protein translation for cell growth. 
 
1.2 PTEN biological functions  
 
1.2.1 PTEN attenuation of the Akt signalling pathway 
PTEN (phosphatase with tensin homology on chromosome 10) is a lipid phosphatase 
that dephosphorylates PI3,4,5P3 back to PI4,5P2, counteracting PI3K activity and blocking cell 
growth and survival effects of the activated EGFR pathway (Figure 1.1) (reviewed in Cantley 
and Neel, 1999).  PTEN has five domains:  a PI4,5P2 binding motif, a phosphatase domain, a 
lipid binding domain (C2) made up of positively charged residues that have been shown to 
interact electrostatically with the plasma membrane, a regulatory domain containing Ser/Thr 
residues that have been shown to be phosphorylated by casein kinase II, and a class I PSD-95, 
Disc-large ZO-1 homologous (PDZ) binding motif (GITKV-COOH) at the C-terminus that has 
been shown to interact with many PDZ domains (Figure 1.2A) (Keniry and Parsons, 2008; 
Maehama and Dixon, 1999; Valiente et al., 2005).  A model has been proposed explaining 
PTEN regulation and localization to the plasma membrane (Rahdar et al., 2009; Vazquez et al., 
2000, 2001).  PTEN is present in the cytosol of quiescent cells in its phosphorylated, closed 
conformation due to constitutive phosphorylation by casein kinase II (Figure 1.2B) (Rahdar et 
al., 2009; Torres and Pulido, 2001).  This closed conformation may be responsible for masking 
the positively charged residues responsible for electrostatic interactions with the plasma 
membrane (Das et al., 2003; Rahdar et al., 2009; Ross and Gericke, 2009).  Upon growth factor 
stimulation, PTEN is dephosphorylated and adopts an open conformation believed to expose its 
positively charged residues for plasma membrane interaction (Rahdar et al., 2009; Ross and 
Gericke, 2009).  The open conformation of PTEN is also hypothesized to expose the PDZ  
Figure 1.2:  Schematic representation of the structure of the PTEN tumor suppressor
protein.  A, PTEN has five domains: a PI4,5P2 binding motif, a phosphatase domain (PASE),
a lipid binding domain (C2) made up of positively charged residues that have been shown to
interact with the negatively charged plasma membrane; a regulatory domain (REG) composed
of residues such as Ser/Thr residues that have been shown to be phosphorylated by casein
kinase II, and a class I PDZ binding motif that has been shown to interact with several PDZ
domains. B, Simplified representation of the closed and open conformation of the PTEN tumor
suppressor protein (modified from Radhar et al., 2009).  Casein kinase II has been shown to
phosphorylate PTEN, however an unknown phosphatase dephosphorylates PTEN.
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binding motif for PDZ domain interactions (Vazquez et. al., 2000, 2001).  The PDZ binding 
motif may localize PTEN to a PDZ domain scaffolding protein that is responsible for 
positioning PTEN in the correct membrane microdomain in order for it to gain access to PI3K 
lipid products for dephosphorylation.   
PTEN has been shown to interact with many PDZ containing proteins including the 
Na+/H+ exchanger regulatory factor 1 (NHERF1) and NHERF2 (Kotelevets et al., 2005; 
Takahashi et al., 2006).  PTEN has been shown to form a ternary complex with PDGFR and the 
NHERF scaffolding proteins (Figure 1.3) (Takahashi et al., 2006).  The NHERF family of 
proteins are scaffolding proteins that contain two PDZ domains (Reczek et al., 1997).  It is 
hypothesized that upon platelet-derived growth factor (PDGF) stimulation, NHERF1 PDZ1 and 
PDZ2 domains bind to both PTEN and PDGFR, respectively, in order to localize PTEN to the 
correct subcellular location at the plasma membrane in the cell to gain access to its lipid 
substrates.  NHERF is located at the plasma membrane under physiological conditions and 
therefore may already be bound to PDGFR (Takahashi et al., 2006).  PTEN binding to NHERF 
is dependent on PDGF stimulation (Takahashi et al., 2006).  Proper localization allows PTEN 
to gain access to its lipid substrates and turn off PI3K/Akt signalling (Takahashi et al., 2006).  
Therefore, the NHERF scaffolding protein places PTEN in close proximity of the PI3K lipid 
products in order for PTEN to efficiently attenuate Akt signalling. 
 
1.2.2 PTEN stability 
PTEN is a tumor suppressor protein that is mutated, deleted or has altered post-
translational modifications that causes its loss of function in many types of cancer cells 
including those of the breast, prostate, lung, endometrium, brain, thyroid, skin, liver and 
lymphoid cancers (Pendaries et al., 2003; Simpson and Parsons, 2001; Sulis and Parsons, 
2003).  A common mutation in PTEN is a truncated version of the protein that lacks its C-
temrinal end, including the PDZ binding motif (Pendaries et al., 2003; Sulis and Parsons, 
2003).  Mice with homozygous deletions of PTEN die in early embryogenesis, whereas 
heterozygous animals develop many malignancies (Suzuki et al., 1998).  Cultured mammalian 
cells that lack the PTEN tumor suppressor proliferate faster, resist apoptosis, have elevated 
activated Akt levels and migrate aberrantly (Dahia et al., 1999; Hu et al., 2007; Subauste et al.,  
PDGFR
PDGF
+
PTEN
+ +
P P
PTEN
P
++
+
P P
NHERF
Figure 1.3:  NHERF is a scaffolding protein that forms a ternary complex with PTEN
and the PDGFR to attenuate Akt signalling (modified from Takahashi et al., 2006).  Upon
PDGF stimulation, PDGFR subunits dimerize and autophosphorylation occurs on the Tyr
residues.  PI3K generates the lipid second messenger PI3,4,5P3, which in turn activates Akt
signalling.  Upon growth factor stimulation, PTEN is dephosphorylated and recruited to the
plasma membrane and binds through is PDZ binding motif to the PDZ1 domain of the NHERF
scaffolding protein.  NHERF is hypothesized to be responsible for bringing PTEN to the
appropriate location at the plasma membrane where it can gain access to its lipid substrate,
PI3,4,5P3.  Therefore, NHERF is a scaffolding protein that is able to localize the antagonistic
PTEN protein to the PDGFR in order to rapidly attenuate PI3K/Akt signalling and ensure it is
transient.
P PPI4,5P2
PI3,4,5P3
Akt PP
Protein
translation for
cell growth
Cell cycle entry &
progressionCellular
migration
Cell survival
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2005; Wang et al., 2007).  PTEN can be mono- and poly-ubiquitinated by neural precursor cell 
expressed developmentally down-regulated 4-1 (NEDD4-1) (Wang et al., 2007), an E3 
ubiquitin ligase (Blot et al., 2004).  Mono-ubiquitination of PTEN in the C2 domain leads to the 
translocation of PTEN into the nucleus, where it is involved in antagonizing nuclear Akt 
signalling (Trotman et al., 2006) and plays a role in maintaining chromosomal integrity (Shen 
et al., 2007).  The focus of this work is the regulatory function at the plasma membrane, so 
these nuclear roles will not be discussed further.  Poly-ubiquitination at the C-terminal end of 
PTEN leads to its rapid degradation by the proteosome (Wang et al., 2007).  Overexpression of 
NEDD4-1, which has been shown in some types of cancers, can lead to the post-translational 
suppression of PTEN (Wang et al., 2007).  A recent publication however, claims that PTEN 
does not associate with NEDD4-1, nor is the half-life of PTEN affected by NEDD4-1 
ubiquitination (Fouladkou et al., 2008).  This study also found that PTEN nuclear localization is 
independent of NEDD4-1 mono-ubiquitination (Fouladkou et al., 2008).  Regardless of whether 
PTEN is mono- or poly-ubiquitinated by NEDD4-1, PTEN has been shown in previous studies 
to be ubiquitinated, which affects its redistribution in the cell and its degradation by the 
proteosome (reviewed in Wang and Jiang, 2008). 
PTEN degradation is known to be mediated through C-terminal ubiquitination and 
proteosomal degradation.  PTEN is poly-ubiquitinated at the C-terminal end (amino acids 352-
403) and is quickly degraded by the proteosome (van Themsche et al., 2009; Wang et al., 
2007).  The C-terminal end of PTEN is also involved in intra- and intermolecular interactions 
with PDZ domains (Kotelevets et al., 2005; Rahdar et al., 2009; Takahashi et al., 2006; 
Valiente et al., 2005; Wu et al., 2000a, 2000b).  In the closed conformation of PTEN, these C-
terminal residues are involved in an intramolecular interaction with its C2 domain (Rahdar et 
al., 2009).  PTEN residues involved in poly-ubiquitination may be unavailable for 
ubiquitination by the E3 ligase NEDD4-1 when PTEN is involved in these intramolecular 
interactions, explaining why PTEN is most stable in its cytosolic, closed conformation (Wang 
and Jiang, 2008).  It is hypothesized that upon growth factor stimulation and simultaneous 
dephosphorylation, PTEN is recruited to the plasma membrane to a high molecular weight 
complex (the PAC) associated with a PDZ domain-containing scaffolding protein (Kotelevets et 
al., 2005; Takahashi et al., 2006; Valiente et al., 2005; Vazquez et al., 2001; Wu et al., 2000a, 
2000b).  PTEN bound to a PDZ domain has been shown to have an increased half-life with 
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respect to a PTEN that cannot be recruited to a PDZ domain (Valiente et al., 2005; Wu et al., 
2000a).  When the PDZ binding motif of PTEN is interacting with a PDZ domain, the C-
terminal residues are again unavailable for poly-ubiquitination, resulting in increased PTEN 
stability (Wang and Jiang, 2008).  Therefore PTEN intra- or intermolecular interactions through 
its C-terminal end may prevent PTEN from poly-ubiquitination and subsequent degradation by 
the proteosome, thereby increasing the half-life of the tumor suppressor protein. 
 
1.2.3 p85 regulation of PTEN 
The p85 subunit of PI3K has been shown to have functions outside of the regulation of 
the p110 subunit of PI3K.  p85 has been shown to positively regulate PTEN dephosphorylation 
of PI3,4,5P3 back to PI4,5P2 (Chagpar, 2004; Pastor, 2008).  p85 is composed of 5 domains; an 
N-terminal Src homology 3 (SH3) domain, a breaking point cluster region homology domain 
flanked by two pro rich sequences, and two Src homology 2 (SH2) domains flanking the p110 
binding site (Figure 1.4) (Harpur et al., 1999).  SH3 domains are known to bind to Pro rich 
sequences (Pawson, 1994).  The breakpoint cluster region homology domain of p85 has been 
shown to have GTPase activating protein for Rab4 and Rab5 proteins in vitro (Chamberlain et 
al., 2004).  Rab4 and Rab5 are monomeric G-proteins involved in vesicle trafficking and fusion 
events during endocytosis and recycling of receptors (reviewed in van Ijzendoorn et al., 2003).  
SH2 domains bind to phosphorylated Tyr residues and those of p85 have been shown to bind to 
phosphorylated Tyr residues of many RTKs (Harpur et al., 1999; Hock et al., 1998; Kubota et 
al., 1998; Liu and Pawson, 1994; Pawson et al., 1993; Pawson, 1994).  p85 Pro rich regions 
have been shown to bind to the SH3 domains within the p85 protein itself and the SH3 domain 
of Lyn and Fyn, which are Src-family non-receptor tyrosine kinases (Harpur et al., 1999; 
Pleiman et al., 1994).  These Pro rich regions have not been shown to bind to WW domains.  
Although p85 is known for its regulatory functions towards the p110 subunit of PI3K, it has 
been described complexed with other proteins and therefore has functions outside of the PI3K 
complex (Chagpar, 2004; Chamberlain et al., 2004; Harpur et al., 1999; Pastor, 2008; Pleiman 
et al., 1994). 
The p85 regulatory subunit of PI3K can bind directly to PTEN and positively regulate  
SH3 BH SH2 SH2p110
Pro Pro
Figure 1.4:  Schematic representation of the domain organization of the p85 protein.  p85
is composed of an N-terminal SH3 domain, a breakpoint cluster region homology (BH)
domain flanked by two Pro rich regions and two SH2 domains flanking the p110 binding site.
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PTEN dephosphorylation of PI3,4,5P3 back to PI4,5P2 (Chagpar, 2004).  Others have found that 
cells lacking p85 were deficient in PTEN attenuation of Akt signalling through 
dephosphorylation of PI3,4,5P3 (Taniguchi et al., 2007).  Although cells had a decrease in PI3K 
levels (due to loss of p85), PI3,4,5P3 and Akt levels were enhanced when compared to wild 
type cells (Taniguchi et al., 2007).  Therefore, p85 may be a critical regulatory component in 
PTEN attenuation of the Akt signalling signalling. 
 
1.3 MAGUK and MAGI scaffolding proteins 
Membrane associated guanylate kinase homologs (MAGUK) scaffolding proteins 
contain many protein binding domains capable of binding to multiple proteins simultaneously 
(Figure 1.5).  Scaffolding proteins are multidomain proteins important in forming 
macromolecular protein complexes that regulate intracellular signalling pathways.  Organizing 
signal transduction proteins into these complexes increases signalling efficiency by decreasing 
the distance over which signal transduction intermediates have to travel (Dimitratos et al., 
1999; Pawson and Scott, 1997).  It is also hypothesized that scaffolding molecules may have 
the ability to orient signalling molecules with respect to each other, in order for more effective 
interactions to take place (Dimitratos et al., 1999; Pawson and Scott, 1997).  MAGUK 
scaffolding proteins share a common sequence similarity, placing them in this family of 
scaffolding proteins (Figure 1.5) (reviewed in Funke et al., 2005).  At the very C-terminal end 
of the protein is the guanylate kinase domain (GK) for which this family of proteins are named.  
These GK domains are typically catalytically inactive and are therefore thought to have evolved 
as protein binding domains, as opposed to a catalytically active enzyme (te Velthuis et al., 
2007).  The GK domain is preceded by a single SH3 domain, which are known to bind to Pro 
rich sequences (Pawson and Schlessingert, 1993).  At the N-terminal end of the protein, there 
are one or more copies of the PDZ domains.  PDZ domains mediate protein-protein interactions 
with small polypeptide sequences usually found at the very C-terminal end of proteins (Doyle 
et al., 1996; Kay and Kehoe, 2004; Morais-Cabral et al., 1996).  MAGUK scaffolding proteins 
share a common domain organization, with one or more PDZ domains followed by a single 
SH3 domain and a catalytically inactive GK domain. 
 One group of MAGUK proteins that does not follow the general domain architecture  
Figure 1.5: Protein domain organization of the MAGUK scaffolding proteins (modified
from Funke et al., 2005).  The N-terminal end of the protein contains one or multiple PDZ
domains followed by a single SH3 domain.  The C-terminal end of the protein contains the
GK domain, for which this family of proteins are named.  The MAGI family of MAGUK
proteins contain identical or similar protein binding domains however, these have a different
primary domain arrangement than its family counterparts.  Its domain arragement is inverted
with respect to the rest of the MAGUK family of scaffolding proteins.  The MAGI family of
proteins have one N-terminal PDZ domain, followed by the GK domain located at the N-
terminal end of the protein.  The GK domain is then followed by two tandem WW domains,
followed by five more PDZ domains.  The MAGI-2 protein contains an additional C-terminal
region which is rich in Gly, Ala, Arg and Pro residues our laboratory has termed the GARP C-
terminal sequence.
PSD-95
ZO-1
PALS
p55
= PDZ = GK = SH3 = GARP= WW
SAP-102
MAGI-2
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 mentioned above, is known as the membrane associated guanylate kinase-inverted (MAGI) 
subfamily (Figure 1.5).  MAGI protein domain organization is inverted with respect to the rest 
of the MAGUK scaffolding proteins, hence their nomenclature (Funke et al., 2005; te Velthuis 
et al., 2007).  The MAGI group of scaffolding proteins has three members; MAGI-1, MAGI-2 
and MAGI-3, which share extensivy sequence similarity (Figure 1.6).  All MAGI proteins 
contain six PDZ domains (numbered 0-5), a single GK domain and two tandem WW domains 
(numbered 1 and 2, respectively).  Overall, the sequence similarity of these domains is high, 
whereas the linker sequences between the domains are low (Wu et al., 2000b).  The MAGI 
group of scaffolding proteins have one N-terminal PDZ domain, followed by the GK domain, 
which is positioned N-terminally rather than C-terminally.  The GK domain is followed by two 
tandem WW domains, which bind to Pro rich sequences, much like the SH3 domains (Macias 
et al., 1996, 2000; Nguyen et al., 1998).  The WW domains are followed by five more PDZ 
domains.  The MAGI group of scaffolding proteins share the same or similar protein-protein 
binding domains as the MAGUK scaffolding proteins however, the primary arrangement of 
these protein domains is inverted when compared to their MAGUK counterparts. 
 MAGUK scaffolding proteins are important in cell signalling pathways and they have 
been shown to be localized to areas important for cellular communication such as cell-cell 
junctions, adherens junctions, tight junctions and neuronal synapses (Deng et al., 2006; 
Dobrosotskaya and James, 2000; Franklin et al., 2005; Shoji et al., 2000).  MAGUK proteins 
have been found in all metazoans studied to date, however they are not present in fungi or other 
unicellular organisms, potentially indicative of their role in cell-cell communication and their 
importance in signal transduction pathways (te Velthuis et al., 2007).  MAGUK scaffolding 
proteins are also absent in plants, which contain cell walls and may require a different 
mechanism for cell-cell communication (te Velthuis et al., 2007).  MAGUK scaffolding 
proteins are ubiquitous throughout different tissues (Dobrosotskaya et al., 1997; Godreau et al., 
2004; Laura et al., 2002; Wood et al., 1998; Wu et al., 2000a, 2000b) where the most diversity 
of MAGUK scaffolding proteins occur in the brain (reviewed in Elias and Nicoll, 2007; te 
Velthuis et al., 2007).  The high incidence of MAGUK scaffolding proteins in the brain is 
appropriate because of the high incidence of neurons and neuronal synapses in these areas, 
thereby exhibiting a need for scaffolding proteins to regulate the many signal transduction  
PDZ0
GK
PDZ1
WW1
WW2
PDZ2
Figure 1.6:  CUSTLAW sequence alignment of the MAGI family members (modified from
Wu et al., 2000b).  Amino acids that are identical or similar are shaded in gray.  All MAGI
proteins contain the six PDZ domains (numbered 0-5), two WW domains and a GK domain.
The homology of the domains remain high whereas the linker sequences between the MAGI
domains are low.  The red bars indicate the sequences representing the domains on the right.
The MAGI sequences represented are the human proteins and their accession numbers are as
follows: MAGI-1 NP_056335, MAGI-2 NP_036433 and MAGI-3 AF213259.  The
CUSTLAW sequence alignments were generated using MacVector software.
13
Figure 1.6:  CUSTLAW sequence alignment of MAGI family members (continued from
previous page).
PDZ3
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pathways.  Although MAGUK scaffolding proteins are known for their scaffolding functions at 
cell-cell communication sites, they also exhibit a wide variety of cellular functions such as 
establishment of cell polarity, tight junction formation, cell proliferation or apoptosis, cell 
differentiation and neuronal synapse transmission (Dobrosotskaya and James, 2000; Georgescu, 
2008; Hirao et al., 1998; Kaech et al., 1998; Kornau, 2006; Lehtonen et al., 2005; Subauste et 
al., 2005; Tepass and Knust, 1993; Woods et al., 1996).  Mutations in MAGUK scaffolding 
proteins often cause defects in cell-cell adhesion, cell polarity and cell proliferation (Gregorc et 
al., 2007; Hoover et al., 1998; Kaech et al., 1998; Tepass et al., 1990; Woods and Bryant, 
1991).  MAGUK proteins can also be palmitoylated, phosphorylated or translocated to the 
nucleus (Bryant and Woods, 1992; Dobrosotskaya et al., 1997; Hsueh et al., 2000; Tanemoto, 
2008; Topinka and Bredt, 1998).  Although MAGUK scaffolding proteins are important in 
bringing together signal transduction intermediates, they have also been shown to play a role in 
other cellular functions. 
MAGUK scaffolding proteins are important in bringing together proteins in a cell in 
close proximity to each other to increase the efficiency of cell signalling and signal transduction 
pathways.  For example, the lethal protein 23 receptor, the EGFR homologue in Caenorhabditis 
elegans, is localized to the basolateral membranes of polarized vulval epithelial cells (Hoskins 
et al., 1996).  Lethal protein 23 has a C-terminal PDZ binding motif that binds to a PDZ domain 
in abnormal cell lineage 2, an interaction that is important for cellular proliferation and 
differentiation in Caenorhabditis elegans vulval cells (Kaech et al., 1998).  Abnormal cell 
lineage 2, a MAGUK scaffolding protein, also binds to adaptor proteins abnormal cell lineage 7 
and abnormal cell lineage 10, vertebrate abnormal cell lineage homologs, and form a complex 
that allows lethal protein 23 basolateral localization in these epithelial cells (Kaech et al., 
1998).  In order for vulval development to occur properly in Caenorhabditis elegans, abnormal 
cell lineage 3 (an EGF-like signal) is secreted into the basal extracellular space of vulval 
precursor cells and activates lethal protein 23 to cause cells to proliferate and differentiate into 
vulval cells (Hoskins et al., 1996).  A defect in the abnormal cell lineage complex formation 
disrupts basolateral localization of lethal protein 23, thereby preventing vulval induction 
(Kaech et al., 1998).  Similar results are seen upon of a loss of function mutant of the lethal 
protein 23 receptor (Kaech et al., 1998). Therefore, MAGUK proteins are important scaffolding 
proteins responsible for mediating cell signalling at proper locations within cells. 
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1.4 Binding specificities and functions of MAGUK protein domains  
 
1.4.1 GK:SH3 domains 
The GK domain of most MAGUK proteins share 40% sequence similarity to yeast 
guanylate kinase (YGK) domains (Kistner et al., 1995; Kuhlendahl et al., 1998; Li et al., 2002), 
whereas the GK domains of MAGI proteins share approximately 22% sequence identity to 
YGK (Figure 1.7).  Previous studies have shown that the GK domain of MAGI proteins share 
only 11% sequence similarity however they did not show the sequences involved in the 
alignment, which could account for the discrepancy in sequence similarity reported here (Adell 
et al., 2004).  Another study has also reported a sequence similarity of 27% between the GK 
domain of MAGI-1 and YGK (Dobrosotskaya et al., 1997).  However, they compared the 
sequence of the first 100 amino acids of the YGK to approximately 100 amino acids of the 
MAGI-1 GK domain, whereas Figure 1.7 shows 160 amino acids. 
Unlike authentic YGKs, the MAGUK GK domains are not enzymatically functional and 
are unable to catalyze ATP-dependent phosphorylation of GMP to GDP (Li et al., 1996) with 
the exception of very few MAGUK proteins that do exhibit very weak catalytic activity 
(Dimitratos et al., 1999).  Although most GK domains of MAGUK proteins are capable of 
binding GMP (Kistner et al., 1995; Kuhlendahl et al., 1998; Li et al., 2002) they are 
catalytically inactive because they are missing key residues important in the catalytic function 
of the GK domain (Figure 1.7) (Kuhlendahl et al., 1998; Li et al., 2002).  For example, 
although MAGIs contain many of the residues important in binding the guanine ring (red 
triangles), residues that bind the phosphate (purple circles) and the Mg2+ (blue square) are less 
well conserved (Figure 1.7) (Dobrosotskaya et al., 1997).  Also, YGK contains a GMP binding 
pocket as well as an ATP binding area important for catalytic function (Li et al., 1996).  The 
ATP binding domain is no longer functional in MAGI GK domains due to the lack of key 
residues that make contact with ATP (Figure 1.7, bracket) (Dobrosotskaya et al., 1997; Kistner 
et al., 1995; Kuhlendahl et al., 1998).  Therefore, it is hypothesized that the GK domains of  
Figure 1.7:  CUSTLAW sequence alignment of YGK and the GK domain of MAGI-1
(MG1), MAGI-2 (MG2) and MAGI-3 (MG3) (modified from Dobrosotskaya et al., 1997).
Amino acids in YGK that bind to ATP are indicated.  GMP binding residues of YGK are
indicated as follows; guanine ring (▼), phosphate (●) and Mg2+ (■). The YGK accession
number is AAA34657 and the MAGI proteins are of the human origin and are of the same
accession numbers described in Figure 1.6.
ATP binding site
▼ ●
● ▼▼ ▼
●■
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MAGUK proteins have evolved as protein-protein interacting modules, as opposed to 
catalytically active domains. GK domains have been shown to bind to a variety of proteins that 
do not necessarily share sequence similarity.  Most of these proteins are localized at areas of the 
cell important in cell-cell communication (e.g., guanylate kinase associated protein and 
P90/SD-95 associated proteins) (Kim et al., 1997; Takeuchi et al., 1997), or aid in the 
trafficking of proteins to these areas (e.g., A kinase anchoring proteins and guanylate kinase 
associated kinesin) (Colledge et al., 2000; Hanada et al., 2000).  These protein-protein 
interactions are independent of the GMP binding pocket. The ability of the GK domain of 
MAGUK scaffolding proteins to bind to a variety of proteins reinforces the hypothesis that the 
GK domain has evolved as a protein interaction module rather than a catalytically active 
domain. 
One last unique binding partner of the GK domain of MAGUK proteins is an 
intramolecular interaction with the adjacent SH3 domain (Figure 1.8A) (McGee and Bredt, 
1999; Nix et al., 2000; Shin et al., 2000; Tavares et al., 2001).  A Hook domain, located 
between the GK and SH3 domain, allows for the GK domain to fold over and make interactions 
with the SH3 domain (Paarmann et al., 2002).  The GK:SH3 interaction is unusual because 
SH3 domains are known to bind to Pro rich sequences (Pawson and Nash, 2003) of which the 
GK domain has none.  It was later shown, however, that the Pro binding site of the SH3 domain 
is not involved in the intramolecular interaction with the GK domain (Tavares et al., 2001).  
Mutations that disrupt the GK:SH3 intramolecular interaction can result in tumor formation, 
improper cellular adhesion and improper cell-cell junction scaffold formations (Lahey et al., 
1994; Woods and Bryant, 1991), causing loss of proper formation of cell-cell junctions and loss 
of cell signalling (Hoskins et al., 1996; Woods et al., 1996).  The GK:SH3 interaction has also 
been shown to produce intermolecular interactions with other GK:SH3 domain containing 
MAGUK proteins (Figure 1.8B) (McGee et al., 2001; Nix et al., 2000).  It is believed that these 
intermolecular interactions are important in forming an interlocked MAGUK scaffolding 
network localized at cell communication borders (McGee et al., 2001).  Although the GK:SH3 
intra- and intermolecular interactions are not well understood,  mutational analysis has shown 
that these interactions are important in the proper functioning of cell signalling pathways and 
proper cell junction formation in cells. 
 
Intramolecular association of PSD-95A
Hook domain
B Intermolecular association of PSD-95
Figure 1.8:  Schematic representation of the intramolecular and intermolecular
association between the GK and SH3 domains of MAGUK scaffolding proteins.  A, The
intramolecular interaction of the GK:SH3 domains through the Hook domain.  B, The
intermolecular interaction of the GK:SH3 domains, which allows the formation of
supramolecular scaffolds localized in areas of the cell important for intercellular
communication.
= PDZ = GK = SH3
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1.4.2 SH3 and WW domains 
Most MAGUK scaffolding proteins contain a single SH3 domain, however the MAGI 
group is the only MAGUK proteins that contain two tandem WW domains (reviewed in Funke 
et al., 2005).  Both of these protein domains bind to Pro rich sequences (Nguyen et al., 1998).  
SH3 domains are usually present within a protein as a single copy and they fold as two 
orthogonal β-sheets which contains five anti-parallel strands assembled into a β-barrel (Figure 
1.9A) (Hoelz et al., 2006; Loll et al., 2008; Martin-García et al., 2007; Wisniewska et al., 
2005).  Two loops, the RT loop (connecting β1/β2) and the Src loop (connecting β2/β3) have 
been shown to make additional contacts with the peptide (Hoelz et al., 2006; Martin-García et 
al., 2007).  A shallow hydrophobic groove, lined with highly conserved aromatic residues, 
makes up the binding pocket that accommodates the Pro rich peptide (Figure 1.9B, gray) 
(Nguyen et al., 1998).  The peptide can also make contact with highly conserved residues in the 
RT loop, Src loop and the highly conserved acidic residues known to make contact with the 
basic Arg residue in the peptide (Figure 1.9B, red) (Hoelz et al., 2006; Nguyen et al., 1998).  
The Pro residues of the peptide pack against the aromatic residues of the SH3 domain, forming 
a hydrophobic buckle (Figure 1.9C) (Nguyen et al., 1998).  The SH3 domains recognize and 
bind to Pro rich sequences often bordered by an Arg residue (PXXPXR) (Figure 1.9C) (Nguyen 
et al., 1998).  Upon binding of the peptide to the SH3 domain, the peptide adopts a Type II 
polyproline helical conformation (Ogura et al., 2006; Pisabarro et al., 1998).  Therefore, SH3 
domains bind to Pro rich sequences flanked by an Arg residue, by forming a hydrophobic 
buckle against the aromatic residues found in the binding pocket of SH3 domains. 
WW domains are protein interaction modules that also bind to Pro rich peptides.  WW 
domains are usually present within a protein as two or more copies (Hofmann and Bucher, 
1995) and they fold as stable, triple stranded, antiparallel β-sheets (Figure 1.9D) (Macias et al., 
1996).  These domains are made up of approximately 30-40 amino acids and they usually 
contain two highly conserved aromatic residues (frequently Trp residues; Figure 1.9E, red) 
spaced approximately 20-22 amino acids apart (Chen and Sudol, 1995; Macias et al., 1996; 
Schultz et al., 2000).  Again, a shallow hydrophobic groove, lined with highly conserved 
aromatic residues, makes up the binding pocket that accommodates the Pro rich peptide (Figure 
1.9E, purple, blue and red) (Nguyen et al., 1998).  It has been shown that WW and SH3  
Glu
Glu
Asp
Trp
Trp
Phe
Figure 1.9:  Comparison of the SH3 and WW domains.  A, Crystal structure of the SH3
domain of  the rat betaPIX, a protein involved in localization of p21-activated kinases [Protein
databank identification number (PDB ID): 2D6F from Hoelz et al., 2006].  SH3 domains
contain two orthogonal β-sheets that contains five anti-parallel strands assembled into a β-
barrel.  B, SH3 domain highlighting the residues important in making contacts with the Pro
rich peptide (peptide not shown).  Acidic residues in the RT loop are highlighted in red.
Aromatic residues making up the hydrophobic groove are highlighted in gray.  C, Schematic
representation of a Pro rich peptide binding to an SH3 domain (taken from Nguyen et al.,
1998).  D, NMR solution structure of the third WW domain of Smurf2, a human E3 ubiquitin
ligase (PDB ID: 2DJY from Chong et al., 2006).  WW domains are approximately 40 amino
acids in length and are arranged as three anti-parallel β-sheets.  E, WW domains highlighting
residues important in binding to the proline rich peptide (peptide not shown).  The conserved
aromatic residues for which the domain is named are highlighted in red (Trp and Phe); the Tyr
(center of the β2 sheet) is highlighted in blue; the residues forming the hydrophobic pocket
(closely spaced His and Leu residues) are highlighted in purple. F, Schematic representation of
a proline rich peptide binding to a WW domain (taken from Nguyen et al., 1998).  The gold
arrows represent β-sheets and the blue tubes represent unstructured loops.  Crystal structures
were downloaded from the PDB and the figures were generated with Cn3D software.
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domains can often compete for the same Pro rich binding motif (Sudol, 1996).  WW domains 
often recognize a Pro rich sequence with an adjacent Tyr residue (PPXY, Figure 1.9F) (Nguyen 
et al., 1998).  The chemistry of the interaction between a WW domain is similar to that of an 
SH3 domain, where the Pros of the peptide pack against aromatic residues in the binding pocket 
of the WW domain, forming a hydrophobic buckle (Figure 1.9F) (Macias et al., 1996; Nguyen 
et al., 1998).  Therefore, WW domains are found in the MAGI group of MAGUK scaffolding 
proteins and they bind to Pro rich sequences in a similar fashion to SH3 domains.   
There are four different classes of WW domains that are based on the different peptide 
motifs that are recognized by individual WW domains (Table 1.1) (reviewed in Espanel et al., 
2003; Ingham et al., 2005).  Although the WW domains exhibit specificity for ligands, an 
individual WW domain has the ability to bind to more than one class of peptide, increasing the 
complexity of classifying these domains (Kato et al., 2004; Wiesner et al., 2002).  There are 
four classes of peptide binding motifs, however the binding of WW domains to their different 
ligand classes is similar.   
WW domains contain some highly conserved residues that are important in binding and 
making contacts with their respective ligands (Figure 1.10 and 1.11).  The WW domain 
contains a shallow, hydrophobic surface that accommodates the Pro rich peptide (Figure 1.10A) 
(Macias et al., 1996).  This hydrophobic surface contains two Trp residues spaced 20-22 amino 
acids apart, for which the domain is named (Figure 1.10B and Figure 1.11A, red).  Although the 
first Trp residue is absolutely conserved, the second can be replaced with a Tyr or Phe (Kanelis 
et al., 2006; Kato et al., 2006; Macias et al., 1996; Pires et al., 2005).  WW domains also 
contain an absolutely conserved Pro near its C-terminal end (Figure 1.11, green).  The 
absolutely conserved N-terminal Trp residue and C-terminal Pro residue are believed to support 
 
Table 1.1:  Table depicting the four different classes of WW domains and the short amino 
acid sequences they recognize (reviewed in Espanel et al., 2003; Ingham et al., 2005). X-
denotes any amino acid.  pS denotes a phosphorylated Ser and pT denotes a phosphorylated 
Thr. 
Class Peptide Motif 
Class I -P/L-P-X-Y- 
Class II -P-P-X-P- 
Class III -P-P-R-P- 
Class IV pS-P or pT-P cores 
 
A B
Figure 1.10:  Peptide binding to a WW domain highlighting residues important in
making contact with the Pro rich peptide.  A, Space filled model of the first WW domain of
human formin binding protein (NP_060362, used with permission from Pires et al., 2005)
showing the surface topology of the hydrophobic surface (red regions) on the WW domain that
accommodates the proline rich peptide.  B, NMR solution structure of the WW domain from
Figure 1.19E (PDB ID: 2DJY from Chong et al., 2006), highlighting key residues important in
binding to the proline rich peptide.  Peptide ligand (green residues) bound to the WW domain
showing the important conserved contacts.  The hydrophobic buckle is created upon binding of
the Pro residues of the ligand to the second aromatic residue (Phe) on the surface of the WW
domain.
Figure 1.11:  CUSTLAW sequence alignment of WW domains.  A, Sequence alignment of
ten individual WW domains. The human Prp40 protein (EAW58085) is a U1 snRNP involved
in RNA splicing.  The human NEDD4-1 protein (NP_006145) is an E3 ubiquitin ligase.  The
human formin binding protein (FBP, NP_060362) is involved in protein transport to the nucleus
and may play a role in RNA splicing.  The Trp residues, for which the domain is named, are
boxed in red.  A well conserved Tyr or aromatic residue in the center of the β2 strand, is
highlighted in blue.  The residues responsible for forming a small hydrophobic pocket are
highlighted in purple.  The always conserved Pro residue at the C-terminal end of the domain, is
highlighted in green.  B, Sequence alignment of the WW domains in MAGI-1 (MG1), MAGI-2
(MG2) and MAGI-3 (MG3).  The second conserved Trp in the second WW domain of the
MAGI proteins is replaced with a Tyr or Phe.  The MAGI WW domains are more similar with
respect to the homologous domains of the other MAGI proteins than they are with respect to the
WW domains within an individual MAGI protein.  ω represents an aromatic residue.  Φ
represents an hydrophobic residue.
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the integrity of the tertiary structure of the domain, as mutations in these residues cause 
improper folding of the WW domain (Macias et al., 2000).  A highly conserved aromatic 
residue in the center of the β2 strand (Figure 1.10B and Figure 1.11, blue) makes contact with a 
center Pro residue in the peptide (Kanelis et al., 2006; Kato et al., 2006; Macias et al., 1996; 
Pires et al., 2005).  In the class I WW domain, a hydrophobic pocket is formed in the β2/β3 
loop region which makes contact with the aromatic ring of Tyr residue of class I peptides 
(Figure 1.10B and Figure 1.11, purple) (Huang et al., 2000; Kanelis et al., 2006; Kato et al., 
2006; Macias et al., 1996).  The residues making up this pocket are dependent on the class of 
the WW domain (reviewed in Espanel et al., 2003; Ingham et al., 2005).  These highly 
conserved residues of the WW domain are important in making contact with their respective 
peptides. 
The MAGI domains are hypothesized to bind to class I peptides as they contain the His 
and Ile/Val residues in the β2/β3 loop region (Figure 1.11B, purple).  The first WW domain of 
the MAGI proteins contains both conserved Trp residues and the second Trp of the second WW 
domain is substituted with a Tyr or a Phe (Figure 1.11B, red).  The WW domains of MAGI are 
more similar to the homologous domains of the other MAGI proteins, than they are with respect 
to the WW domains within the individual MAGI protein. Although MAGI WW domains bound 
to peptide complex have yet to be crystallized, it is hypothesised that it will bind to a class I 
peptide based on their primary amino acid sequences. 
Additional binding energy and specificity is provided by contacts made outside the core 
region of the peptide and the WW domain (the β1/β2 and β2/β3 loops connecting the three β-
strands) (Henry et al., 2003; Kanelis et al., 2006; Peng et al., 2007; Pires et al., 2005).  For 
example, the epithelial Na+ channel contains a -P-P-X-Y- motif that has been shown to bind to 
the third WW domain of NEDD4-2 (Henry et al., 2003).  The Ala-504 and Pro-505 residues 
within the β1/β2 loop of the NEDD4-2 WW3 domain has been shown to make contacts with the 
Pro rich region of the epithelial Na+ channel, and a mutational analysis where these were 
mutated to His-504 and Thr-505 showed a 2-3 fold decrease in binding (Henry et al., 2003).  
Although WW domains contain a consensus binding motif, additional binding may occur 
outside the binding pocket of the WW domain and increase specificity of the interaction, as 
well as binding affinities. 
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Mutations that can abolish binding of the WW domain to its respective ligand are 
important in order to study the importance of the interaction between cell signalling 
intermediates in signal transduction pathways.  Mutations in the WW domain residues that form 
the hydrophobic pocket that makes contact with an internal Pro of the peptide, will eliminate 
binding to its respective class I ligand (Figure 1.11, purple) (Kanelis et al., 2006; Macias et al., 
1996).  Mutating the well conserved WW domain Tyr residue within the β2 stand (Figure 1.11, 
blue) to an Ala or Leu also eradicates peptide binding (Kato et al., 2006; Macias et al., 1996).  
Mutating the second Trp (or Tyr) in the WW domain to an Ala also abolishes peptide binding 
(Kato et al., 2006; Macias et al., 1996).   
Mutations in the Pro rich peptides also eliminate binding to its respective WW domain.  
Replacing the center Pro residue of the peptide, which makes contact with the center β2 Tyr of 
the WW domain, with an Ala residue, can abolish binding to the WW domain (Macias et al., 
1996).  Also, mutating the Tyr residue in the class I peptide has also been shown to eradicate 
binding to its respective WW domain (Kato et al., 2006; Macias et al., 1996).   Mutational 
analysis that eliminates binding of the WW domain from its respective ligand is an important 
tool that can allow insight into the importance of interactions in specific signal transduction 
pathways.   
 
1.4.3 PDZ domains  
The third, and most prevalent protein binding domain found within MAGUK proteins 
are the PDZ domains.  PDZ-containing proteins can be divided into two groups; the first group 
encompasses proteins that only contain PDZ domains, usually present in multiple copies within 
an individual protein (reviewed in Jeleń et al., 2003).  The second group of PDZ-containing 
proteins possess single or multiple PDZ domains, in combination with other functional domains 
(Jeleń et al., 2003).  MAGUK proteins belong to the latter group.   
According to the simple modular architecture research tool, PDZ domains are one of the 
most common protein interaction modules (http://SMART.embl-heidelberg.de).  The simple 
modular architecture research tool is a database that identifies and annotates genetically mobile 
domains and the analysis of domain architectures within proteins (Schultz et al., 2000).  PDZ 
domains contain approximately 80-100 amino acids which form two α-helices (α1 and α2) and 
six β-strands (β1-β6) (Figure 1.12A) (Doyle et al., 1996; Morais-Cabral et al., 1996).  The 
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domain folds into a six stranded β-sandwhich (Doyle et al., 1996; Morais-Cabral et al., 1996).  
The peptide binds in a groove between the β2 strand and the α2 helix, forming an additional 
antiparallel β-strand with the PDZ domain, termed β-addition (Figure 1.12B and C) (Doyle et 
al., 1996; Harrison, 1996).  PDZ domains recognize short C-terminal peptide motifs of 
approximately 3-4 amino acids in length (nomenclature beginning with the C-terminal peptide 
0, -1, -2, -3 and so on) (Doyle et al., 1996), however is has been documented that residues up to 
-8 of the C-terminal peptide can also be significant for ligand binding specificity (Birrane et al., 
2003; Niethammer et al., 1998; Songyang et al., 1997).  PDZ domains are known to interact 
with many cell surface receptors and can link these to their respective effector enzymes (Brône 
and Eggermont, 2005; Deng et al., 2006; He, 2006; Morais-Cabral et al., 1996), demonstrating 
the importance of PDZ domains in signal transduction pathways.  Therefore, the presence of 
PDZ domains is integral to the scaffolding function of MAGUK proteins in signal transduction 
pathways.   
PDZ domains are classified into four different classes based on the carboxy-terminal 
sequences to which they bind (Table 1.2).    PDZ domains display overlapping specificity  
toward their different target ligands, thereby adding to the complexity of the classification of 
PDZ domains (Birrane et al., 2003; Kang et al., 2003; Nourry et al., 2003; Pan et al., 2007).  A 
conserved carboxylate-binding loop (R/K-XXX-G-Φ-G-Φ or GLGF motif) is found in the loop 
connecting β1 and β2 (Figure 1.12A-B and Figure 1.13, red) (Doyle et al., 1996).  The 
carboxylate-binding loop creates a cavity and surrounds the hydrophobic C-terminal residue (at 
position 0) of the peptide ligand, which is most often a Val, however an Ile can also be tolerated 
here (Doyle et al., 1996; Morais-Cabral et al., 1996).  The GLGF motif forms a cradle with the  
 
Table 1.2:  Classification of PDZ domains based on the C-terminal peptide to which they 
bind (reviewed in Dev 2004; Jeleń et al., 2003; Nourry et al., 2003).  (X-any amino acid, Φ - 
hydrophobic, Ψ – basic, hydrophilic). 
Class C-terminal peptide 
Class I -X-[S/T]-X-Φ-COOH 
Class II -X-Φ-X-Φ-COOH 
Class III -X-[D/E]-X-Φ-COOH 
Class IV -X-X-C-COOH, -X-Ψ-[D/E]-COOH 
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Figure 1.12:  Structure of a PDZ domain.  A, Ribbon diagram showing the structure of the
third PDZ domain of the rat PSD-95, a MAGUK scaffolding protein (PTB ID: 1TP5 from Saro
et al., 2004).  PDZ domains are made up of 80-100 amino acids which are arranged into two α-
helices (α1 and α2), and six β-sheets (β1-β6). The basic Arg and the Leu and Phe, within the
GLGF motif, forms the carboxylate binding loop, and are higlighted in red.  The α2-1 residue
(His), important in making contact with the -2 position of the peptide, is highlighted in purple.
B, PDZ domain bound to a class I ligand with Val (0) and Thr (-2) residues highlighted in blue.
C, Spacefill model depicting the surface topology of the PDZ domain bound to a C-terminal
peptide, highlighting the peptide binding groove.  For the short peptide (yellow), oxygen atoms
are shown in red and nitrogen atoms are shown in blue (used with permission from Doyle et
al., 1996).  D, Schematic representation of the contacts identified between the PDZ domain
and its peptide.  Darker black lines represent the peptide whereas the lighter black lines
represent amino acids from the PDZ domain.  Dashed lines represent hydrogen bonds.  The
green box indicates the -2 position of the peptide and the purple box indicates the His at
position at α2-1 (used with permission from Doyle et al., 1996).
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Figure 1.13:  CUSTLAW sequence alignment of PDZ domains.  Sequence alignment of
thirteen PDZ domains of human origin representing the well conserved residues that are
characteristic of a PDZ domain. PSD-95 (AAB07736) and DLG (NP_996407) are MAGUK
scaffolding proteins.  PDZ-GEF (NP_057424) is a guanine nucleotide exchange factor protein
containing a PDZ domain.  NHERF-1 and -2 (NP_004243 and NP_004776) and MUPP1
(ACC61870) are PDZ scaffolding proteins.  MAST205 (BAB40778) is a Ser/Thr kinase.  The
well conserved basic residue and the GLGF motif with the carboxylate binding loop are boxed
in red.  The carboxylate binding loop forms a hydrophobic pocket that accommodates the 0
residue of the peptide.  The α2-1 residue that makes contact with the -2 position of the peptide,
is highlighted in purple.
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three amides that hydrogen bond with the terminal carboxylate group of the peptide (Figure 
1.12D).  Also present in the carboxylate binding loop is a basic residue (Arg or Lys), which is 
conserved in approximately 85% of known PDZ domains and is found 3-4 amino acids from 
the GLGF motif (Doyle et al., 1996; Morais-Cabral et al., 1996).  This basic residue 
coordinates a water molecule that in turn stabilizes the negative charge of the carboxylate group 
of the terminal residue of the peptide (Figure 1.12A-B-D) (Doyle et al., 1996; Gee et al., 2000; 
Harris et al., 2003; Morais-Cabral et al., 1996).  A mutation in this basic residue to an Met or 
Ala often abolishes binding of the PDZ domain to its respective peptide (Chi et al., 2006; 
Harris et al., 2003).  Therefore, the conserved carboxylate binding loop, containing the basic 
residue as well as the GLGF motif, are the hallmarks of a PDZ domain and are important in 
binding the terminal residue of its respective peptide ligand. 
 
1.4.3.1 General binding characteristics of PDZ domains and their peptide ligands  
PDZ domains undergo very little change in conformation upon binding to their peptide 
ligand (Doyle et al., 1996; Morais-Cabral et al., 1996).  In addition, they demonstrate low 
affinities for their ligands (Kd < 1-50 µM) (reviewed in Jemth and Gianni, 2007) which is 
indicative of the transient, reversible binding required for signal transduction pathways.  
Although PDZ domains exhibit specificity when binding peptides, an individual PDZ domain 
often has the ability to bind to different classes of peptide ligands (Birrane et al., 2003; Kim and 
Sheng, 2004; Madsen et al., 2005; Nourry et al., 2003; Tonikian et al., 2008; Vaccaro et al., 
2001).  The side chains of the peptide at positions 0 (C-terminus) and -2 make direct contact 
with the PDZ domain, whereas the side chains at position -1 and -3 are solvent accessible  
(Novak et al., 2002).  The residues at positions -1 and -3 have few contacts with the PDZ 
domain, thus substitution mutations at these sites generally do not affect binding (Morais-
Cabral et al., 1996; Niethammer et al., 1998; Pan et al., 2007; Songyang et al., 1997; Valiente 
et al., 2005).  The residue at position -2 is important in PDZ domain and ligand interactions 
because this residue is stabilized by hydrogen bonds with specific amino acids in the β2 and α2 
regions of the PDZ domain (Figure 1.12D) (Dobrosotskaya, 2001; Doyle et al., 1996; Songyang 
et al., 1997).  The first residue of the α2 domain (α2-1) of the PDZ domain is crucial in 
determining the specificity of that PDZ domain (Doyle et al., 1996; Morais-Cabral et al., 1996).  
For example, class I peptides contain a Ser/Thr residue at the -2 position of the peptide ligand 
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and this makes a hydrogen bond with the N-3 of the His positioned in the α2-1 of a class I PDZ 
domain (Figure 1.12B-D and Figure 1.13A, purple) (Doyle et al., 1996; Nourry et al., 2003; 
Novak et al., 2002).  For class II PDZ domains, a second hydrophobic pocket is created to 
accommodate the aromatic or hydrophobic residue at position -2 of the ligand (Table 1.2) 
(Nourry et al., 2003).  Therefore, α2-1 is a Val/Ile residue (Daniels et al., 1998; Im et al., 
2003).  For class III peptides, a Tyr residue is often present at the α2-1 position because a 
hydroxyl group is required to form hydrogen bonds with the negatively charged residue at 
position -2 of the ligand (Table 1.2) (Tochio et al., 1999).  Therefore, the residue positioned -2 
of the peptide ligand are important in determining the specificity of binding to PDZ domains.  
In addition, residues more N-terminal of the peptide ligand are expected to play supplementary 
roles in fine-tuning the specificity of PDZ domain binding.   
Class I and II PDZ domains are the most abundant classes, whereas the remaining 
classes are less common and often show conflicting binding properties (Bezprozvanny and 
Maximov, 2001).  The last class of PDZ binding domains are not well defined as there are not 
many examples representing them.  Additionally, many review articles claim that there are only 
three classes of PDZ domains (Jeleń et al., 2003; Nourry et al., 2003) and therefore class IV 
PDZ domains may be the exception rather than the rule.  Class IV PDZ domains do not bind the 
traditional small hydrophobic residue such as the Val residue at position 0 found in class I, II 
and III ligands.  Instead, they preferentially bind a terminal Cys or a hydrophilic residue (Table 
1.2) (Borrell-Pagès et al., 2000; Maximov et al., 1999; Vaccaro et al., 2001).  Some examples 
of the class IV PDZ domains include the first PDZ domain in the Mint1 protein, which 
preferentially binds to the C-terminal end of N-type Ca2+ channel (-DHWC-COOH) (Maximov 
et al., 1999).  Although there is no crystal structure showing these interactions, it is believed 
that the Leu in position α2-1 is also important in providing specificity to ligand binding and 
makes contact with the -2 His of the peptide ligand (Maximov et al., 1999).  Crystal structures 
are needed for these PDZ domains complexed with ligands in order to further analyse their 
binding specificities. 
MAGI PDZ domains are composed mainly of class I PDZ domains because most of 
them contain a His residue at position α2-1 (Figure 1.14, purple).  The PDZ0 domain of the  
β1 β2 β3
β4 β5 α β6
Figure 1.14:  CUSTLAW sequence alignment of the MAGI PDZ domains. sequence
alignment of the PDZ domains of MAGI-1 (MG1, NP_056335), MAGI-2 (MG2, NP_036433)
and MAGI-3 (MG3, AF213259).  Most of the PDZ domains of MAGI-2 are of class I with the
anomaly being PDZ0.  The MAGI PDZ domains are more similar with respect to homologous
PDZ domains of other MAGI proteins than they are with respect to the PDZ domains within an
individual MAGI protein. The well conserved basic residue, and the GFGF motif forming the
carboxylate binding loop, are boxed in red.  The carboxylate binding loop forms a hydrophobic
pocket that accommodates the 0 residue of the peptide.  The α2-1 His residue that makes
contact with the -2 position of the peptide, is highlighted in purple.
+
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MAGI proteins is quite different in sequence in that it has diverged from the GFGF motif when 
compared to PDZ1-PDZ5 of MAGI-2 (G-Ψ/Ω-L-G-Φ, where Ω-hydrophilic and Φ-
hydrophobic) (Figure 1.14, red) and it has an Arg, Ile or Asn residue at position α2-1, 
respectively (Figure 1.14, purple).  MAGI PDZ domains have been shown to bind a variety of 
class I peptides (Adamsky et al., 2003; Deng et al., 2006; Dobrosotskaya and James, 2000; 
Valiente et al., 2005; Vazquez et al., 2001; Wu et al., 2000a, 2000b; Xu et al., 2001) including 
the C-terminal PDZ binding motif of PTEN (ITKV-COOH), which has been shown to bind to 
the PDZ2 of all MAGI proteins (Dobrosotskaya et al., 1997; Wu et al., 2000a, 2000b).  The 
PDZ domains of MAGI have not been shown to bind to any other classes of ligands.  Also, no 
protein has been shown to bind to any of the PDZ0 domains.   Therefore, binding of ligands to 
the MAGI PDZ domains are hypothesized to be to class I peptides, however other classes are 
also possible as PDZ domains often exhibit dual specificities. 
Mutational analysis where PDZ domains are mutated as to abolish binding can give 
insight about the importance of specific interactions between PDZ domains and their respective 
peptide ligands.  Class I PDZ domains contain a His residue, the first residue in the α2-1 PDZ 
domain, important for making contact with Ser/Thr at the -2 position of Class I peptides.  This 
His residue is highly conserved amongst class I PDZ domains (Doyle et al., 1996; Morais-
Cabral et al., 1996).  The N-3 from the His residue makes hydrogen bonds with the hydroxyl 
groups of Ser/Thr -2 position of the peptide ligand (Doyle et al., 1996; Morais-Cabral et al., 
1996; Novak et al., 2002) (Figure 1.14D, purple).  Previous studies have used mutation of this 
His to Leu to abrogate binding (Dobrosotskaya, 2001; Doyle et al., 1996).  Therefore a 
mutation of this residue should abolish binding to class I peptides.  Similar contacts exist in 
most PDZ domains and therefore, similar point mutations can abolish binding while still 
maintaining the integrity of the tertiary structure of the PDZ domains. 
Mutations in the C-terminal PDZ binding motif of the peptide ligand can also abolish 
binding.  One of the most common mutations is of the terminal Val residue (0 position) to an 
Ala residue since this will often abolish binding of a Class I, II or III ligand to its PDZ domain 
(Jeleń et al., 2003; Valiente et al., 2005).  Another residue in the ligand that is critical for 
making contact with the PDZ domain is the residue at the -2 position (a Thr/Ser in Class I 
ligands).  A point mutation changing this residue to an Ala, or any residue that cannot maintain 
the hydrogen bond with the N3 of the highly conserved His residue at position α2-1 will abolish 
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binding (Dobrosotskaya, 2001; Jemth and Gianni, 2007).  Discrete mutations that can abolish 
binding between PDZ domains and their respective ligands are useful in determining how loss 
of interactions can affect cell signalling. 
 
1.4.3.2 PDZ domains also bind lipids  
PDZ domains have recently been shown to have the ability to interact with 
phosphatidylinositol lipids and their phosphorylated derivatives (Izawa et al., 2008; Kachel et 
al., 2003; Mortier et al., 2005; Pan et al., 2007; Sugi et al., 2008; Zimmermann, 2006).  PDZ 
domain and lipid interaction has been implicated in receptor signal transduction, membrane 
trafficking, cytoskeleton remodelling and nuclear processes (Mortier et al., 2005; Wu et al., 
2007; Zimmermann et al., 2002, 2005).  PDZ domain interaction with phosphorylated 
phosphoinositides not only provides a mechanism of protein localization to the plasma 
membrane, it may provide a mechanism to respond to sensing of phosphorylated 
phosphoinositide signalling (Wu et al., 2007).  The binding of PDZ domains to lipids is a novel 
interaction that is just now emerging. 
Studies have suggested different mechanisms of interaction between PDZ domains and 
their lipids.  The first mechanism involves positively charged residues located on the surface of 
the PDZ domain that are believed to interact electrostatically with the negatively charged lipids 
of the plasma membrane (Mortier et al., 2005; Sugi et al., 2008; Zimmermann et al., 2002, 
2005).  This interaction often seems to compete with peptide ligand binding, leading to the 
suggestion that the lipid binding domain and peptide binding site overlap (Kachel et al., 2003; 
Sugi et al., 2008; Zimmermann et al., 2002, 2005).  Studies have found that the PDZ1 domain 
of syntenin-1 bound more strongly to phosphatidylinositol (3,4) bisphosphate (PI3,4P2), and 
that the PDZ2 domain bound more strongly to the syndecan receptor, suggesting that syntenin-1 
may be recruited to the membrane through binding of PDZ1 to the plasma membrane as well as 
through binding of PDZ2 to the receptor (Mortier et al., 2005; Sugi et al., 2008; Zimmermann 
et al., 2002, 2005).  This same study showed that PDZ binding to lipids is strongest when the 
PDZ domains of syntenin-1 are expressed in tandem (Mortier et al., 2005).  Also of importance, 
the PDZ domains of syntenin-1 have been shown to interact with the highest affinity for 
PI3,4P2, and with less affinity towards other bisphosphorylated and trisphosphorylated lipids, 
and showed no binding of phosphatidylinositol or mono-phosphorylated phosphoinositides 
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(Mortier et al., 2005).  Therefore PDZ domains can interact with the lipids of the plasma 
membrane and do exhibit specificity when binding to lipids.   
Recent structural studies of syntenin-1 revealed one mechanism of PI3,4P2 binding to 
the first PDZ domains (Sugi et al., 2008).  Positively charged residues, and residues capable of 
forming hydrogen bonds, are positioned close to α2-helix of the PDZ domain (Sugi et al., 
2008).  These residues are responsible for making contacts with negatively charged phosphates 
found in the lipids (Sugi et al., 2008).  The positively charged residues in syntenin-1 important 
in making interactions with the plasma membrane are Lys-214 and Lys-250, which are located 
in the β5/α2 (Figure 1.15A) (Sugi et al., 2008).  Mutations in these residues abolished PI4,5P2 
binding by syntenin-1 (Mortier et al., 2005; Zimmermann et al., 2005).  The hydrophobic 
pocket of the PDZ domain, can bind the diacylglycerol moiety of PI4,5P2 (Figure 1.15A) (Sugi 
et al., 2008).  Therefore, it is hypothesized  that the diacylglycerol moiety can fit into the ligand 
binding groove, in agreement with the previous studies which show competitive binding 
between PI4,5P2 and peptide ligands (Mortier et al., 2005; Sugi et al., 2008; Zimmermann et 
al., 2005).  These studies have shown that the PDZ domain of syntenin-1 has the ability to 
interact electrostatically with the plasma membrane and the membrane lipid can insert itself 
into the hydrophobic pocked of the PDZ domain, competing with peptide ligand interactions. 
In a similar fashion, the PDZ domain of partitioning-defective protein-3 has been shown 
to bind to inositol phosphate (Wu et al., 2007).  Three positively charged residues in the PDZ2 
domain of partitioning-defective protein-3 are important in binding to phosphoinositol (Wu et 
al., 2007).  These positively charged residues were located in the β1/β2 and α2/β6 loop, which 
is believed to be responsible for binding to the phosphoinositol 3-phosphate head group (Wu et 
al., 2007).  Also, a membrane insertion loop, containing hydrophobic residues (Leu-494, Pro-
495, Ile-500) between the positively charged cluster and lipid head binding pocket, was capable 
of inserting in the plasma membrane (Wu et al., 2007).  These positively charged residues do 
not necessarily coincide with the positively charged residues found in syntenin-1 above and 
therefore may confer the specificity required to bind to phosphoinositol rather than PI4,5P2. 
Figure 1.15:  Mechanisms by which PDZ domains are able to interact with
phospholipids.  A, Spacefill model of the first PDZ domain of syntenin-1.  Syntenin-1
PDZ1 domain can interact electrostatically through the positively charged residues on the
surface of the PDZ domain and the negatively charged lipid heads.  Phospholipids (PIP2) can
bind in the hydrophobic groove and compete for ligand binding.  Blue indicates positively
charged residues at the surface whereas red depicts negatively charged residues (used with
permission from Sugi et al., 2008).  B, The PDZ domain of PICK1 is hypothesized to
contain a Cys-Pro-Cys motif that embeds itself into the membrane, orienting positively
charged residues on the surface of the PDZ domain to make contact with the negatively
charged lipids within the plasma membrane (used with permission from Pan et al., 2007).
This interaction does not compete for the peptide binding groove.
B
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A second PDZ-lipid binding mechanism involves a Cys-Pro-Cys motif that may insert 
into the plasma membrane, exposing a positively charged surface of the PDZ domain to interact 
with the plasma membrane (Figure 1.15B) (Pan et al., 2007).  Protein interacting with C kinase-
1 is a protein that contains an N-terminal PDZ domain responsible for localization to the plasma 
membrane (Jin et al., 2006; Pan et al., 2007; Xu and Xia, 2006). The Cys-Pro-Cys motif 
interaction, in addition to several positively charged residues (Arg-76, Lys-79 and Lys-81) 
located in the β5 (βE) and β5/α2 (βE/αB) loop, are believed to be responsible for the 
localization of protein interacting with C kinase 1 to the plasma membrane (Pan et al., 2007).  
The model proposes that the Cys-Pro-Cys motif, located in the β2/β3 (βB/βC) loop, inserts into 
the lipid membrane, while nearby positive residues on the PDZ domain interact with the 
negatively charged lipids (Pan et al., 2007).  Unlike the studies mentioned above, this lipid 
binding site does not overlap with the peptide ligand binding site because peptide binding can 
still occur (Pan et al., 2007).  The positively charged residues responsible for making contact 
with the plasma membrane are on a distant, opposite surface of the peptide ligand binding 
groove (Pan et al., 2007).  Cys residues are potential sites of palmitoylation (reviewed in 
Nadolski and Linder, 2007) and the authors did not rule out this option in the above model.  
Therefore, this model proposes that a Cys-Pro-Cys motif, in addition to positively charged 
residues on the surface of the PDZ domain, interact with the lipids within the plasma 
membrane. 
In summary, PDZ domains can interact with lipids of the plasma membrane (Mortier et 
al., 2005; Pan et al., 2007; Wu et al., 2007; Zimmermann et al., 2002, 2005).  These 
interactions have been shown to be important in protein localization to the plasma membrane 
and it has also been shown that PDZ domains can bind to a variety of phosphoinositides 
including inositol phosphate, phosphoinositol, mono-, bi- and triphosphorylated 
phosphoinositides.  So far, studies have shown two mechanisms of localization to the plasma 
membrane; 1) through electrostatic interactions (Mortier et al., 2005; Sugi et al., 2008; Wu et 
al., 2007; Zimmermann et al., 2002, 2005) and 2) through Cys-Pro-Cys motif insertion (Pan et 
al., 2007).  Whatever the mechanism, PDZ domain interaction with the plasma membrane has 
been implicated in many important functions such as receptor signal transduction, membrane 
trafficking, cytoskeleton remodelling and nuclear processes (Mortier et al., 2005; Pan et al., 
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2007; Wu et al., 2007; Zimmermann et al., 2002, 2005).  Therefore, PDZ domain interaction 
with the plasma membrane is a physiologically important interaction in cells. 
 
1.4.4 GARP C-terminal sequence 
 The GARP C-terminal sequence, located at the C-terminal end of the MAGI-2 protein, 
is made up of 333 residues.  Our laboratory has named this region the GARP C-terminal 
sequence because it is rich in Gly, Ala, Arg and Pro residues and it is unique to MAGI-2.  Basic 
local alignment search tool is an algorithm for comparing primary amino acid sequences and 
matching these with other sequences that share homologies (Altschul et al., 1990).  According 
to a basic local alignment search sequence search, the GARP C-terminal sequence of MAGI-2 
(amino acids 1233-1455) had no sequence homology with any other sequences nor does it 
contain any putative conserved domain sequences.  Therefore, the GARP C-terminal sequence 
of MAGI-2 is unique and has no known function. 
 Zonnula occulens is a MAGUK scaffolding protein that is important in the maintenance 
of tight junctions and cellular polarity (Willott et al., 1993).  The last 994 residues are acidic 
and Pro rich.  Although the C-terminal ends of Zonnula occulens proteins do not have 
characteristic protein binding domains, it has been shown to bind both cytosolic, cytoskeletal 
and transmembrane proteins, and disruption of these interactions has been shown to disrupt the 
integrity of tight junctions (reviewed in Gonzalez-Mariscal et al., 2000). Also of note, the C-
terminal end contains many PXXP motifs which have been shown to bind to selected SH3 
domains (Katsube et al., 1998).  The C-terminal end of Zonnula occulens lacks a protein 
binding domain and is rich in Pro residues much like that of the GARP C-terminal sequence of 
MAGI-2.  Therefore, the GARP C-terminal sequence may have similar functions as that of the 
C-terminal end of the Zonnula occulens MAGUK scaffolding proteins.  
 
1.5 MAGI scaffolding proteins 
 MAGI is part of a subfamily of MAGUK scaffolding proteins which contains three 
members:  MAGI-1, -2 and -3 (Dobrosotskaya et al., 1997; Wu et al., 2000b).  As mentioned 
above, the MAGI family of proteins are inverted with respect to their family member 
counterparts.  In addition to sharing great sequence similarity, these genes are alternatively 
spliced (Figure 1.16), adding another degree of complexity in distinguishing between these 
38 
 
protein variants (Dobrosotskaya et al., 1997; Shoji et al., 2000; Sierralta and Mendoza, 2004; 
Wood et al., 1998).  Much of the published literature have used antibodies that do not 
discriminate between the MAGI family, nor their individual splice variants (Subauste et al., 
2005; Wood et al., 1998).  Therefore the different MAGI proteins are difficult to discriminate. 
MAGI-1 has three alternatively spliced partners: MAGI-1a, -b and -c, all of which have 
different C-terminal ends (Figure 1.16A) (Dobrosotskaya et al., 1997; Laura et al., 2002).  
These splice variants have been shown to be both tissue specific and localized to different 
compartments of the cell (Dobrosotskaya et al., 1997; Laura et al., 2002).  The MAGI-2 gene 
has also been shown to have three different promoters on distinct exons and their protein 
products have been named MAGI-2α, -β and -γ (Figure 1.16B) (Deng et al., 2006).  According 
to the RefSeq database, MAGI-3 has two isoforms which differ in the C-terminal ends (Figure 
1.16C) (NP_001136254 and NP_690664, http://www.ncbi.nlm.nih.gov.cyber. 
usask.ca/RefSeq/).  It is not uncommon for genes encoding PDZ domains to be alternatively 
spliced (Sierralta and Mendoza, 2004).  Alternatively spliced genes allow for multiple mRNA 
to be formed from one gene which adds to the eukaryotic genetic diversity.  Often, 
differentially spliced variants of a protein will be localized to specific tissues, restricted to 
discrete areas of the cell and may have different or similar functions than their spliced variants.  
Little is known about the mechanisms that control the specificity of MAGI expression in a cell 
or at a particular stage of development.  There is also little known about the roles of the MAGI 
proteins encoded by these splice variants.  The ability to discriminate between the different 
MAGI proteins and the different variants is important to distinguish which MAGI protein(s) are 
performing a given function at a given time. 
MAGI proteins are expressed ubiquitously throughout mammalian tissues, with 
different expression profiles for each family member.  Mammalian expression of MAGI-1 is 
found in the kidney, liver, lung, testis, heart, skeletal muscle and brain (Dobrosotskaya et al., 
1997; Laura et al., 2002).  MAGI-2 is expressed in the tissues in the brain and liver as well as in 
epithelial cells (Deng et al., 2006; Hu et al., 2007; Shoji et al., 2000; Vazquez et al., 2001; 
Wood et al., 1998; Wu et al., 2000a).  MAGI-3 is expressed in most tissues with the exception  
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Figure 1.16:  MAGI proteins encoded by alternative spliced mRNAs.  A, MAGI-1
variants encoded by alternative splicing: MAGI-1a, b and c (modified from Laura et al.,
2002).  B, MAGI-2 variants encoded by alternative splicing:  MAGI-2 α, β and γ (modified
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of skeletal muscle, leukocytes and spleen (Franklin et al., 2005; Wu et al., 2000b).  Therefore, 
MAGI proteins are collectively found throughout mammalian tissues. 
Cellular localization of the MAGI proteins is prominent at the plasma membrane at 
areas of cell-cell communication, such as neuronal synapses and tight junctions (Laura et al., 
2002; Wu et al., 2000a, 2000b).  The MAGI family of scaffolding proteins have also been 
found to be present diffusely throughout the cytoplasm, as well as in the nucleus (Adamsky et 
al., 2003; Deng et al., 2006; Wu et al., 2000a, 2000b).  MAGI-2 has been shown to be localized 
mostly at the plasma membrane in the cell body, as well as in the dendrites and the synaptic 
area of neurons (Hirao et al., 1998; Shoji et al., 2000).  Therefore, although the main purpose of 
the MAGI scaffolding proteins may be to act as scaffolding molecules at the plasma membrane, 
they may have additional scaffolding functions in the cytoplasm as well as the nucleus. 
 MAGI is not known to be lipid modified or strongly anchored to the plasma membrane, 
and the lack of strong anchorage to the plasma membrane allows for more rapid translocation 
within the cell in response to transient stimulation (Xu et al., 2001).  MAGI proteins interact 
directly or indirectly with many cell surface receptors and cytoskeletal components, which may 
provide a mechanism for MAGI localization to the plasma membrane (Adamsky et al., 2003; 
Buxbaum et al., 2008; He, 2006; Hirao et al., 1998; Ide et al., 1999; Kawajiri et al., 2000; Shoji 
et al., 2000; Wood et al., 1998).  For example, the PDZ1 domain of MAGI-3 has been shown to 
interact with the cell surface β1-adrenergic receptor (He, 2006).  A mutation in the C-terminal 
PDZ binding motif of the receptor causes a redistribution of MAGI-3 to the nucleus (He, 2006).  
Therefore, binding of MAGI to a receptor at the cell surface may be a prominent mechanism by 
which MAGI proteins are localized to the plasma membrane.  Also, studies have shown that all 
MAGI-1 splice variants are capable of localizing to the plasma membrane however, a truncated 
mutant containing only the sequences encoding PDZ0-WW2 was unable to localize to the 
plasma membrane (Laura et al., 2002).  The same study found that truncated proteins 
containing combinations of PDZ1 through PDZ5 were capable of localizing to the plasma 
membrane (Laura et al., 2002).  Therefore, the PDZ1-PDZ5 domains are necessary for MAGI-1 
localization to the plasma membrane (Laura et al., 2002).  This finding is not surprising since it 
is well documented that PDZ domains  interact with various cell surface receptors. 
Another mechanism by which MAGI proteins could localize to the plasma membrane is 
through association with the phosphorylated phosphoinositides of the plasma membrane 
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through their PDZ domains.  Glutathione S-transferase (GST) fused MAGI-3 has been shown 
to interact with PI3,4P2 with low affinity (Kd of approximately 1 mM) (Mortier et al., 2005).  
However, another study showed no interaction of MAGI-3 individual PDZ domains 3,4 and 5 
with liposomes coated with PI3,4,5P3 (Wu et al., 2007), a different lipid than mentioned above.  
This last study was performed with individual GST fused MAGI-3 PDZ domains and perhaps 
this specific PDZ/lipid interaction requires the tandem expression of the MAGI-3 PDZ 
domains, which has been demonstrated in previous studies (Zimmermann et al., 2002, 2005).  
Also, both studies cited above tested binding of MAGI-3 PDZ domains against two different 
types of lipids, and MAGI-3 PDZ domains may bind specifically to PI3,4P2 and not PI3,4,5P2 
(Mortier et al., 2005; Wu et al., 2007).  Therefore, MAGI PDZ domains may be responsible for 
localizing MAGI scaffolding proteins to the plasma membrane through interactions with cell 
surface receptors or by direct binding to the lipids of the plasma membrane. 
MAGI proteins have been shown to share high sequence similarity (Figure 1.6) (Wu et 
al., 2000b) and therefore bind to many of the same proteins (Figure 1.17).  For example, the 
PDZ1 domain of MAGI-2 and MAGI-3 have both been shown to bind to the β1-adrenergic 
receptor, a cell surface receptor involved in neuronal signalling (He, 2006; Xu et al., 2001).  
The PDZ5 domains of the MAGI proteins have been shown to associate with α- and  β- catenin, 
cytoskeletal proteins (Kotelevets et al., 2005; Subauste et al., 2005).  PTEN has also been 
shown to interact with all MAGI proteins through their PDZ2 domain (Kotelevets et al., 2005; 
Wu et al., 2000a, 2000b).  In addition, MAGI proteins have been shown to interact with various 
cell surface receptors such as receptor tyrosine phosphatase β, the ErbB4 RTK and N-methyl-
D-aspartate receptors, all of which mediate cell signalling pathways (Adamsky et al., 2003; 
Buxbaum et al., 2008; Hiaro et al., 1998).  Similar binding partners to MAGI domains is not 
always the case between MAGI proteins.  For example, the PDZ1 domain of MAGI-2 and 
MAGI-3 has been found to bind to the C-terminal, cytoplasmic domain of the transforming 
growth factor-α precursor however, MAGI-1 does not (Franklin et al., 2005).  Therefore, 
determining the protein interactions of one of the MAGI proteins may generally function as a 
working model for the MAGI group of scaffolding proteins.  In addition, the  
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Figure 1.17:  MAGI interacting partners.  The MAGI family members share high sequence
similarity and therefore bind to many  of the same proteins, with  some exceptions.  The MAGI
proteins have been shown to interact with various cell surface receptors such as the receptor
protein tyrosine phosphatase (RPTP), ErbB4 RTK and N-methyl-D-aspartate (NMDA)
receptor through their PDZ binding motifs.  All of the PDZ5 domains of the MAGI proteins
have been shown to associate with the cytoskeletal element β-catenin and MAGI-2 has been
shown to also interact with α-catenin.  MAGI-2 and MAGI-3 PDZ1 domains have been shown
to bind brain angiogenesis inhibitor 1 (BAI-1), a protein involved in inhibiting brain
angiogenesis.  MAGI-2 and MAGI-3 PDZ1 domain has also been shown to bind to the
cytoplasmic domain of the pro-transforming growth factor-alpha (pro-TGFα), which is
important in localizing pro-TGFα at the proper location at the plasma membrane near its
respective receptors.  The GK domain of MAGI-2 has been shown to bind to SAP90/PSD-95-
associated protein (SAPAP), a neuroglin that promotes the clustering of receptors and is
known to associate with the plasma membrane.  The WW domains of MAGI-2 have been
shown to bind to β-dystroglycan, a cell adhesion molecule that plays a role in the organization
of the neuronal synapses.
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MAGI-2 GK domain has been shown to associate with SAP/PSD-95 associated protein, a 
neuroglin that is localized to the plasma membrane and is involved in the clustering of receptors 
(Deng et al., 2006).  The WW domains of MAGI-2 have also been shown to bind to β-
dystroglycan, which are required for the structural integrity of neuronal synapses (Deng et al., 
2006).  Therefore, MAGI proteins have been shown to bind to many of the same proteins 
similarly. 
 
1.6 Regulation of PTEN by MAGI-2 proteins 
MAGI proteins have already been identified as scaffolding molecules involved in many 
cell signalling pathways, localized in areas such as tight junctions in cells.  PTEN has been 
found in two forms in cells; as a monomeric 65 kDa unit and in a high molecular weight 
complex of approximately 600 kDa (Vazquez et al., 2001).  This 600 kDa complex has been 
termed the PTEN-associated complex (PAC) and it is hypothesized that upon 
dephosphorylation and activation, PTEN is recruited to the plasma membrane to a high 
molecular weight protein complex, where it is believed to gain access to its lipid substrates 
(Valiente et al., 2005; Vazquez et al., 2001; Wu et al., 2000a, 2000b).  The PAC is believed to 
contain PTEN associated to a PDZ containing scaffold, such as MAGI-2, and the p85 protein 
(Vazquez et al., 2001).  It has been previously shown that p85 can bind directly to PTEN and 
positively regulate its lipid phosphatase activity towards PI3,4,5P3 (Chagpar, 2004). This new 
regulatory function for p85 may be necessary in PTEN mediated attenuation of Akt signalling 
(Chagpar, 2004; Pastor, 2008).  All MAGI proteins have been shown to co-localize with PTEN 
at tight junctions in epithelial cells, areas that are known to have activated Akt (Dobrosotskaya 
et al., 1997; Wu et al., 2000a, 2000b).  Therefore, this suggests that MAGI-2, PTEN and p85 
are able to co-localize at the plasma membrane, at appropriate sites in order to gain access to 
lipid substrates and attenuate PI3K/Akt signalling.  
PTEN has been shown to bind to the PDZ2 domain of all MAGI proteins 
(Dobrosotskaya et al., 1997; Wu et al., 2000a, 2000b).  In order for PTEN to interact with 
MAGI-2, PTEN must be dephosphorylated at Thr residues 382 and 383, thereby rendering it in 
its open, active conformation (Tolkacheva et al., 2001; Vazquez et al., 2000).  Binding of 
PTEN to the PDZ domain of MAGI proteins has been shown to increase the half-life of PTEN 
(Georgescu, 2008; Valiente et al., 2005; Wu et al., 2000a, 2000b).  This is probably due to the 
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fact that the C-terminal PTEN ubiquitination site is protected from ubiquitination when the 
nearby PDZ binding motif binds to the PDZ2 domain of MAGI (Wang and Jiang, 2008; Wang 
et al., 2007).  Also, a common PTEN mutation found in tumor cells is one that results in 
truncation of its C-terminal end, such that it lacks the PDZ binding motif (Vazquez et al., 
2000).  This PTEN mutant has phosphatase activity, yet is unable to attenuate Akt effectively, 
probably due to an increase in ubiquitination thereby decreasing PTEN half-life (Vazquez et al., 
2000, 2001; Wang et al., 2007; Wu et al., 2000a, 2000b).  Therefore, PTEN requires binding to 
a PDZ scaffolding protein, such as MAGI-2, for proper localization within the plasma 
membrane and protection against ubiquitination for effective attenuation of PI3K/Akt 
signalling. 
MAGI-2 has been shown to be present at tight junctions, where it is present in the E-
cadherin-β-catenin-α-catenin complex (Figure 1.18).  Catenins play a pivotal role in E-cadherin 
function in that they link cadherins to cytoskeletal components of the cell, such as actin (Ozawa 
et al., 1990).  PTEN is hypothesized to be located at these tight junctions through binding of the 
PDZ2 domain of MAGI-2 (Subauste et al., 2005; Wu et al., 2000a).  A cytoskeletal mutation 
that disrupts these tight junction complexes and causes improper localization of MAGI-2, 
showed elevated Akt activation and no PTEN protein expression, despite normal PTEN mRNA 
levels (Subauste et al., 2005).  These results suggest that PTEN is unable to bind to MAGI-2, 
thereby rendering PTEN ubiquitination sensitive such that it is quickly degraded by the 
proteosome (Subauste et al., 2005).  Many tumor cells have found mRNA levels of PTEN to be 
normal however, without any protein expression (Bastola et al., 2002; Dahia et al., 1999).  It is 
thought that without proper localization of “open” and activated PTEN to a PDZ domain, PTEN 
is unstable and quickly degraded by the proteosome (Rahdar et al., 2009; Subauste et al., 2005; 
Vazquez et al., 2000; Wu et al., 2000a).  Therefore, MAGI-2 is important in forming 
complexes at tight junctions to ensure the proper localization of PTEN upon its activation. 
The p85 regulatory subunit has been shown to bind directly to β-catenin in a 
phosphorylation-dependent manner, and is present in the E-cadherin complex (Woodfield et al., 
2001).  Also of significance is the fact that EGFR is present in an E-cadherin complex through 
direct binding to β-catenin upon EGF stimulation (Hoschuetzky et al., 1994).  It is well  
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Figure 1.18:  Proposed model of MAGI-2 scaffolding functions in the PTEN-mediated
attenuation of PI3K/Akt signalling. The PAC has been speculated to redistribute PTEN to
the plasma membrane at the proper location to gain access to its lipid substrates.  MAGI-2 has
been shown to be present at tight junctions, complexed with E-cadherin through β-catenin.
EGFR and p85 have also been shown to bind to β-catenin and be present in the E-cadherin/β-
catenin complex.  Upon growth factor stimulation, EGFRs dimerize and phosphorylated
receptor recruits the PI3K complex to the plasma membrane, generating PI3,4,5P3.  Lipid
second messenger PI3,4,5P3 recruits and activates Akt, which activates proteins that promote
anti-apoptotic signalling, cell cycle entry, cellular migration and cellular survival.  Upon
growth factor stimulation, PTEN is believed to localize to the plasma membrane
electrostatically and through association with the PAC.  The PAC is believed to contain p85
and a PDZ scaffolding protein, such as MAGI-2. PTEN has been shown to associate through
its C-terminal PDZ binding motif with the PDZ2 domain of MAGI-2.  p85, a positive regulator
of PTEN, may bind directly to PTEN, or to one of the WW domains of MAGI-2.  Therefore
MAGI-2 may act as a scaffolding protein, bringing together proteins responsible for the
attenuation of the PI3K/Akt signalling pathway.
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established that EGF treatment of epithelial cells causes destabilization of cadherin-based cell 
adhesion complexes, which leads to the reduction of intercellular adhesion and increased cell 
motility (Fujii et al., 1996; Hazan and Norton, 1998).  The human hepatocarcinoma tumor cell 
lines (MHCC-97H, BEL-7404, HepG2) lack MAGI-2 expression and also have elevated Akt 
and focal adhesion kinase signalling (Hu et al., 2007), a phenotype reminiscent of PTEN null 
cells (Dahia et al., 1999; Hu et al., 2007; Subauste et al., 2005).  Akt and focal adhesion kinase 
signalling pathways are known to be downregulated by PTEN (reviewed in Hlobilková et al., 
2003).  Once these MAGI-2 null cells were transfected with MAGI-2 cDNA, PTEN protein 
expression was restored, Akt and focal adhesion kinase signalling was attenuated, and cell 
migration was inhibited (Hu et al., 2007).  Therefore, the MAGI-2 complexes formed at tight 
junctions in cells plays a pivotal role in the ability of PTEN to downregulate Akt signalling in 
cells. 
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2.0 RATIONALE AND OBJECTIVES 
We hypothesize that upon growth factor stimulation, PTEN is recruited to the PAC, 
which has been hypothesized to contain MAGI-2 and p85 (Vazquez et al., 2000).  The PAC 
may also contain EGFR and/or PDGFR, signalling molecules involved in the activation of the 
PI3K/Akt signalling pathway.  Recruitment to the PAC may be important in bringing PTEN in 
close proximity to its lipids substrates in order to effectively attenuate Akt signalling.  
Therefore, the MAGI family of scaffolding proteins may improve the efficiency of PTEN 
signalling through the assembly of a high molecular weight complex at the plasma membrane at 
sites of RTK-mediated PI3K lipid product generation, where PTEN would have access to its 
substrates. 
 
2.1 Hypothesis 
 MAGI-2 is the scaffolding protein responsible for bringing together proteins that both 
activate (RTKs and PI3K) and attenuate (PTEN and p85) Akt signalling, to ensure that cellular 
proliferation and cellular survival signals are transient. 
 
2.2 Objectives 
 The goal of this thesis was to determine if the MAGUK scaffolding protein, MAGI-2, 
can interact with proteins involved in the PI3K/Akt signalling pathway, such as p85, EGFR, 
PDGFR, as well as to confirm PTEN binding.  We chose MAGI-2 over MAGI-1 and MAGI-3 
because it has been hypothesized to be present in the PAC (Vazquez et al., 2000) and for ease 
of cloning. 
1) To create clones of MAGI-2 full length (FL) and its respective domains tagged to a Myc 
epitope for eukaryotic protein expression. 
2) To create clones of MAGI-2 FL and its respective domains fused to GST for bacterial 
protein expression. 
3) Through pull-down experiments, determine if MAGI-2 domains can associate with proteins 
involved in the PI3K/Akt signalling pathway (PTEN, p85, EGFR and PDGFR).   
A) First, to test whether the pull-down system is working properly, we would confirm 
PTEN binding to the PDZ2 domain of MAGI-2 (Valiente et al., 2005; Vazquez et al., 2000, 
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2001; Wu et al., 2000a).  PTEN contains a C-terminal binding motif (QITKV-COOH, a class I 
ligand). 
B) We hypothesize that one of the MAGI-2 PDZ domains could bind to the C-terminal 
PDZ binding motifs of PDGFR (EDSFL-COOH, a class I ligand) and/or EGFR (EFIGA-
COOH, a class II ligand).   
C) We hypothesize that p85 may bind through one of its two Pro rich regions [P1: 
amino acids 82-96 (SPPTPKPRPPRPLP, class II and III, respectively) and P2: amino acids 
300-314 (ERQPAPALPPKPPKP, both of which are class II) (Kapeller et al., 1994)] to one or 
both of the WW domains of MAGI-2. 
4) Through immunoprecipitation experiments, determine if Myc-MAGI-2 FL can associate 
with proteins involved in the activation and/or attenuation of PI3K/Akt signalling in cells 
(PTEN, p85, EGFR and PDGFR). 
5) To create a MAGI-2 specific antibody that can distinguish MAGI-2 from its MAGI family 
counterparts. 
 The information obtained from these experiments will give us a better understanding of 
the role of the MAGI scaffolding proteins in the attenuation of PI3K/Akt signalling.  From this 
data, we will be able to construct a more detailed model of PI3K/Akt signalling and its 
downregulation through PTEN.  This model can then be used to explain how MAGI scaffolding 
proteins help in bringing together counteracting cell signalling proteins and how they can 
improve the efficiency of signal termination.  Also, with a MAGI-2 specific antibody, future 
work can determine if the results obtained are specific for MAGI-2. 
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3.0 MATERIALS AND METHODS 
 All of the chemicals were of analytical grade or higher, and were purchased from VWR, 
Sigma-Aldrich or BDH, unless otherwise stated.  The names and addresses of the distributors 
are listed in table 3.1.  The list of commercially available kits is listed in table 3.2.  All reactions 
were incubated at room temperature, unless otherwise stated. 
 
Table 3.1:  Names and addresses of reagent distributors. 
Company Name Address 
American Type Culture Collection Manassas, VA, USA 
Applied Biosystems Canada Streetsville, ON, Canada 
BDH, Inc. Toronto, ON, Canada 
Bio-Rad Laboratories, Ltd. Mississauga, ON, Canada 
Cedarlane Laboratories, Ltd. Burlington, ON, Canada 
EMD Chemicals®, Inc. Gibbstown, NJ, USA 
Fermentas Canada, Inc. Burlington, ON, Canada 
GE Healthcare Bio-Sciences, Inc. Baie d’Urfé, QC, Canada 
HyClone Logan, UT, USA 
Invitrogen Canada, Inc. Burlington, ON, Canada 
MacVector, Inc. North Carolina, USA 
Millipore ™ Billerica, MA, USA 
New England Biolabs, Ltd. Pickering, ON, USA 
Novagen Mississauga, ON, Canada 
PerkinElmer Life Sciences, Inc. Boston, MA, USA 
Qiagen, Inc. Mississauga, ON, Canada 
Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA 
Sigma-Aldrich Co. Oakville, ON, Canada 
VWR International Mississauga, ON, Canada 
 
Table 3.2:  Commercially available kits. 
Commercial Kit Name Company Catalogue Number 
HiSpeed Plasmid Maxi Kit Qiagen 12662 
RNeasy Mini Kit Invitrogen 74104 
Superscript™ First Strand 
Synthesis System for RT-PCR 
Invitrogen 11904-018 
QIAprep Miniprep®Spin Kit Qiagen 27106 
QIAquick Gel Extraction Kit Qiagen 28704 
QIAquick PCR Purification Kit Qiagen 27106 
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3.1 Bacterial strains and growth media 
For DNA isolation, plasmid DNA was transformed into Echerichia coli (E. coli) TOP10 
cells [F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 recA1 araD139 
Δ(araleu)7697 galU galK rpsL (StrR) endA1 nupG] (Invitrogen, Cat# C4040).  These cells are 
deficient in endonucleases and are designed to allow for stable replication of a high copy 
number of plasmids.  Cells were grown in Luria-Bertani (LB, EMD Chemicals®) broth [2.5% 
(w/v) per litre] containing 1% (w/v) bacto-trypone, 1% (w/v) NaCl and 0.5% (w/v) bacto-yeast 
extract, pH 7.0. All plasmids in this study contained the ampicillin resistance (ampR) gene; 
therefore, TOP10 cells transformed with plasmids were grown in LB containing 0.1 mg/mL 
ampicillin (LBA). 
For protein purification, plasmid DNA was transformed into E. coli BL21 cells [F- 
ompT hsdSB (rB- mB-) gal dcm (DE3)] (Novagen, Cat# 69450).  BL21 cells are deficient in 
proteases and facilitate protein overexpression and purification.  BL21 cells were grown in the 
same conditions as TOP10 cells. 
 
3.2 Cell lines and standard tissue culture conditions 
 African green monkey (Cercopithecus aethiops) kidney fibroblast-like cells (COS-1), 
mouse embryonic fibroblast cells (NIH 3T3) and human epithelial metastatic breast cancer cells 
(MCF-7) were obtained from American Type Culture Collection (CRL-1650, CRL-1658 and 
HTB-22, respectively).  Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM, 
Invitrogen) pH 7.4, supplemented with 10% fetal bovine serum (FBS, Hyclone), 1% (v/v) 
penicillin G and streptomycin [(100 units/mL penicillin G and 100 µg/mL streptomycin) (P/S, 
Invitrogen)] in a humidified incubator at 37°C with 5% CO2. 
 
3.3 Molecular cloning of MAGI-2 
 
3.3.1 Reverse-transcriptase polymerase chain reaction of MAGI-2 encoding inserts 
 In order to obtain the complementary DNA (cDNA) encoding MAGI-2 FL and MAGI-2 
domains, we used reverse-transcriptase polymerase chain reaction (RT-PCR) of RNA isolated 
from eukaryotic MCF-7 cells.  A sample of total RNA was isolated from MCF-7 cells using the 
RNeasy Mini Kit (Invitrogen), according to the supplier’s instructions.  In order to visualize the 
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extracted RNA from MCF-7 cells, the RNA was subjected to electrophoresis on an agarose gel 
containing 1% (w/v) agarose in 1.23 M formaldehyde in morpholinopropanesulfonic acid 
running buffer (20 mM morpholinopropanesulfonic acid, 5 mM sodium acetate and 1 mM 
ethylenediaminetetraacetic acid). 
 RT-PCR was performed with 0.5-5 µg total RNA, according to Superscript™ First 
Strand Synthesis System for RT-PCR (Invitrogen), using the supplied random primers, in a 
final volume of 20 µL. 
 PCR was performed with Pyrococcus furiosus (Pfu) DNA polymerase (Fermentas).  For 
Pfu driven PCR, the 10x Pfu buffer containing MgS04, supplied with the enzyme was used, 
along with deoxyribonucleoside triphosphates (dNTPs) (Amersham Biosciences).  
Concentrations of the reaction components were determined by following the manufacturer’s 
instructions.  For the amplification of the PDZ0 domain of MAGI-2, the following components 
were used in the reaction: 2 mM MgSO4, 0.2 mM dNTPs, a range of 0.1-0.3 µM of each 5' and 
3' primer, 550 ng/µL dimethyl sulfoxide, a range of 5-15 µL of total RT product template DNA 
and 2.5 Units of Pfu DNA polymerase, to a final volume of 100 µL with Pfu buffer containing 
MgSO4 and distilled water.  PCR were carried out in a Geneamp 2700 thermocycler (Applied 
Biosystems) using an intial melting step of 95°C for 4 min, followed by a 30 cycles of :  95°C 
for 30 secs (melting), 45-70°C for 45 secs (annealing) and 72°C incubation for 30 secs 
(extension).  Extension times varied depending on the size of the expected product; generally, 
Pfu driven extensions were determined using a 0.5 kb/min rule.  The reaction ended with a 
72°C for 7 min and was used immediately or stored at -20°C.   
 
3.3.2 Polymerase chain reaction of MAGI-2 encoding inserts 
 The pcDNA3 plasmid, containing the cDNA for human MAGI-2 FL (NM_012301), 
was a generous gift from Dr. Sawyers (University of California, Los Angeles, CA).  The human 
MAGI-2 cDNA was cloned into pcDNA3.3, as previously described (Wood et al., 1998; Wu et 
al., 2000a).  In order to create clones encoding MAGI-2 FL and its respective domains, MAGI-
2 was amplified by PCR using the pcDNA3-MAGI-2 plasmid as a template.  PCR primers were 
designed using MacVector software (version 9.0, MacVector Inc.).  Primers were designed to 
amplify MAGI-2 FL and to flank individual domains of MAGI-2, in order to cover all regions 
of the protein.  Primers also introduced unique restriction sites to ease cloning; 5' primers 
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introduced a BglII restriction site, whereas the 3' primers introduced an EcoRI restriction site 
(Table 3.3). 
PCR was performed with either Pfu DNA polymerase, or a recombinant form of 
Thermococcus kodakaraensis (KOD) DNA polymerase (Novagen).  For Pfu driven PCR, the 
10x Pfu buffer containing MgS04, supplied with the enzyme, was used, along with dNTPs.  
Concentrations of the reaction components were determined by following the manufacturer’s 
instructions.  For the amplification of the PDZ0 domain of MAGI-2, the following components 
were used in the reaction: 2 mM MgSO4, 0.2 mM dNTPs, 0.2 µM of each 5' and 3' primer, 550 
ng/µL dimethyl sulfoxide, 10 ng total template DNA and 2.5 Units of Pfu DNA polymerase to a 
final volume of 100 µL with 10x Pfu buffer containing MgSO4 and distilled water.  PCR were 
carried out in a thermocycler, using an intial step of 95°C for 4 min, followed by a 30 cycles of:  
95°C for 30 sec, 58°C for 45 sec, and 72°C for 30 sec.  Extension times varied depending on 
the size of the expected product; generally.  The reaction was completed with an incubation of 
72°C for 7 min and was used immediately or stored at -20°C. 
KOD DNA polymerase was used for the PCR of MAGI-2 FL because we could not get 
a PCR product with Pfu DNA polymerase.  KOD DNA polymerase was chosen, over other 
DNA polymerases, because it had a higher fidelity than Pfu DNA polymerase.  In addition, 
KOD DNA polymerase is documented to work well with long sequences (up to 6 kb) and with 
GC rich regions (the nucleotides encoding to the GARP C-terminal sequence were up to 78% 
GC in areas).  For KOD driven PCR, the 10x KOD Buffer #1 was utilized, along with dNTPs 
supplied with the enzyme.  Concentrations of the reaction components were determined by 
following manufacturer’s instructions.  For MAGI-2-FL PCR, the following components were 
used in the reaction: 1.5 mM MgCl2, 0.2 mM dNTPs, 0.4 µM of each 5' and 3' primer, 4 ng total 
template DNA and 1 Unit of KOD DNA polymerase, to a final volume of 50 µL with 1x KOD 
Buffer #1 and distilled water.  KOD driven PCR were carried out using an initial step of 97°C 
for 15 sec, followed by a 25 cycles of: 98°C for 15 sec (melting), 65°C for 5 sec (annealing) 
and 72°C for 4 sec (extension).  Extension times varied depending on the size of the expected 
product;  
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generally, KOD driven extensions were determined using a 6 kb/min rule.  The reaction ended 
with a final temperature of 72°C for 7 min and the sample was used immediately or stored at     
-20°C.  An aliquot (5 µL) of each PCR product was resolved by agarose gel electrophoresis to 
determine if the correct sized PCR product was successfully generated (section 3.3.3). 
 
3.3.3 Agarose gel electrophoresis  
Agarose gels, and low melt agarose gels, consisted of 1-1.5% agarose (w/v) in Tris-
acetate electrophoresis buffer (2 mM ethylene diamine tetraacetic acid disodium in 40 mM 
Tris-acetate) containing approximately 1% (w/v) ethidium bromide.  DNA was loaded with 
bromophenol blue (Bio-Rad) or xylene cyanole (Bio-Rad) loading dyes, depending on the size 
of the DNA fragment (bromophenol blue was used with fragments larger than 1 kb and xylene 
cyanol was used with fragments smaller than 1 kb).  Generally, 1 µL of loading dye was used 
with 10 µL volume of DNA solution and loaded into the individual wells of the agarose gel.  
Electrophoresis was performed for at least 20 min at 100 volts (V).  The gel was subjected to 
ultraviolet light in order to visualize the DNA.  The gel was photographed using a Gel-Doc 
2000 system and Quantity One Software (Bio-Rad).   
 
3.3.4 Restriction enzyme digestion of MAGI-2 PCR products 
All PCR products were purified using the QIAquick PCR purification Kit (Qiagen) 
according to supplier’s instructions, in order to remove enzymes, nucleotides, salts, primers and 
other impurities.  PCR cleaned products were eluted in 25 µL of distilled water, passed through 
the column twice to maximize the amount of DNA extracted through the column.   
PCR products of MAGI-2 FL or individual domains were digested with BglII 
(Fermentas) and EcoRI (New England Biolabs).  Generally, the entire volume of the PCR 
cleanup product from above (25 µL) was digested with a total of 20 units of each restriction 
enzyme.  The reaction proceeded in 1x One-Phor-All buffer (Amersham Biosciences) in a final 
volume of 40 µL, at 37°C for 1 hr.  In order to remove enzymes, salts, and other impurities, the 
digested product was purified according to the QIAquick PCR Purification Kit protocol.  The 
digested PCR product was eluted in 17 µL of distilled water, passed through the column three 
times. 
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3.3.5 Restriction enzyme digestion of the pMyc3 vector 
 The pMyc3 vector (2 µg) was digested with BglII and EcoRI as described for the 
MAGI-2 PCR products, and reactions were similarly subjected to a cleanup.  The pMyc3 vector 
is based on the pRc/CMV2 vector (Invitrogen, Cat# V750-20) (Chamberlain et al., 2004). 
 
3.3.6 DNA ligation of the MAGI-2 PCR products into the pMyc3 vector 
 The BglII and EcoRI digested MAGI-2 PCR products were ligated into the similarly 
digested pMyc3 vector.  DNA ligations were performed using Quick T4 DNA ligase (New 
England Biolabs) and the supplied buffer, according to manufacturer’s instructions.  Generally, 
ligation reactions were performed using 5-10 fold molar excess of MAGI-2 PCR product insert 
than pMyc3 vector, in a final volume of 20 µL.  For example, 200 ng of the 5.7 kb vector was 
ligated with 60-120 ng of the 350 bp insert.  The reaction proceeded for 15 min at room 
temperature.   
 
3.3.7 Preparation of competent cells for transformations 
 E. coli TOP10 cells were inoculated in 5 mL LB, shaking overnight at 37°C.  The next 
day, the 5 mL culture was poured into 100 mL LB and incubated in 37°C shaking incubator 
until an absorbance of 0.4 (550 nm) was reached.  The 100 mL culture was collected and 
centrifuged at 2500 x g for 15 min.  The supernatant was removed and cells were resuspended 
in 30 mL of cold, sterile RF1 buffer [100 mM RbCl, 50 mM MnCl2, 10 mM CaCl2, 15% (w/v) 
glycerol in 30 mM potassium acetate, pH 7.5] and placed on ice for 15 min.  Cells were pelleted 
as before and the supernatant was removed.  Cells were resuspended in 7.2 mL cold, sterile RF2 
buffer [10 mM RbCl, 75 mM CaCl2 and 15% (w/v) glycerol in 10 mM 
morpholinopropanesulfonic acid, pH 6.8] and placed on ice for 15 min.  Two hundred µL of the 
competent E. coli cells were aliquoted into 1.5 mL sterile tubes and frozen quickly with liquid 
nitrogen and stored at -80°C until ready to use. 
 Competent E. coli TOP10 cells were transformed with half (10 µL) of the above ligation 
reaction mixture.  Transformed cells were placed on ice for 30 min and heat shocked at 42˚C 
for 2 min.  Cells were placed on ice for 10 min and 800 µL of LB was added.  Cells were 
incubated at 37°C for 45-60 min to allow expression of the antibiotic resistant gene (ampR).  
Following incubation, the cells were centrifuged at 2500 x g, and the entire cell pellet was 
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plated onto LBA agar plates [1.5% (w/v) agar] to select for transformed E. coli cells.  Plates 
were incubated overnight at 37°C.   
 
3.3.8 Isolation of plasmid DNA from bacterial cells 
For plasmid DNA isolation from bacterial cells, individual bacterial colonies were 
selected and incubated in 5 mL (small preparations) or 250 mL (large preparations) LBA broth, 
shaking overnight at 37°C.  Small and large plasmid purification preparations were performed 
with the QIAprep® Spin Miniprep Kit or the HiSpeed Plasmid Maxi Kit (Qiagen), respectively, 
according to the manufacturer’s instructions.  Successful ligations were verified by a restriction 
enzyme digestion, followed by agarose gel electrophoresis, to verify that the expected size of 
insert and plasmid DNA were present.  The integrity of the MAGI-2 PCR inserts were verified 
by DNA sequencing once the PCR products had been inserted into a vector (National Research 
Council Canada, Plant Biotechnology Institute, Saskatoon, SK or DNA Sequencing Facility, 
The Center for Applied Genomics, Hospital for Sick Children, Toronto, ON).   
 
3.3.9 Subcloning of MAGI-2 inserts from pMyc3 into the pGEX6P1 vector 
 MAGI-2 inserts from above were subcloned into the pGEX6P1 vector, in order to create 
glutathione S-transferase (GST)-MAGI-2 plasmids.  Four µg of pMyc3-MAGI-2 DNA were 
digested with BglII and EcoRI to release the MAGI-2 insert.  The digested product was 
electrophoresed on a low melt agarose gel and the MAGI-2 insert DNA was excised.  The 
MAGI-2 DNA fragment was purified using the QIAquick Gel Extraction Kit (Qiagen), 
according to the supplier’s instructions except that the DNA was eluted in 20 µL distilled water 
and passed through the column three times. 
 Two µg of pGEX6P1 vector were digested with BamHI (New England Biolabs) and 
EcoRI.  The digested product was subject to purification, as described previously. 
 The MAGI-2 insert was ligated into the pGEX6P1, as described previously (section 
3.3.6).  BamHI and BglII restriction sites have compatible sticky ends; however, the 
BamHI/BglII restriction sites are destroyed upon ligation of the insert into the vector.  
Successful ligations were verified by a single restriction enzyme cut, followed by gel 
electrophoresis.  A comparison of the size difference between pGEX6P1 plasmid containing 
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MAGI-2 insert was compared to the empty vector.  Positive clones were sequenced through the 
splice site between the GST and MAGI-2 encoding regions at the above mentioned facilities.   
 
3.4 Coomassie blue stained gels and immunoblot analysis 
 
3.4.1 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis  
 Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) (Laemmli, 1970) for protein staining or for immunoblot analysis.  Gels were cast 
using the Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad) using a 1 mm spacer.  The 
polyacrylamide gels consisted of two parts, the resolving gel (bottom) and the stacking gel 
(top).  The resolving gel contained between 7.5-15% (w/v) acrylamide/bisacrylamide solution 
(29.2:0.8 acrylamide to bisacrylamide) in 375 mM Tris-HCl, pH 8.8, and 0.1% (w/v) SDS.  
Polymerization of the gel was initiated upon the addition of 0.06% (w/v) ammonium persulfate 
and 0.1% (v/v) N,N,N’,N’-tetra-methylethylenediamine.  The resolving gel was poured in 
between the two glass plates and allowed to polymerize for at least 40 min.  Water saturated 
butanol was added to the surface of the resolving gel in order to prevent oxygen free radicals, 
generated by the ammonium persulfate, from escaping into the air.  The stacking gel consisted 
of 4.5% acrylamide/bisacrylamide solution containing 125 mM Tris-HCl, pH 6.8, and 0.1% 
(w/v) SDS.  Polymerization of the stacking gel was initiated upon the addition of ammonium 
persulfate and N,N,N’,N’-tetra-methylethylenediamine, as described above.  After removing 
the butanol, the stacking gel was poured on top of the resolving gel and a comb containing 10 
or 15 wells was inserted to form the wells.  The stacking gel was allowed to polymerize for at 
least 8 min.   
 Protein samples were resuspended in SDS sample buffer [10% (w/v) glycerol, 5% (v/v) 
β-mercaptoethanol, 2.3% (w/v) SDS and 0.05% (w/v) bromophenol blue, pH 6.8], boiled at 
100°C for 5 min and loaded into each well.  The unstained protein standards were used for 
Coomassie blue stained gels and consisted of the following molecular weights in kDa:  200, 
150, 120, 100, 85, 70, 60, 50, 40, 30, 25, 20, 15 & 10 (Fermentas, Cat# 0661).  Prestained 
protein standards were used for immunoblot analysis and consisted of the following molecular 
weights in kDa:  170, 130, 100, 70, 55, 40, 35, 25, 15 &10 (Fermentas, Cat# 0671).   
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The gel was electrophoresed in running buffer [25 mM Tris-HCl, 192 mM glycine and 
0.1 % (w/v) SDS] at 180 V until the bromophenol blue ran off the bottom of the gel (Laemmli, 
1970).   
 
3.4.2 Coomassie blue stain analysis 
SDS-PAGE gels were stained in Coomassie blue stain [0.14% (w/v) Coomassie blue-
250, 41.4% (v/v) methanol and 5.4% (v/v) glacial acetic acid] for at least 20 min and were 
destained in destaining solution [41.4% (v/v) methanol and 5.4% (v/v) glacial acetic acid] until 
the protein bands could be visualized.  Pictures of the gels were taken with the Gel-Doc 2000 
system using Quantity One software (Bio-Rad). 
 
3.4.3 Immunoblot analysis 
 For immunoblot analysis, SDS-PAGE gels were incubated in transfer buffer [20% (v/v) 
methanol, 0.58% (w/v) glycine and 0.038% (w/v) SDS in 48 mM Tris-HCl, pH 9.2] for 15-20 
min.  Concurrently, 6 pieces of 3 MM filter paper (Whatman) was soaked into the transfer 
buffer and a nitrocellulose membrane (Whatman) was hydrated in distilled water.  Both the 3 
MM and nitrocellulose membrane were sized according to the dimensions of the gel (8.2 x 5.4 
cm).     The transfer system used was an Owl Panter™ Semi-Dry Electroblotter (VWR, Cat# 
27372-374).  Three 3 MM papers were layered on the base of the apparatus, followed by the 
SDS-PAGE gel and the pre-soaked nitrocellulose membrane.  Three more 3 MM papers were 
layered on top, to complete the transfer sandwich.  Air bubbles were rolled out of the layers and 
the proteins were transferred from the gel onto the nitrocellulose membrane at a constant 
current of 400 mA for 15 min per gel.   
The membrane was blocked in blocking solution [0.1 M Tris-HCl, pH 8.0, 150 mM 
NaCl and 0.05% (v/v) Tween-20 (TBST), supplemented with 5% (w/v) Carnation skim milk 
powder] for 1 hr at room temperature or overnight at 4°C.  Primary antibodies were diluted in 
the blocking solution according to manufacturer’s recommendations (Table 3.4).  Secondary 
antibodies, conjugated to horseradish peroxidase (HRP), were diluted 1:2000 in the blocking 
solution (Santa Cruz, sc-2004 anti-rabbit and sc-2005 anti-mouse).  Primary antibodies were 
incubated for 1 hr at room temperature or overnight at 4°C.  The nitrocellulose membrane was 
washed three times with TBST (5 min each).  The membrane was incubated in secondary 
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antibody for 1-6 hr at room temperature and washed as described before.  The membrane was 
incubated for 1 min in Western Lightning enhanced chemiluminescence reagent (PerkinElmer) 
and exposed to X-Omat Blue XB-1 film (Kodak) for up to 10 min in a darkroom.  The film was 
developed in a Kodak M35A X-Omat processor. 
 
Table 3.4 Primary antibodies used for immunoblot (IB) and immunoprecipitation (IP) 
experiments. 
Antibody Company Catalogue number Species Application 
Concentration 
(IB)  or Amount 
(IP) 
Figure 
IB 1 µg/mL 3.9A, 
EGFR UBI 05-104 Rabbit 
IP 10 µg 3.10B,C & 3.11B 
IB 5 µg/mL 3.8B FLAG Sigma-Aldrich F3165 Mouse IP 12.5 µg 3.11C 
GST Santa Cruz sc-138 Mouse IB 0.5 µg/mL 3.3B,C 
HA Santa Cruz sc-7392 Mouse IP 10 µg  
PDGFR 
New 
England 
Biolabs 
3175 Mouse IB 1 µg/mL 3.9B 
PTEN-
HRP Santa Cruz 
sc-7974-
HRP Mouse IB 1 µg/mL 3.8A 
Myc Santa Cruz sc-40 Mouse IB 1 µg/mL 
3.7, 
3.10A, 
3.11A & 
3.12D 
Myc Santa Cruz sc-789 Rabbit IP 10 µg & 12.5 µg 3.10A & 3.11A 
GARP 
Anderson, 
affinity 
purified (to 
amino acids 
1233-1455) 
N/A Rabbit IB 1:100 3.12C 
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To re-probe the nitrocellulose membrane with a different primary and secondary 
antibody, the membrane was washed in TBST and incubated in stripping buffer [2% (w/v) SDS 
and 100 mM β-mercaptoethanol in 62.5 mM Tris-HCl, pH 6.8] at 80°C for 30 min.  The 
membrane was then rinsed in TBST, blocked and re-probed with primary and secondary 
antibodies, as previously described. 
 
3.5 Induction and purification of GST-MAGI-2 proteins from bacterial cells 
 Bl21 E. coli cells were transformed with pGEX6P1-MAGI-2 DNA, as previously 
described for TOP10 cells.  Transformed cells were grown in LBA, in a shaking incubator at 
37°C until an absorbance of 0.5 (600 nm) was attained, indicating that the cells were in log 
phase.  Protein expression was induced with 0.3 mM isopropyl β-D-thiogalactopyranoside 
(IPTG) overnight at room temperature.  Bacterial cells were pelleted and lysed enzymatically 
with lysozyme [10 mg/mL in phosphate buffered saline (PBS, 137 mM NaCl, 2.7 mM KCl, 4.3 
mM Na2HPO4, 1.4 mM KH2PO4, pH 7.3)] on ice for 30 min and mechanically through 
sonication (3x 10 sec at a setting of 1.5).  Triton X-100 were added to a final concentration of 
1% (v/v) and the cells were centrifuged at 21,920 x g to remove insoluble debris (pellet).  
Soluble cell lysate was filtered through a 0.8 micron filter to remove particulate.  GST-fused 
MAGI-2 proteins were bound to glutathione-Sepharose 4B beads (Amersham Pharmacia, Cat# 
27-4574).  The immobilized GST-MAGI-2 proteins were washed in PBS to remove unbound 
protein.  An aliquot of the purified GST-fusion protein suspension was resolved by SDS-PAGE 
and the protein was either stained with Coomassie blue or transferred to nitrocellulose and 
immunoblotted with anti-GST mouse monoclonal (anti-GSTMs, Santa Cruz, Cat# 138) (Table 
3.4).  The quality and purity of the GST-fused MAGI-2 proteins were assessed by visualizing 
the size of the fused proteins compared to that of the expected protein size and the number of 
additional proteins and/or degradation products.   
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3.6 Limited trypsin digestion 
 
3.6.1 Eluting the GST-MAGI-2 proteins from the glutathione-Sepharose beads 
 
 In order to elute GST-MAGI-2 proteins from glutathione-Sepharose beads, immobilized 
GST-MAGI-2 proteins were centrifuged at 2500 x g and excess PBS supernatant was removed.  
The beads were incubated for 30 min in reduced glutathione buffer (15 mM reduced glutathione 
in 50 mM Tris-HCl, pH 8.0).  The beads were then centrifuged again at 2500 x g and the 
supernatant containing the eluted protein was kept.  An aliquot of the supernatant containing the 
eluted GST-fusion protein was resolved by SDS-PAGE and stained with Coomassie blue.  The 
amount of protein present was determined using bovine serum albumin protein standards of 
known concentration. 
 
3.6.2 Limited trypsin digest of GST-MAGI-2 proteins 
 A limited trypsin digest was performed on all GST-MAGI-2 proteins to determine if the 
portions of the MAGI-2 proteins were folded properly while fused to GST.  A 1:1000 protease 
to protein ratio was used for the limited protein digestion of the GST-MAGI-2 proteins.  The 
reaction proceeded in the following mixture at 37°C:  400-600 µg GST-MAGI-2 protein, 1 mM 
β-mercapthoethanol and 0.4-0.6 µg of trypsin (L-1-Tosylamide-2-phenylethyl chloromethyl 
ketone treated, Sigma-Aldrich, Cat# T-8642) in 20 mM Tris-HCl, pH 8.0, to a final volume of 1 
mL.  A 10 µL aliquot was taken from the reaction mixture before the addition of the trypsin.  
Once the trypsin was added, 10 µL aliquots were taken at the following time points:  0, 5, 10, 
20, 30, 40, 60 min and overnight.  These aliquots were added directly to SDS sample buffer and 
boiled for 5 min in order to inactivate the trypsin.  These were resolved by SDS-PAGE and 
stained with Coomassie blue. 
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3.7 Cell culture techniques 
 
3.7.1 Growth factor stimulations 
 NIH 3T3 and COS-1 cells were grown in DMEM + 10% FBS + 1% P/S at 37°C in a 5% 
CO2 incubator.  These were grown to approximately 60-70% confluency and starved of FBS for 
24 hrs in DMEM containing 0.5 % FBS.   
Growth factor stimulations in NIH 3T3 cells were performed with PDGF-BB 
(Cedarlane, Cat# 220-BB-050) since these cells endogenously express PDGFR.  PDGF-BB was 
resuspended in PDGF dilution buffer [10 mM acetic acid and 2 mg/mL bovine serum albumin, 
(BSA)] and further diluted in spent starving media to a final concentration of 50 ng/mL.  PDGF 
stimulations proceeded for the different times indicated in each experiment. 
Growth factor stimulations in COS-1 cells were performed with EGF (Sigma-Aldrich, 
Cat# E-9644) since these cells endogenously express EGFR.  EGF was resuspended in 10 mM 
acetic acid, and then further diluted in EGF dilution buffer [2% (w/v) BSA in PBS].  EGF was 
then further diluted in spent starving media to a final concentration of 80 nM.  EGF 
stimulations proceeded for the different times indicated in each experiment. 
 
3.7.2 Transient transfection of COS-1 cells 
 In order to test whether the newly generated plasmids encoding Myc-MAGI-2 proteins 
had the ability to express in eukaryotic cells, pMyc3-MAGI-2 DNA was transiently transfected 
into COS-1 cells.  Transient transfections were performed using lipofectAMINE™ (Invitrogen, 
Cat# 18324) according to the manufacturer’s instructions.  Briefly, on day 1, COS-1 cells (85-
90% confluent) were trypsinized and re-seeded on 10 cm culture plates in a 1:10 dilution and 
grown overnight in DMEM + 10% FBS + 1% P/S.  On day 2, cells were approximately 25-30% 
confluent and were transfected with 6 µg DNA Myc-MAGI-2 FL, or its respective domains.  
Briefly, solution A [600 µL of Opti-MEM®I reduced serum medium (Invitrogen, Cat# 31985-
062) containing 6 µg DNA] and solution B (600 µL Opti-MEM®I reduced serum medium 
containing 18 µL lipofectAMINE™ reagent) were mixed and incubated at room temperature 
for 15 min.  Each 10 cm plate of cells was washed with warm serum-free DMEM.  To each 10 
cm plate of cells, 4.8 mL of serum free DMEM and the combined solutions A and B were 
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added and cells were incubated at 37°C and 5% CO2 for 5 hr.  Six mL of DMEM containing 
20% FBS were added to the existing transfection media on each plate and the cells were 
incubated overnight at 37°C and 5% CO2.  On day 3 transfection medium was replaced with 
DMEM + 10% FBS + 1% P/S.  On day 5 cells were approximately 80-90% confluent and were 
washed and lysed in 1 mL of lysis buffer (described in section 3.7.4).  Ten µL aliquots were 
mixed with SDS sample buffer and resolved by SDS-PAGE and transferred to nitrocellulose 
and immunoblotted with anti-Myc mouse monoclonal (anti-MycMs) (Santa Cruz, Cat# sc-40) 
(Table 3.4). 
In order to generate cell lysates for pull-down experiments, COS-1 cells transiently 
transfected with FLAG-p85 (Chamberlain et al., 2004) or HA-PTEN-C124S (phosphatase dead 
mutant of PTEN) (Chagpar, 2004) were transfected according to the protocol above.  These 
were lysed in 1 mL lysis buffer, and prepared for pull-down or immunoprecipitation assays 
(described in section 3.7.4). 
 
3.7.3 EGF stimulation of transiently transfected COS-1 cells 
EGF stimulations were performed on transiently transfected COS-1 cells, which were 
used in the immunoprecipitation assays (see section 3.9).  On day 1, COS-1 cells with a 
confluency of 85-90%, were trypsinized and re-seeded on 10 cm culture plates, in a 1:10 
dilution.  Cells were left to grow on day 2.  On day 3, cells were approximately 50-60% 
confluent and were transfected with 3 µg or 6 µg DNA total (Myc-MAGI-2, HA-PTEN-C124S 
or FLAG-p85) as described above.  On day 4, cells were approximately 80-90% confluent and 
were starved with starving media for 6 hours.  Cells were left unstimulated, or stimulated for 5 
min with EGF, as previously described.  Cells were washed and prepared immunoprecipitations 
assays, as described in section 3.7.4.  
 
3.7.4 Cell lysate preparation 
To prepare cell lysates for pull-down or immunoprecipitation assays, 10 cm plates of 
cells (of approximately 85-90% confluency) were placed on ice and washed once with cold 
PBS.  Each 10 cm plate of cells was scraped into 1 mL lysis buffer [50 mM N-(2-hydroxyethyl) 
piperazine-N’-(2-ethanesulfonic acid), pH 7.5, 150 mM NaCl, 10% (v/v) glycerol, 1% (v/v) 
triton X-100, 1.5 mM MgCl2, 1 mM ethylene glycol-bis (B-aminoethylether) N,N,N,N, 
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tetraacetic acid, 10 mM sodium pyrophosphate, 100 mM sodium fluoride, containing 10 µg/mL 
aprotinin, 10 µg/mL leupeptin and 1 mM aminoethyl, 2-benzenesulfonyl (protease inhibitors) 
and 1 mM sodium orthovanadate].  Cells were incubated on ice for at least 10 min and 
centrifuged at 21,920 x g for 10 min, in order to remove insoluble cellular debris (pellet).  
Lysates were used immediately or stored at -80°C. 
 
3.7.5 Whole cell lysate preparation 
Whole cell lysates were solubilised in SDS sample buffer.  Briefly, one plate of 85-90% 
confluent cells was washed in PBS, scraped into warm 300 µL SDS sample buffer and passed 
through a 27 gauge needle several times to reduce viscosity.  Whole cell lysates were boiled at 
100°C for 5 min and used immediately or stored at -80°C. 
 
3.8 Pull-down experiments  
In order to test protein-protein interactions in vitro, a pull-down assay was employed.  
GST and GST-MAGI-2 fusion protein (10 µg each) were immobilized on glutathione-
Sepharose beads and incubated with 100-200 µL of COS-1 cell lysates (10-20% of a 85-90% 
confluent 10 cm plate) expressing HA-PTEN-C124S or FLAG-p85, mixing for 1 hr at 4°C.  To 
confirm whether PTEN could bind to the PDZ domains of MAGI-2, COS-1 cell lysates 
expressing HA-PTEN-C124S were mixed with 10 µg of GST, GST-MAGI-2 FL, GST-PDZ 
domains, as well as the GST-GARP C-terminal sequence of MAGI-2.  To test whether p85 
could bind to the WW domains of MAGI-2, COS-1 cells expressing FLAG-p85 were mixed 
with 10 µg of GST and GST-fused WW domains. 
To test whether MAGI-2 PDZ domains associated with EGFR, COS-1 cells (expressing 
endogenous levels of EGFR) were either left unstimulated, or stimulated with EGF for 5 min.  
Cell lysates were lysed in lysis buffer (1 mL of lysate; 100% of a 85-90% confluent 10 cm 
plate) were mixed with 10 µg GST and GST-PDZ domains of MAGI-2, mixing for 1 hr at 4°C.  
To test whether MAGI-2 PDZ domains associated with PDGFR, NIH 3T3 cells (expressing 
endogenous levels of PDGFR) were tested similarly, however these were left unstimulated or 
stimulated with PDGF-BB for 5 min.   
Protein complexes immobilized on glutathione-Sepharose beads were centrifuged at 
2500 x g for 1 min and washed three times with 500 µL wash buffer [20 mM N-(2-
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hydroxyethyl) piperazine-N’-(2-ethanosulfonic acid), pH 7.5, containing 150 mM NaCl, 0.1% 
(v/v) triton X-100 and 10% (w/v) glycerol] wash buffer containing the aforementioned protease 
inhibitors and sodium orthovanadate.  Samples were resuspended in 20 µL of SDS sample 
buffer, heated at 100°C for 5 min and resolved by SDS-PAGE.  The protein was transferred to a 
nitrocellulose membrane and immunoblotted for the protein of interest.  The antibodies used in 
these experiments were anti-PTENMs-HRP (1 µg/mL, Santa Cruz, Cat# sc-7974-HRP), anti-
FLAGMs (5 µg/mL, Sigma-Aldrich, Cat# F3165) to detect p85, anti-EGFRMs (1 µg/mL, UBI, 
Cat # 05-104) or anti-PDGFRMs (1 µg/mL, New England Biolabs, Cat# 3175) according to 
manufacturer’s instructions (Table 3.4). 
 
3.9 Co-immunoprecipitation experiments 
 In order to test protein-protein interactions in cells, a co-immunoprecipitation assay was 
employed.  All co-immunoprecipitation experiments were performed with COS-1 cell lysates 
derived from cells transfected with plasmids encoding proteins of interest.   
 To determine if MAGI-2 formed complexes in cells with PTEN, a co-
immunoprecipitation was performed with Myc-MAGI-2 and HA-PTEN-C124S.  COS-1 cells 
were co-transfected with 3 µg DNA encoding Myc-MAGI-2 FL and 3 µg of DNA encoding the 
phosphatase dead mutant of PTEN (HA-PTEN-C124S).  Cells were left unstimulated or 
stimulated with EGF for 5 min and lysed in 1 mL lysis buffer.  Cell lysates used in an 
immunoprecipitation experiment were pre-cleared once to remove residual protein that may 
bind non-specifically with rabbit or mouse antibodies and/or beads.  Five µg of rabbit IgG 
agarose conjugated (Rb IgG-AC, Santa Cruz, Cat# 2345) and 5 µg of mouse IgG agarose 
conjugated (Ms IgG-AC, Santa Cruz, Cat# 2343) and 50 µL of a 50% suspension of protein G 
beads (Sigma-Aldrich, Cat# P-7700) were mixed with 875 µL cell lysates, mixing at 4˚C for 1 
hr.  These were centrifuged at 21,920 x g and the supernatant was removed and used in the 
immunoprecipitation assay.  One hundred and twenty five µL of these lysates (12.5% of a 85-
95% confluent 10 cm plate) were used in an co-immunoprecipitation assay where 5 µg of rabbit 
IgG and 5 µg of mouse IgG, 10 µg of anti-Myc rabbit polyclonal (anti-MycRb, Santa Cruz, Cat# 
789) to immunoprecipitate MAGI-2 or 10 µg of anti-HA mouse monoclonal (anti-HAMs, Santa 
Cruz, Cat# sc-7392) to immunoprecipitate PTEN, along with an excess of protein G beads (20 
µL of a 50% suspension) were mixed for 1 hr at 4˚C.  Samples were washed as for pull-down 
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experiments and resuspended in 20 µL SDS sample buffer.  The samples were resolved by 
SDS-PAGE and transferred to a nitrocellulose membrane.  The nitrocellulose membrane was 
cut in half at the 100 kDa marker.  Using an immunoblot approach, the top of the membrane 
(containing > 100 kDa proteins) was probed with anti-MycMs (1 µg/mL, Santa Cruz, Cat# sc-
40) to detect Myc-MAGI-2.  The bottom portion of the immunoblot (containing < 100 kDa 
proteins) was probed with anti-PTENMs conjugated to HRP (Table 3.4). 
 The result obtained in this Myc-MAGI-2/HA-PTEN co-immunoprecipitation 
experiment above could not be replicated.  First, we had non-specific binding, which were 
eventually eliminated by pre-clearing the cell lysates 2x for 1 hour, as described above.  A 
range of co-transfections of HA-PTEN-C124S (1, 3 and 5 µg) and Myc-MAGI-2 (1, 3, 5 and 10 
µg) was also used to determine which ratio of transfections could give optimal expression.  We 
also used a range of cell lysate volumes from 50-500 µL (5-50% of a 85-90% confluent 10 cm 
plate).  Unfortunately, the results seen in the first experiment were never seen again. 
 In order to determine if MAGI-2 formed complexes in cells with EGFR, an 
immunoprecipitation was performed where Myc-MAGI-2 and EGFR could co-
immunoprecipitate.  COS-1 cells were transfected with 3 µg of DNA encoding Myc-MAGI-2 
FL.  Cells were left unstimulated or stimulated with EGF for 5 min and lysed in lysis buffer.  
Cell lysates used in co-immunoprecipitation assays were pre-cleared to remove residual protein 
that may bind non-specifically with rabbit antibodies.  Ten µg of Rb IgG-AC and 50 µL of a 
50% suspension protein A beads (Sigma-Aldrich, Cat# P-3391) were mixed with 2.8 mL cell 
lysate mixing at 4°C for 1 hour.  These were then centrifuged at 21,920 x g and the pre-clear 
was repeated on the supernatant once more.  Four hundred µL of these lysates (40% of a 85-
90% confluent 10 cm plate) were used in an immunoprecipitation assay where 10 µg of rabbit 
IgG, anti-MycRb (Santa Cruz, Cat# sc-789) to immunoprecipitate Myc-MAGI-2 or  anti-
EGFRRb (UBI, Cat# 06-847) along with an excess of Protein A beads (20 µL of a 50% 
suspension) were mixed for 1 hr at 4°C.  Samples were washed as for pull-down experiments 
and resuspended in 20 µL SDS sample buffer.  The samples were resolved by SDS-PAGE and 
transferred to a nitrocellulose membrane.  The membrane was first immunoblotted for MAGI-2 
with anti-MycMs (1 µg/mL, Santa Cruz, Cat# sc-40), then stripped and re-probed with anti-
EGFRRb (1:1000, UBI, Cat# 06-847) (Table 3.4). 
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To determine if MAGI-2 and p85 formed complexes in cells, an immunoprecipitation 
experiment was performed to determine if MAGI-2 and p85 could co-immunoprecipitate along 
with EGFR.  COS-1 cells were co-transfected with 3 µg of DNA encoding Myc-MAGI-2 FL 
and 3 µg of DNA encoding FLAG-p85. Cells were left unstimulated or stimulated with EGF for 
5 min and lysed in lysis buffer.  Cell lysates were pre-cleared once using 10 µg of Rb IgG-AC 
and 50 µL of a 50% suspension protein A beads mixed with 2.8 mL cell lysate mixing at 4°C 
for 1 hour.  These were then centrifuged at 20,920 x g.  Two hundred µL of the supernatants 
(20% of a 85-90% confluent 10 cm plate) were used in an immunoprecipitation assay where 
12.5 µg of rabbit IgG-AC and 12.5 µg mouse IgG-AC, anti-MycRb antibody (Santa Cruz, Cat# 
sc-789) to immunoprecipitate MAGI-2, or FLAG antibody (Sigma-Aldrich, Cat# F3165) to 
immunoprecipitate p85, along with 20 µL of a 50% suspension Protein G beads were mixed for 
1 hr at 4°C.  Samples were washed and immunoblotted.  The membrane was cut at the 100 kDa 
mark and the upper membrane (containing > 100 kDa proteins) was probed with anti-MycMs (1 
µg/mL, Santa Cruz, Cat# sc-40) to detect MAGI-2.  This membrane was stripped and re-probed 
with anti-EGFRRb (1:1000, UBI, Cat# 06-847).  The bottom portion of the blot was probed with 
anti-FLAGMs (5 µg/mL, Sigma-Aldrich, Cat# F3165) to detect p85 (Table 3.4).   
 
3.10 MAGI-2 rabbit polyclonal antibody 
A MAGI-2 polyclonal antibody was created to distinguish MAGI-2 from other MAGI 
proteins.  The anti-MAGI-2 antibody was raised against a portion of the MAGI-2 protein 
containing amino acids 1233-1455 (GARP C-terminal sequence, Table 3.3), a region unique to 
MAGI-2.  The GST-GARP protein antigen was generated as described above.  Briefly, the C-
terminal end of MAGI-2 was subjected to PCR amplification of the region encoding amino 
acids 1233-1455.   The GARP region was subcloned into the pGEX6P1 vector which was 
transformed into BL21 cells and induced with IPTG to overexpress the GST-GARP protein.  
BL21 cells were lysed and GST-GARP protein was immobilized on glutathione-Sepharose 
beads and washed.  The GARP protein was cleaved from the immobilized GST using 
PreScission protease (Amersham Biosciences), following the manufacturer’s recommendations.  
 One hundred µg of purified GARP protein was injected into a rabbit and the rabbit was 
allowed to generate polyclonal antibody against the protein for 3 weeks.  A test bleed was 
performed where a sample of approximately 10 mL of blood was taken from the rabbit.  The 
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crude serum was used to probe an immunoblot containing COS-1 lysates expressing Myc-
MAGI-2 and compared to a control Myc immunoblot.   
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4.0 RESULTS 
 
4.1 MAGI-2 expression in eukaryotic and prokaryotic cells. 
 
4.1.1 Myc-MAGI-2 expression in eukaryotic cells 
The DNA encoding MAGI-2 FL and its individual domains were amplified through 
PCR and cloned into the pMyc3 vector (Figure 4.1).  These plasmids encoding Myc-MAGI-2 
FL and individual domains were transfected into COS-1 cells.  Lysates from these transfected 
cells were confirmed to express Myc-MAGI-2 fusion proteins, as determined using an 
immunoblot analysis with anti-Myc antibodies (Figure 4.2).  Sizes of the Myc-tagged MAGI-2 
proteins were estimated using MacVector software based on the amino acid sequence (Table 
4.1).  The bands representing Myc-MAGI-2 FL and its respective domains were of the apparent 
molecular weight indicated in Table 4.1, confirming that Myc-tagged MAGI-2 proteins are 
expressed in eukaryotic cells from these newly generated plasmids.  A schematic representation 
of the tagged MAGI-2 proteins is shown in Figure 4.3.  Therefore, these Myc-tagged MAGI-2 
proteins could be used in immunoprecipitation experiments.   
 
Table 4.1: Estimated protein sizes of MAGI-2 FL and its individual domains: alone or 
fused to either a triple Myc epitope or GST.  The size of the Myc tag is 4.1 kDa and the GST 
protein is 26.5 kDa.  Protein sizes were estimated using MacVector software, based on the 
amino acid sequence. 
MAGI-2 
domains Amino acids 
Protein size 
(kDa) 
Myc-MAGI-2 
protein size 
(kDa) 
GST-MAGI-2 
protein size 
(kDa) 
MAGI-2 FL 1-1455 159 163 185 
PDZ0 1-104 11 15 38 
GK 105-297 22 26 48 
WW1 298-340 5 9 32 
WW2 341-403 8 12 34 
PDZ1 404-558 17 21 44 
PDZ2 559-733 19 23 45 
PDZ3 734-827 11 15 37 
PDZ4 828-1083 27 31 54 
PDZ5 1084-1232 17 21 44 
GARP 1233-1455 22 26 49 
Figure 4.1:  Cloning strategy of MAGI-2 FL and its respective domains into the pMyc
vector.  PCR primers were designed to introduce restriction enzyme sites BglII at the 5' end
and EcoRI at the 3' end of the PCR product.  Briefly, DNA encoding MAGI-2 FL and
individual domains were amplified through PCR.  PCR products were digested with BglII and
EcoRI and ligated into the similarly digested pMyc3 vector.  Successful cloning was
determined by digesting the resulting plasmid with BglII and EcoRI, to assess if the insert of
the appropriate size was present.  The pMyc3-MAGI-2 plasmid inserts were sequenced to
verify that no mutations were introduced during PCR and that the correct reading frame was
maintained between the Myc and MAGI-2 encoding regions.
MAGI-2 template strand
Amplification of MAGI-2 DNA
through PCR
Restriction enzyme digestion
with BglII and EcoRI
Ligation into pMyc3 vector also
digested with BglII and EcoRI
restriction enzymes
Myc Myc Myc
pMyc3 + MAGI-2 inserts
BglII EcoRI
MAGI-2
BglII
EcoRI
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Figure 4.2: Expression and detection of Myc-MAGI-2 proteins in eukaryotic COS-1 cells.
COS-1 cells were transfected with 6 µg of DNA encoding MAGI-2 FL or individual MAGI-2
domains.  Cell lysates (10 µL) were resolved by SDS-PAGE, transferred to nitrocellulose and
the resulting immunoblot was probed with anti-Myc antibodies.  Secondary antibodies linked
to HRP were used to probe the immunoblot and chemiluminescence was used to visualize the
bound antibodies.  A, Lysate from COS-1 cells, transfected with Myc-MAGI-2 FL (arrow).  B,
Lysates from COS-1 cells, transfected with Myc-MAGI-2 domains, as indicated.  The
molecular weights of standards are indicated in kDa.
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Figure 4.3:  Schematic representation of the tagged (GST or Myc) MAGI-2 fusion
proteins.  A, Schematic representation of the MAGI-2 structure.  B and C, Myc or GST fusion
proteins were created as described in the methods.  Briefly, MAGI-2 FL and its respective
domains were cloned into the pMyc3 or pGEX6P1 vectors, encoding Myc or GST tags,
respectively.  The amino acids present in each fusion protein of MAGI-2 are indicated, as well
as the MAGI-2 domain boundaries.  A red box indicated the Myc or GST fusion, the purple
boxes represent the PDZ domains, a blue box represents the GK domain, yellow boxes
represent the WW domains, a pink box represents the GARP domain.
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4.1.2 GST-MAGI-2 expression in prokaryotic cells 
DNA encoding MAGI-2 FL and individual domains were subcloned into the pGEX6P1 
vector (Figure 4.4).  E. coli BL21 cells were transformed with pGEX6P1-MAGI-2 plasmids 
and protein expression was induced with IPTG.  A schematic representation of the GST-MAGI-
2 proteins is shown in Figure 4.3.  GST-MAGI-2 proteins were immobilized on glutathione-
Sepharose beads, and the purified proteins were resolved by SDS-PAGE.  The SDS-PAGE gel 
was either stained with Coomassie blue (Figure 4.5A) or the protein was transferred to a 
nitrocellulose membrane, and probed with anti-GST antibodies (Figure 4.5B-C).  Protein sizes 
of GST-MAGI-2 FL and the MAGI-2 domains were estimated using MacVector software, as 
previously described (Table 4.1).  The bands representing GST-MAGI-2 domains (Figure 4.5A-
C) were of the apparent molecular weight.  The bands representing GST-WW or GST-PDZ 
domains showed little or no degradation products associated with them and were of the correct 
estimated molecular weight.  GST-GK and GST-GARP had a lot of degradation products, as 
indicated by their irregular banding pattern and therefore an arrow shows the band 
corresponding to the most intact protein (Figure 4.5C).  The DNA encoding GST-MAGI-2 FL 
was a truncated version of the full length protein.  GST-MAGI-2 FL contained a lot of 
degradation products, and was not well expressed in prokaryotic cells (Figure 4.5B).  Therefore, 
these GST-MAGI-2 proteins (the WW and PDZ domains) could be used in pull-down assays.  
  
4.2 Limited trypsin digests of GST-MAGI-2 fusion proteins to determine whether isolated 
MAGI-2 domains could fold properly when fused to GST 
In order to determine whether the MAGI-2 domains were folding properly when fused 
to GST, a limited trypsin digest was performed.  Typically, a folded protein will have buried 
residues inside the protein, protecting these from proteolytic digestion. Once the digested 
products are resolved by SDS-PAGE and stained with a general protein stain, bands 
corresponding to the digested protein will be minimal.  If a protein is not folding properly, more 
of these residues will be exposed and sensitive to proteolytic digestion.  Therefore, when these 
products are resolved by SDS-PAGE and stained, the bands corresponding to the unfolded 
protein will be abundant.  For example, a similar experiment was performed on PTEN to 
distinguish the “open” vs. “closed” conformations (Vazquez et al., 2001).  When PTEN is  
Plasmid digested with BglII and EcoRI to
release MAGI-2 insert.  Low melt agarose
gel purification of MAGI-2 insert fragment.
Ligate MAGI-2 insert into pGEX6P1
vector digested with BamHI and
EcoRI
Figure 4.4:  Subcloning of the DNA encoding MAGI-2 FL and its respective domains into
the pGEX6P1 vector.  Subcloning was achieved by digesting the pMyc3 plasmid containing
MAGI-2 insert, with BglII and EcoRI.  The digested product was then electrophoresed on a
low melt 1-1.5% agarose gel and the band size corresponding to the MAGI-2 insert was
excised from the gel.  The DNA was purified from the gel, using a Gel Purification Kit.
MAGI-2 DNA was ligated into the pGEX6P1 vector, previously digested with BamHI and
EcoRI.  BglII and BamHI have compatible 5' sticky overhangs, however the BamHI/BglII
restriction sites are destroyed upon ligation of the insert into the vector.  Successful ligations
were analyzed by size determination of pGEX6P1 plasmid containing the MAGI-2 insert using
EcoRI digestion and also by DNA sequencing.
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pMyc3 + MAGI-2 inserts
BglII EcoRI
MAGI-2
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Figure 4.5:  Expression and detection of GST-MAGI-2 proteins expressed in BL21  E.
coli cells.  BL21 cells were transformed with plasmid DNA encoding GST-MAGI-2 FL or
individual GST-MAGI-2 domain fusion proteins.  Cells were induced with IPTG, lysed and
GST-MAGI-2 proteins were immobilized on glutathione-Sepharose beads.  Purified proteins
were resolved by SDS-PAGE and stained with Coomassie blue (A) or transferred onto
nitrocellulose and immunoblotted with a GST antibody (B and C), in order to visualize the
distinct purified GST-MAGI-2 proteins.  Arrows indicate size of expected protein for samples
showing multiple bands.
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“closed”, a limited proteolytic digestion revealed little degradation of the protein when samples 
were resolved by SDS-PAGE.  It is hypothesized that when PTEN is in the “closed” 
conformation, many of the residues sensitive to proteolytic digestion are buried inside the 
protein and unavailable for proteolytic digestion (Vazquez et al., 2001).  However, an activated, 
“open” PTEN exposes more of its residues and a limited proteolytic digestion shows more 
cleavage when the sample is resolved by SDS-PAGE (Vazquez et al., 2001).  Therefore, to 
determine if GST-MAGI-2 proteins were folding properly, MAGI fusion protein was treated 
with a limited trypsin digest (1:1000 ratio of protease to protein).   
The negative control used in this assay was GST (Figure 4.6A), which showed almost 
no degradation, even after an overnight incubation with trypsin.  The purified GST-MAGI-2 FL 
protein had abundant proteolysis associated with the FL protein product (Figure 4.6B) 
suggesting that the FL MAGI-2 protein may not fold properly when expressed in bacteria as a 
GST-MAGI-2 FL protein or that the regions between the various domains may be exposed for 
trypsin digestion.   
WW domains have been shown to fold into stable protein structures (Macias et al., 
1996; Macias et al., 2000; Umadevi et al., 2005).  GST-WW1 and GST-WW2 domains showed 
little degradation, indicating that the WW domains fold as stable structures when expressed as a 
bacterial GST-WW protein (Figure 4.6C).  The GK protein is quickly cleaved from the GST 
portion, within 5 min of trypsin digestion (Figure 4.6D).  The linker region between GST and 
the GK domain may present a site for trypsin digestion.   This suggests that GK domain can be 
cleaved quite easily from the GST portion of the protein; however, it is able to form a stable 
trypsin-resistant structure on its own (Figure 4.6D).  GST-GARP has a small ~15 kDa region 
that is cleaved soon after the trypsin has been added.  This suggests that the C-terminal end of 
the GARP protein may be sensitive to proteolytic digestion because it is unable to fold into a 
stable, globular structure (Figure 4.6E). 
PDZ domains have also been shown to fold into stable protein structures (Daniels et al., 
1998; Doyle et al., 1996; Morais Cabral et al., 1996).  All GST-PDZ domains, with the 
exception of GST-PDZ0, showed little degradation, when subjected to a limited trypsin digest 
(Figure 4.7).  Limited digestion of the PDZ domains occurred one of two ways; either a small 
portion was degraded at the C-terminal end (approximately 5-10 amino acids removed with  
Figure 4.6:  Limited trypsin digest of GST-MAGI-2 proteins to determine if the MAGI-2
domains are folding properly while fused to GST.  Protein overexpression of GST-MAGI-2
FL and respective domains were induced by IPTG in BL21 cells.  Cells were lysed and GST-
MAGI-2 proteins were purified on glutathione-Sepharose beads.  Purified GST-MAGI-2
proteins were then eluted off of the glutathione-Sepharose beads, using reduced glutathione
buffer.  Limited trypsin digestion was performed at 37°C where the protease to protein ratio
was 1:1000.  Protein sizes are estimated based on the amino acid sequence.  A, GST.  B, GST-
MAGI-2 FL.  C, GST-WW domains.  D, GST-GK domain.  E, GST-GARP domain.  Samples
were left untreated (no trypsin), treated for the indicated time points (in minutes) or left treated
overnight (O/N).
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Figure 4.7:  Limited trypsin digest of GST-MAGI-2 PDZ proteins to determine if the
MAGI-2 domains are folding properly while fused to GST.  GST-MAGI-2 PDZ domains
were prepared and treated as described in Figure 4.6. Protein sizes are estimated based on the
amino acid sequence. Samples were left untreated (no trypsin), treated for the indicated time
points (in minutes) or left treated overnight (O/N).
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GST-PDZ2 and GST-PDZ4) or the GST portion was cleaved from the stable PDZ portion 
(GST-PDZ1, GST-PDZ3 and GST-PDZ5).  GST-PDZ0 however, was degraded within 5 min 
upon the addition of trypsin, indicating that this PDZ domain is not able to form a stable 
structure when expressed in bacteria.   
 
4.3 Pull-down experiments to determine in vitro complex formation between various 
MAGI-2 domains and PTEN, p85, EGFR and PDGFR 
 
4.3.1 MAGI-2 PDZ domains 2 and 5 interact with PTEN 
A pull-down experiment was performed to test whether the GST-PDZ domains of 
MAGI-2 could bind to PTEN.  PTEN contains a short, C-terminal amino acid sequence 
(QITKV-COOH) that contains a consensus class I PDZ binding motif (section 1.4.3 and Table 
1.2; reviewed in Jeleń et al., 2003).  Previous experiments have shown that the PDZ2 domain of 
MAGI-2 could bind to PTEN (Hu et al., 2007; Valiente et al., 2005; Vazquez et al., 2001; Wu 
et al., 2000a) along with other PDZ domains of other scaffolding proteins (Valiente et al., 
2005).  Therefore we wanted to test our pull-down experimental system, and confirm PTEN 
binding to PDZ2 of MAGI-2.  As a source of PTEN protein, an N-terminal, triple 
hemagglutinin (HA) tagged, phosphatase dead mutant (C124S) of PTEN was used.  The 
phosphatase dead C124S mutant PTEN has improved stability over the wild type PTEN protein 
(Das et al., 2003).  Briefly, COS-1 cells were transiently transfected with DNA encoding HA-
PTEN-C124S (Maehama and Dixon, 1999) and lysates were mixed with 10 µg of GST-PDZ 
protein domains of MAGI-2 (PDZ0-PDZ5), GST-MAGI-2 FL and GST-GARP or a negative 
control GST protein, previously immobilized on glutathione-Sepharose beads.  Bound 
complexes were resolved by SDS-PAGE, and proteins were transferred to a nitrocellulose 
membrane for immunoblot analysis.  The immunoblot was probed with anti-PTEN-HRP 
antibody and visualized by chemiluminescence.  PTEN bound to PDZ2 (Hu et al., 2007; as 
previously shown in Valiente et al., 2005; Vazquez et al., 2001; Wu et al., 2000a), PDZ5 and 
the truncated MAGI-2 FL (Figure 4.8A).  Little or no PTEN bound to GST, GST-GARP and 
GST-PDZ0, 1, 3 and 4.  The result that MAGI-2 PDZ2 domain was able to bind PTEN is in 
agreement with previous studies and therefore suggests that our pull-down system is working  
Figure 4.8:  MAGI-2 PDZ and WW domains interact with PTEN and p85, respectively.
A, GST, GST-MAGI-2 FL, GST-PDZ domains and GST-GARP domains of MAGI-2 (10 µg
each) were immobilized on glutathione-Sepharose beads.  These were incubated for 1 hr at
4°C with lysates from COS-1 cells expressing HA-PTEN-C124S (phosphatase dead mutant
of PTEN) in a GST pull-down assay.  Unbound protein was washed off and the samples
were resolved by SDS-PAGE and transferred to nitrocellulose.  Using an immunoblot blot
analysis, HA-PTEN-C124S was detected with anti-PTEN antibody conjugated to HRP.
Bound proteins were visualized using chemiluminescence.  A GST control was used to
detect any non-specific binding to the GST protein or the beads.  The input lane contains 10
µL of cell lysate, to confirm that PTEN was present in the pull-down system and as a
control for the PTEN immunoblot.  B, GST, and GST-WW domains of MAGI-2, were used
in a pull-down assay with lysates from COS-1 cells expressing FLAG-p85, as described for
panel A.  The immunoblot analysis consisted of a FLAG antibody to detect FLAG-p85 and
corresponding secondary antibodies conjugated to HRP.  The results shown are typical for at
least 3 independent experiments.
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correctly.  We also show a novel finding where MAGI-2 PDZ5 also has the ability to bind to 
PTEN.  This suggests that MAGI-2 has the potential to interact with PTEN through both its 
PDZ2 and PDZ5 domains.  This result also suggests that the truncated GST-MAGI-2 may have 
partial binding abilities, regardless of its ability to form an ideally folded full length protein 
within prokaryotic cells. 
 
4.3.2 MAGI-2 WW domains both interact with p85 
A pull-down experiment was performed to test whether the GST-WW domains of 
MAGI-2 could associate with p85.  WW domains, like SH3 domains, are known to bind to Pro 
rich regions (Kapeller et al., 1994; Nguyen et al., 1998).  p85 has two Pro rich sequences; P1: 
amino acids 82-96 (SPPTPKPRPPRPLP, class II and III binding motifs, respectively) and P2: 
amino acids 300-314 (ERQPAPALPPKPPKP, class II binding motifs) (Kapeller et al., 1994) 
as detailed previously in section 1.4.2 and Table 1.1.  It was therefore hypothesized that p85 
may have the ability to bind to one, or both, of the WW domains of MAGI-2.  Briefly, COS-1 
cells were transiently transfected with DNA encoding an N-terminal, triple FLAG-tagged p85 
(FLAG-p85) and lysates were mixed with 10 µg GST-WW1 or GST-WW2 proteins, or a 
negative control GST protein, previously immobilized on glutathione-Sepharose beads.  The 
resultant complexes were resolved by SDS-PAGE and transferred to a nitrocellulose membrane 
for immunoblot analysis.  Bound p85 was detected using anti-FLAG antibodies (Figure 4.8B).  
The FLAG-p85 protein did not bind to the negative control however, did associate with both 
WW domains of MAGI-2.  These results suggest that both of the WW domains of MAGI-2 
have the ability to interact with p85.  
 
4.3.3 MAGI-2 PDZ domains do not associate with the EGFR 
Previous studies have shown the C-terminal end of two EGFR family proteins can 
interact with PDZ domains (Kaech et al., 1998; Lazar et al., 2004).  The C-terminal end of the 
EGFR homologue in Caenorhabditis elegans contains a class I PDZ binding motif (KETCL-
COOH).  It has been shown to bind to the PDZ domain of the LIN-7 PDZ containing 
scaffolding protein, which is hypothesized to mediate localization to the basolateral membrane 
and is critical in cell differentiation (Kaech et al., 1998).  The MAGI-2 PDZ1 domain has 
already been shown to associate with the C-terminal class I PDZ binding motif of the human 
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ErbB4 RTK (RNTVV-COOH) (Buxbaum et al., 2008).  Therefore, a pull-down experiment 
was used to test whether the GST-PDZ domains of MAGI-2 could associate with the EGFR.  
The C-terminal end of the human EGFR contains a class II PDZ binding motif (EFIGA-
COOH) (based on the Homo sapiens EGFR sequence XP_005219).  Although the African 
green monkey (Cercopithecus aethiops) EGFR sequence is not known, we hypothesize that it 
will be conserved and similar to the human EGFR sequence.  Briefly, lysates from COS-1 cells 
that were stimulated with EGF for 5 min or left unstimulated, were mixed with 10 µg of GST, 
and all GST-PDZ domains of MAGI-2, previously immobilized on glutathione-Sepharose 
beads.  Bound complexes were resolved by SDS-PAGE and immunoblotted with anti-EGFR 
antibodies.  It was shown that EGFR was not pulled down with GST or the GST-PDZ proteins 
(Figure 4.9A).  This result suggests that the monkey EGFR is unable to bind to MAGI-2 
through its PDZ domains under the conditions tested.  The human EGFR amino acid sequence 
is identical to the monkey EGFR sequence, the PDZ binding motif of EGFR encodes a class II 
PDZ domain (Table 1.2).  MAGI PDZ domains are predicted to be of the class I variety and 
therefore may not bind a class II PDZ binding motif. 
 
4.3.4 MAGI-2 PDZ domains do not associate with the PDGFR 
Previous studies have shown PDGFR binding to PDZ domains (Demoulin et al., 2003; 
Maudsley et al., 2000).  The C-terminal end of the human PDGFR (EDSFL-COOH) can bind 
to the first PDZ domain of the NHERF scaffold protein (Maudsley et al., 2000).  The C-
terminal end of the mouse PDGFR contains a class I PDZ binding motif (EDSFL-COOH) 
(based on the Mus musculus PDGFR protein sequence NP_032835) and therefore, it is 
hypothesized to bind to one of the MAGI-2 PDZ domains.  A pull-down experiment was used, 
performed as described above, to determine if MAGI-2 PDZ domains could associate with the 
PDGFR.  The cells that were used in this experiment however, were mouse NIH 3T3 stimulated 
with PDGF-BB for 5 min or left unstimulated since they express endogenous PDGFRs.  The 
bound complexes were resolved by SDS-PAGE and immunoblotted with anti-PDGFR 
antibodies. It was shown that PDGFR was not pulled down with the MAGI-2 GST-PDZ  
 
Figure 4.9:  MAGI-2 PDZ domains do not associate with endogenous EGFR or PDGFR.
A, COS-1 cells were stimulated for 5 min with EGF or left unstimulated and lysed.  GST and
GST-PDZ domains of MAGI-2 (10 µg each) were immobilized onto glutathione-Sepharose
beads and incubated for 1 hr at 4°C with lysates from COS-1 cells (expressing endogenous
EGFR) in a GST pull-down assay.  Unbound protein was washed off and the samples were
resolved by SDS-PAGE and transferred to nitrocellulose.  Using an immunoblot analysis,
EGFR was detected with anti-EGFR antibodies and corresponding secondary antibodies
conjugated to HRP.  Bound proteins were visualized using chemiluminescence and film.  GST
control was used to detect any non-specific binding to the GST protein or the beads.  B, NIH
3T3 cells were either stimulated for 5 min with PDGF-BB or left unstimulated and lysed as
described in panel A.  GST and GST-PDZ domains of MAGI-2 were used in a pull-down
assay with lysates from NIH 3T3 cells (expressing endogenous PDGFR) as described for panel
A.  An immunoblot analysis was used with PDGFR antibodies, and bound proteins were
visualized as described above. The input lane contains 10 µL cell lysate, to confirm that EGFR
or PDGFR was present in the system and as a control for the EGFR or PDGFR immunoblots.
The results shown are typical for at least 3 independent experiments.
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proteins (Figure 4.9B).  These results suggest that either the PDGFR is unable to bind MAGI-2 
through its PDZ binding domains under the conditions tested.  
 
4.4 Co-immunoprecipitation experiments to determine if MAGI-2 associates with PTEN, 
EGFR or p85 in cells 
 
4.4.1 MAGI-2 does not consistently co-immunoprecipitate with PTEN 
To determine whether MAGI-2 could form a complex with PTEN in cells, a co-
immunoprecipitation assay and immunoblot analysis was used.  COS-1 cells were co-
transfected with Myc-MAGI-2 FL and HA-PTEN-C124S and stimulated with EGF for 5 min, 
or left unstimulated.  Cell lysates were immunoprecipitated separately with anti-Myc (to 
immunoprecipitate MAGI-2), anti-HA (to immunoprecipitate PTEN) and control 
immunoglobin G (IgG).  These were resolved by SDS-PAGE, transferred to nitrocellulose and 
the immunoblot was cut in half.  The top portion of the immunoblot (containing proteins > 100 
kDa) was probed with anti-Myc antibody (to detect MAGI-2) (Figure 4.10).  The bottom 
portion of the immunoblot (containing proteins < 100 kDa) was probed with anti-PTEN-HRP 
(Figure 4.10).  In the first experiment, PTEN did co-immunoprecipitate with MAGI-2 after 5 
min EGF stimulation (Figure 4.10A, lane 6), however, MAGI-2 did not co-immunoprecipitate 
with PTEN (Figure 4.10A, lanes 3 and 4).  Attempts to repeat this experiment showed that 
PTEN and MAGI-2 did not co-immunoprecipitate (Figure 4.10B).  Therefore, these results are 
inconclusive and may reflect the low abundance and/or the transient nature of any complexes 
formed. 
 
4.4.2 MAGI-2 does not co-immunoprecipitate with the EGFR 
To determine whether MAGI-2 could form a complex with EGFR in cells, COS-1 cells 
transfected with Myc-MAGI-2 FL and were stimulated with EGF for 5 min, or left 
unstimulated.  Cell lysates were immunoprecipitated separately with anti-Myc (to 
immunoprecipitate MAGI-2), anti-EGFR and control IgG.  The immunoblot was prepared as 
described previously and the immunoblot was first probed with an anti-Myc antibody (to detect 
MAGI-2) (Figure 4.11A).  The membrane was then stripped and re-probed with an anti-EGFR  
 
Figure 4.10:  MAGI-2 does not consistently associate with PTEN in cells.  COS-1 cells
were transfected with 3 µg of DNA encoding Myc-MAGI-2 FL and 3 µg of DNA encoding
HA-PTEN-C124S. Cells were left unstimulated or stimulated with EGF for 5 min and
lysed.  Cell lysates were first pre-cleared with mouse and rabbit IgG-AC and protein G
beads.  The lysates were centrifuged and the supernatant of these lysates were used in a co-
immunoprecipitation assay where 10 µg of anti-Myc (lanes 5 and 6) or anti-HA  antibody
(lanes 3 and 4) were incubated for 1 hr at 4°C with COS-1 cells expressing Myc-MAGI-2
and HA-PTEN-C124S.  An IgG immunoprecipitation was also performed to detect any non-
specific binding (lanes 1 and 2).  Unbound protein was washed off and the samples were
resolved by SDS-PAGE and transferred to nitrocellulose.  The nitrocellulose membrane was
cut at the 100 kDa marker.  The upper portion of the immunoblot was probed with anti-Myc
(to detect MAGI-2). The bottom portion of the immunoblot was probed with anti-PTEN-
HRP antibody.  The samples were visualized using chemiluminescence and film.  A, First
experiment showing PTEN co-immunoprecipitates with MAGI-2 after 5 min EGF
stimulation.  B, Attempts to replicate the results of the first experiment showed that PTEN
and MAGI-2 did not co-immunoprecipitate in cells.  The input lane contains 10 µL cell
lysate (lane 7), to confirm that PTEN and Myc-MAGI-2 was present in the system and as a
control for PTEN and Myc immunoblots. The result shown in panel B are representative of 5
independent experiments.
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Figure 4.11:  MAGI-2 does not associate with EGFR in cells.  COS-1 cells were
transfected with 3 µg of DNA encoding full length Myc-MAGI-2. Cells were left
unstimulated or stimulated with EGF for 5 min and  lysed.  Cell lysates were pre-cleared
with rabbit IgG-AC and protein A beads.  The lysates were centrifuged and the supernatant
lysates were used in a co-immunoprecipitation assay, where 10 µg of Myc (lanes 7 and 8) or
EGFR (lanes 5 and 6) antibody were incubated for 1 hr at 4°C with COS-1 cells expressing
Myc-MAGI-2 and endogenous EGFR.  An IgG immunoprecipitation was also performed to
detect any non-specific binding (lanes 3 and 4).  Unbound protein was washed off and the
samples were resolved by SDS-PAGE and transferred to nitrocellulose.  Using an
immunoblot analysis, MAGI-2 and EGFR were detected with anti-Myc and anti-EGFR
antibodies, respectively, and corresponding secondary antibodies conjugated to HRP.  The
samples were visualized using chemiluminescence and film.  The membrane was
immunoblotted with anti-Myc (A) to detect MAGI-2.  The membrane was stripped and re-
probed with anti-EGFR (B).  C, Longer exposure of panel B to visualize the EGFR band in
the lysate input lane. The input lane contains 10 µL (lane 1) cell lysate to confirm that Myc-
MAGI-2 and EGFR were present in the system and to control for Myc and EGFR
immunoblot.  Lane 2 is an empty lane.  The results shown for the Myc immunoprecipitation
are typical for at least 3 independent experiments.  The result shown for the EGFR
immunoprecipitation is the result of one experiment.
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antibody (Figure 4.11B-C).  Myc-MAGI-2 did immunoprecipitate with the anti-Myc and EGFR 
did immunoprecipitate with anti-EGFR however, no co-immunoprecipitation between MAGI-2 
and EGFR were found.  These results suggest that MAGI-2 and EGFR do not form a complex 
in cells under the conditions tested.   
 
4.4.3 MAGI-2 does not co-immunoprecipitate with p85 
Because we had determined that p85 could interact with the WW domains of MAGI-2, 
the next step was to determine whether this interaction could take place in cells.  COS-1 cells 
were co-transfected with Myc-MAGI-2 FL and FLAG-p85 and stimulated with EGF for 5 min 
or left unstimulated.  Cell lysates were used in a co-immunoprecipitation experiment and 
immunoprecipitated separately with anti-Myc (to immunoprecipitate MAGI-2), anti-FLAG (to 
immunoprecipitate p85) and control IgG.  The immunoblot was prepared as previously 
described and the upper portion of the immunoblot (containing proteins > 100 kDa proteins) 
was first probed with anti-Myc antibody (to detect MAGI-2, Figure 4.12A).  The membrane 
was then stripped and re-probed with anti-EGFR antibody (Figure 4.12B).  The bottom portion 
of the blot (containing < 100 kDa proteins) was probed with anti-FLAG antibody (to detect 
p85, Figure 4.12C).  Myc-MAGI-2 did immunoprecipitate with the anti-Myc, and FLAG-p85 
did immunoprecipitate with the anti-FLAG.  MAGI-2 did not co-immunoprecipitate p85 or 
EGFR.  The p85 protein did co-immunoprecipitate EGFR upon 5 min stimulation with EGF, as 
previously shown (Fry and Waterfield, 1993).  These results suggests that MAGI-2 and p85 do 
not form a complex cells under the conditions tested.  These results also confirmed the results 
from Figure 4.11B-C where MAGI-2 and EGFR did not form a complex in cells under the 
conditions tested.  The FLAG immunoblots have non-specific bands in the IgG control lanes 
and therefore these results are inconclusive.  Because the band representing FLAG-p85 in the 
FLAG immunoprecipitate (Figure 4.12C, lanes 5-6) we speculate that the FLAG 
immunoprecipitate did in fact immunoprecipitate FLAG-p85 protein.  Because the intensity of 
the non-specific bands in the IgG immunoprecipitation (Figure 4.12C, lanes 3-4) are similar to 
that of the Myc immunoprecipitation (Figure 4.12C, lanes 7-8), we speculate that the bands in 
the Myc immunoprecipitation are due to non-specific binding and not actual complex formation 
between FLAG-p85 and Myc-MAGI-2.    
Figure 4.12:  MAGI-2 does not associate with p85 in cells.  COS-1 cells were co-
transfected with 3 µg of DNA encoding Myc-MAGI-2 FL and 3 µg of DNA encoding
FLAG-p85. Cells were left unstimulated or stimulated with EGF for 5 min and  lysed.  Cell
lysates were pre-cleared with mouse and rabbit IgG-AC and protein G beads.  These lysates
were centrifuged and the supernatant was used in an immunoprecipitation assay where 25 µg
of Myc (lane 7 and 8) or FLAG (lane 5 and 6) antibody were incubated for 1 hr at 4°C, with
COS-1 cells expressing Myc-MAGI-2 and FLAG-p85.  IgG immunoprecipitations were also
performed to detect any non-specific binding.  Unbound protein was washed off and the
samples were resolved by SDS-PAGE and transferred to nitrocellulose.  Using an
immunoblot analysis MAGI-2, EGFR and  p85 were detected with anti-Myc, anti-EGFR and
anti-FLAG antibodies, respectively, and corresponding secondary antibodies conjugated to
HRP.  The immunoblot was visualized using chemiluminescence and film.  The membrane
was cut in half at the 100 kDa mark and the upper membrane (containing protein sizes > 100
kDa) was immunoblotted with anti-Myc (A) to detect MAGI-2.  The upper membrane was
then stripped and re-probed with anti-EGFR (B). The lower portion of the membrane
(containing protein sizes < 100 kDa) was probed with anti-FLAG (C) to detect p85.  Non-
specific binding is present in the FLAG immunoblot IgG lanes. The input lane contains 10
µL (lane 1) cell lysate to confirm that Myc-MAGI-2, EGFR and p85 were present in the
system and to control for Myc, EGFR and FLAG immunoblot.  Lane 2 is an empty lane.
The results shown for the Myc immunoprecipitation are typical for at least 3 independent
experiments.  The result shown for the FLAG immunoprecipitation is the result of one
experiment.
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4.5 Rabbit polyclonal MAGI-2 antibody can detect Myc-MAGI-2 FL 
MAGI-2 is a subfamily of MAGI proteins (MAGI-1 and MAGI-3) which share 
substantial sequence similarly (Figure 1.6).  Most commercially available MAGI-2 antibodies 
do not specifically detect MAGI-2 since they also detect the other MAGI proteins.  Therefore, 
we generated a rabbit polyclonal antibody that would be specific for MAGI-2.  A CUSTLAW 
sequence alignment shows a unique MAGI-2 C-terminal domain of approximately 200 amino 
acids (Figure 4.13A) (Wu et al., 2000b).  Our lab termed this stretch of amino acids the GARP 
C-terminal sequence because it is rich in Gly, Ala, Arg and Pro residues.  According to a basic 
local alignment search sequence search, the GARP C-terminal sequence of MAGI-2 (amino 
acids 1233-1455) had no sequence homology, nor any putative conserved domains detected 
within this sequence and the GARP C-terminal sequence of MAGI-2 has no known function 
known to date (Eugene et al., 1990).  Therefore, we focused on this unique MAGI-2 sequence 
to generate the MAGI-2 polyclonal antibody.  The GARP protein was purified (Figure 4.13B) 
(as described in the materials and methods) and used as an antigen injected into a rabbit.  The 
rabbit generated polyclonal antibodies against the unique GARP protein corresponding to the 
C-terminal end of MAGI-2.  A test bleed was performed approximately 3 weeks after antigen 
injection and crude serum was used to probe an immunoblot containing COS-1 cell lysates 
expressing Myc-MAGI-2 FL (Figure 4.13C), and compared to a control Myc immunoblot 
(Figure 4.13D).  These results suggest that the MAGI-2 polyclonal antibody, raised against the 
GARP C-terminal sequence of MAGI-2, has the ability to detect MAGI-2 FL in cells. 
 
 
 
 
 
 
 
 
 
 
Figure 4.13:  Designing the MAGI-2 polyclonal antibody.  A, C-terminal amino acid
sequence alignments of MAGI-1, -2 & -3 showing the unique, approximately 100 amino acid
sequence of MAGI-2 representing the GARP C-terminal sequence (outlined in red) (Wu et al.,
2000b).  Protein antigen was generated through PCR amplification of the region encoding
amino acids 1233-1455 of the MAGI-2 protein and subcloning it into the pGEX6P1 vector.
The plasmid was transformed into BL21 cells and the resulting pGEX6P1-GARP bacterial
colony was induced with IPTG to overexpress GST-GARP.  BL21 cells were lysed, and GST-
GARP protein was isolated on glutathione-Sepharose beads.  The GARP protein was cleaved
from GST using PreScission protease. B, MAGI-2 GARP protein was resolved by SDS-PAGE
and visualized by Coomassie blue staining.  This GARP protein antigen was used to generate
polyclonal antibodies in rabbit.  C, Transfected COS-1 cells overexpressing Myc-MAGI-2 FL
protein immunoblotted with crude rabbit serum expressing the newly generated MAGI-2
GARP antibody/serum.  D, Myc antibody as a positive control to detect the Myc tag on Myc-
MAGI-2 FL (185 kDa).
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5.0 DISCUSSION 
PTEN is a tumor suppressor protein and its loss of function is correlated with a variety 
of cancers (Pendaries et al., 2003; Simpson and Parsons, 2001; Sulis and Parsons, 2003).  
PTEN loss of function is often correlated with the loss of proper attenuation of the Akt 
signalling pathway, a pathway which promotes cellular survival, cell cycle entry and 
progression and protein translation for cell growth (Cantley and Neel, 1999; Schlessinger, 
2000).  PTEN is hypothesized to be recruited to a high molecular weight complex at the plasma 
membrane, known as the PTEN-associated complex (PAC), and it is suggested to associate 
with MAGI-2 at this location (Vazquez et al., 2000, 2001).  The association of PTEN with 
MAGI-2 may recruit PTEN to the proper localization of PTEN to its lipid substrates so that it 
can effectively attenuate Akt signalling (Vazquez et al., 2000, 2001).  The goal of this project 
was to test the ability of MAGI-2 to act as a scaffolding protein to bring together several 
signalling molecules, including PTEN, and attenuate the PI3K/Akt pathway via PTEN.   
 
5.1 MAGI-2 expression in eukaryotic and prokaryotic cells 
In order to study the scaffolding functions of MAGI-2, MAGI-2 FL and its domains 
were cloned into eukaryotic and prokaryotic expression vectors.  These plasmids were 
transfected or transformed into cells and their encoded proteins were used in protein-protein 
interaction assays such as immunoprecipitations and pull-down experiments.  This allowed us 
to map some of the domains of MAGI-2 that are involved in binding to proteins involved in the 
attenuation of PI3K/Akt signalling. 
Myc-MAGI-2 proteins are well expressed in eukaryotic cells as little or no degradation 
products were seen and the proteins were of the appropriate estimated molecular weight (Figure 
4.2).  The Myc-MAGI-2 FL protein does have degradation products associated with it and this 
band is seen just under the 130 kDa marker (Figure 4.2A).  The Myc-MAGI-2 genes are under 
the transcriptional control of the cytomegalovirus promoter, a strong promoter that allows 
abundant gene expression (Bendig 1988; Davis and Huang, 1988).  One of the results of 
overexpression of proteins in eukaryotic cells is the activation of proteases that degrade protein, 
causing the presence of degraded product in the cells (Bendig 1988).  The Myc-MAGI-2 
proteins were well expressed in eukaryotic cells and therefore could be used in 
immunoprecipitation experiments. 
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GST-MAGI-2 proteins were also well expressed in bacterial cells (Figure 4.5), however 
did exhibit more degradation.  The GST-MAGI-2 protein products had degradation products 
associated with them, especially the GST-MAGI-2 FL protein (Figure 4.5A-B).  Degradation 
products were also seen with GST-PDZ0, GST-PDZ1, GST-PDZ2 and GST-PDZ4, as well as 
the GST-GK domain and the GST-GARP (Figure 4.5A-C).  MAGI-2 FL protein had abundant 
degradation product associated with it and a truncated (approximately 120 kDa fragment) of the 
protein was the largest, reasonably abundant protein observed (Figure 4.5A-B).  MAGI-2 may 
be post-translationally modified in eukaryotic cells, alterations that are not available in bacterial 
cells.  These modifications include Pro cis/trans isomerisation, glycosylation, lipidation, 
phosphorylation, N-terminal residue alteration or protein folding that may require a molecular 
chaperone (Baneyx and Palumbo, 2003; Bendig 1988; Cereghino and Cregg, 2000; Daly and 
Hearn, 2005; Palomares et al., 2004; Takano et al., 1999).  These post-translational 
modifications may be important in the proper translation and/or proper folding of the MAGI-2 
FL protein (Cereghino and Cregg, 1999; Daly and Hearn, 2005; Frydman, 2001; Palomares et 
al., 2004).  Some MAGUK scaffolding proteins have been shown to be post-translationally 
modified by palmitoylation, phosphorylation and sumoylation (Chao et al., 2008; Gardoni et 
al., 2006; Samuels et al., 2007; Topinka and Bredt, 1998).  MAGI-2 is not known to be post-
translationally modified, however the fact that it is not well expressed in bacterial cells suggests 
that post-translational modifications or co-expression with a stabilizing chaperone proteins may 
be necessary for the proper expression of this protein.   
A second explanation for the poor quality of expression of MAGI-2 protein in bacterial 
cells is that the MAGI-2 cDNA sequence encodes a human protein with different codon 
preferences, as compared to bacterial proteins.  Thus, the tRNAs present in the bacterial BL21 
cells may not be sufficiently abundant, resulting in truncated proteins (dos Reis et al., 2004; 
Kuland, 1991; Robinson et al., 1984).  Therefore, we could attempt expressing GST-MAGI-2 
in E. coli Rosetta gami bacterial cells (Novagen), which have six additional tRNAs (for the 
codons AUA, AGG, AGA, CUA, CCC and GGA), which are limiting in BL21 cells.  We could 
also attempt to express GST-MAGI-2 FL in yeast cells or insect cells (using baculovirus 
expression) that are of eukaryotic origin and therefore contain transcriptional and translational 
machinery and support post-translational modifications (Cereghino and Cregg, 1999; Daly and 
Hearn, 2005; Fleer, 1992; Sudbery, 1996).  If we are still unable to express GST-MAGI-2 FL in 
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cells, it may be beneficial to create two clones, one that encodes the first half of the MAGI-2 
protein (PDZ0-WW2) and a second that encodes the second half of the protein (PDZ1-GARP).  
These proteins may be better expressed in bacterial cells due to the fact that they are not as 
large as the MAGI-2 FL protein (Kurland and Dong, 1996).  MAGI-2 FL expression may not 
be occurring properly due to a combination of situations such as the lack of post-translational 
modifications, preferential codon usage by the organism or that the protein is too large for 
bacterial expression.     
To determine if the GST-MAGI proteins were folding properly while fused to GST, a 
limited trypsin digest was performed (Figure 4.6 and 4.7).  Typically, a properly folded protein 
will have buried residues inside the protein, protecting these from proteolytic digestion, when 
the digested products are resolved by SDS-PAGE and stained with a general protein stain.  The 
bands representing the digested protein will be minimal if the protein is folded into a stable, 
tertiary structure.  If a protein is not folding properly, more of these residues will be exposed for 
proteolysis and sensitive to proteolytic digestion.  When these products are resolved by SDS-
PAGE and stained, the bands representing the unfolded protein will be abundant.   
The negative control used in this assay was GST (Figure 4.6A), which showed little or 
no degradation after an overnight incubation with trypsin.  The purified GST-MAGI-2 FL 
protein had abundant proteolysis associated with it (Figure 4.6B) suggesting that the GST-
MAGI-2 FL protein may not fold properly when expressed in bacteria or that the regions 
between the various domains may be exposed for trypsin digestion.  GST-MAGI-2 FL however 
was used in the PTEN pull-down assay (Figure 4.8A) and the various MAGI-2 fragments were 
capable of binding to PTEN, thereby suggesting that the MAGI-2 protein retained some binding 
capabilities.   
WW domains have been shown to fold into stable tertiary protein structures (Macias et 
al., 1996; Macias et al., 2000; Umadevi et al., 2005).  GST-WW1 and GST-WW2 domains 
showed little proteolysis, indicating that the WW domains fold as stable structures when 
expressed as bacterial GST-WW proteins (Figure 4.6C).  A short C-terminal peptide of 
approximately 10 amino acids is cleaved off of the C-terminal end of the protein.  The GK 
protein is quickly cleaved from the GST portion, within 5 min of trypsin digestion (Figure 
4.6D).  The linker region between GST and the GK domain and may present an opportunity for 
trypsin digestion.   This suggests that GK domain can be cleaved quite easily from the GST 
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portion of the protein; however, it is able to form a stable trypsin-resistant structure on its own.  
GST-GARP has a small ~15 kDa region that is degraded soon after the trypsin has been added.  
This suggests that the C-terminal end of the GARP protein may be sensitive to proteolytic 
digestion because it is unable to fold into a stable, globular, tertiary structure (Figure 4.6E).  
Therefore, GST-MAGI-2 domains form stable structures while fused to GST, whereas the 
GST-MAGI-2 FL, GST-PDZ0 and GST-GARP fusion proteins may not form stable structures.  
Perhaps future studies could include transforming yeast cells which may be able to perform 
necessary post-translational modifications that the protein requires for stable expression in 
cells.  
PDZ domains have also been shown to fold into stable, independent tertiary protein 
structures (Daniels et al., 1998; Doyle et al., 1996; Morais Cabral et al., 1996).  All GST-PDZ 
domains, with the exception of GST-PDZ0, showed little or no proteolysis when subjected to a 
limited trypsin digest (Figure 4.7).  Limited digestion of the PDZ domains occurred one of two 
ways; either a small portion was degraded at the C-terminal end (approximately 5-10 amino 
acids removed with GST-PDZ2 and GST-PDZ4) or the GST portion was cleaved from the 
stable PDZ portion (GST-PDZ1, GST-PDZ3 and GST-PDZ5).    GST-PDZ0 however, was 
degraded within 5 min upon the addition of trypsin, indicating that this PDZ domain is not able 
to form a stable structure when expressed in bacteria.  The sequence alignment of the MAGI 
PDZ domains show that PDZ0 is the least conserved of the PDZ domains of MAGI (Figure 
1.16).   The carboxy binding loop (which is GFGF in the MAGI PDZ domains as opposed to 
the GLGF motif in most PDZ domains) of the PDZ0 domains of the MAGI proteins is not as 
well conserved as it is in the rest of the PDZ domains of the MAGI proteins.  The GFGF motif 
is crucial for the structural integrity PDZ domains (Doyle et al., 1996; Morais Cabral et al., 
1996) which may explain why the PDZ0 domain of MAGI-2 is unable to form a stable tertiary 
structure on its own fused to GST.  Therefore, the PDZ0 domain of the MAGI proteins may 
rely on other tertiary structures of the MAGI protein in order for it to gain tertiary stability on 
its own.  Therefore, if we create a mutant that includes the sequences of PDZ0-WW2, we may 
be able to form a better tertiary folded structure. 
One method to reduce the amount of degradation product observed through our limited 
proteolysis experiment is to restrict the sequences of our mutants to include only the sequences 
that encode the domains.  Amplification of the DNA sequences through PCR included all 
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residues of the protein therefore we did not restrict the primers to the boundaries of the 
structural domains (Figure 4.3C).  For example, the GK domain contains amino acids 105-260 
however in our protein, we included amino acids 105-297.  These extra sequences may not 
form stable, secondary or tertiary structures, thereby being prone to degradation in prokaryotic 
cells.  Therefore, if we restrict the amino acid sequence to the domain itself, and get rid of the 
excess amino acids flanking the sequence, we may see less degradation products associated 
with our GST-MAGI-2 proteins.  
 
5.2 MAGI-2 association with PI3K signalling molecules 
 
5.2.1 MAGI association with PTEN  
 Once the Myc-MAGI-2 FL clone was prepared, we wanted to test whether it could 
associate with PTEN in cells and whether or not this association was dependent on EGF 
stimulation.  Immunoprecipitation experiments were performed where Myc-MAGI-2 and HA-
PTEN-C124S where co-transfected into cells that were stimulated with EGF for 5 min, or left 
unstimulated.  PTEN and MAGI-2 were independently immunoprecipitated and the membrane 
was immunoblotted with Myc (to detect MAGI-2) and PTEN to determine their presence in the 
immunoprecipitation complexes.  In the HA immunoprecipitation (to immunoprecipitate 
PTEN), no MAGI-2 was detected (Figure 4.10A lanes 3-4) however, PTEN was detected in the 
Myc immunoprecipitation after 5 min of EGF stimulation (Figure 4.10A, lanes 6).  One of the 
reasons why we may not detect MAGI-2 in the PTEN immunoprecipitation could be because 
PTEN is present in many protein complexes in the cell, such as other endogenous PDZ 
containing scaffolds (Dobrosotskaya et al., 1997; Hu et al., 2007; Kotelevets et al., 2005; 
Takahashi et al., 2006; Valiente et al., 2005; Wu et al., 2000a), p85 (Chagpar, 2004), lipids 
(Das et al., 2003; Georgescu, 2008; Murray and Honig, 2002) and in the nucleus (reviewed in 
Planchon et al., 2008), and therefore only a small percentage of PTEN may be available for 
MAGI-2 interactions.  However, the presence of PTEN in the Myc immunoprecipitation was 
encouraging because it was in agreement with the hypothesis that MAGI-2 recruitment of 
PTEN to the PAC is important in attenuating PI3K/Akt signalling in cells.  In addition, here we 
had shown that this recruitment was dependent on EGF stimulation. 
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Attempts to repeat the above results were unsuccessful and we were unable to detect 
PTEN in the Myc-MAGI-2 immunoprecipitations (Figure 4.10B). At first, we observed non-
specific binding where our IgG control immunoprecipitations appeared to contain some PTEN.  
Once the non-specific association was cleared through longer pre-clearing steps with anti-IgG 
antibody and protein G beads, we saw no detection of PTEN in the IgG immunoprecipitation as 
well as none in the Myc-MAGI-2 immunoprecipitations.  We also tried different combinations 
of transfections of HA-PTEN-C124S with Myc-MAGI-2.  Upon EGF stimulation and 
dephosphorylation of PTEN, PTEN is quickly degraded by the proteosome (Fujita et al., 2006; 
Georgescu et al., 2000; Torres and Pulido, 2001; Wang et al., 2007).  Therefore, we attempted 
to stimulate cells for 1 min, in addition to 5 min, because the 5 min time point may have a 
decrease in PTEN levels in the cell due to proteosomal degradation.  Unfortunately, we were 
still unable to detect PTEN upon MAGI-2 immunoprecipitation and our results remain 
inconclusive. 
 Further attempts to reproduce results showing PTEN association with MAGI-2 upon 
EGF stimulation could include decreasing the EGF stimulation time points (ranging between 
10-60 secs) because of PTEN sensitivity to degradation upon activation (Fujita et al., 2006; 
Georgescu et al., 2000; Torres and Pulido, 2001; Wang et al., 2007).  Therefore a shorter time 
point may be required to ‘catch’ PTEN at the plasma membrane bound to MAGI-2.  We could 
also try using a PTEN mutant [PTEN-C124S-STT/AAA (S380A/T382A/T383A)] (Chagpar, 
2004; Das et al., 2003) that is less sensitive to degradation and is in its constitutively open 
conformation, thereby making PTEN more prone to bind to MAGI-2, which has been shown to 
work in previous studies (Vazquez et al., 2001).  Vazquez and colleagues were also unable to 
immunoprecipitate wild type PTEN and MAGI-2 concurrently, and they speculated that it was 
because the PTEN pool available for binding to a MAGI-2 PDZ domain was too low (Vazquez 
et al., 2001).  However, a constitutive open and active PTEN may be degradation sensitive and 
therefore may be degraded before reaching the plasma membrane (Huang and Wang, 2008; 
Wang et al., 2007).  Therefore, we may need to inhibit PTEN ubiquitination and/or proteosomal 
degradation in order to see MAGI-2/PTEN association at the plasma membrane.  Cells 
expressing fluorescently tagged PTEN and MAGI-2 are stimulated and PTEN localization to 
the plasma membrane are analysed using a fluorescence resonance energy transfer approach 
(Hangaur and Bertozzi, 2008).  Live imaging of protein-protein interactions could give a better 
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idea of a time course to use when stimulating cells for these immunoprecipitation experiments.  
Further attempts to repeat these experiments may allow us to detect PTEN association with 
MAGI-2 upon EGF stimulation. 
 One last explanation as to why the immunoprecipitation experimental results are not 
consistent is that perhaps our N-terminal tag may be interfering with important protein 
interaction sites.  Therefore, repositioning the N-terminal tag to the C-terminal end may 
improve binding capabilities.  Relocating the N-terminal tag to the C-terminal end however, 
may also interfere with binding.  For example, moving the HA tag on PTEN to its C-terminal 
end is not advisable because the last 3 amino acids of PTEN contain the PDZ binding motif 
(Valiente et al., 2005; Vazquez et al., 2000).  Therefore, a C-terminal tag at the C-terminal 
position will almost definitely prevent binding of a PDZ binding motif to a PDZ domain.  
Therefore, if we suspect that the N-terminal tag is interfering with important binding sites 
between target proteins, these can be relocated to the C-terminal end of the protein. 
 Regardless of the fact that PTEN may bind to MAGI-2 upon EGF stimulation, it is well 
documented that the PDZ2 domain of MAGI-2 can in fact bind to PTEN (Valiente et al., 2005; 
Vazquez et al., 2001; Wu et al., 2000a), and PTEN and MAGI-2 interactions can better 
attenuate Akt activation and signalling (Hu et al., 2007; Wu et al., 2000a).  A PTEN mutant 
lacking the C-terminal binding PDZ binding motif can not bind to the PDZ2 domain of MAGI-
2, or other MAGI family members, and also does not attenuate Akt activation (Valiente et al., 
2005; Wu et al., 2000a, 2000b).  Akt attenuation by PTEN through binding to MAGI-2 (or 
other MAGI proteins) may be due to localizing PTEN to the appropriate microdomain at the 
plasma membrane in order for PTEN to gain better access to its lipid products (Dobrosotskaya 
et al., 1997; Wu et al., 2000a, 2000b) or may be due to the fact that PTEN binding to a PDZ 
domain has been shown to increase PTEN half-life in cells (Wu et al., 2000a, 2000b).  Unlike 
previous studies, we have shown that PTEN can bind to the PDZ5 domain of MAGI-2, in 
addition to the PDZ2 domain (Figure 4.8A).  The fact that MAGI-2 may have the ability to bind 
to more than one PTEN molecule at a time may be significant in that this may improve the 
efficiency of the attenuation of Akt signalling by increasing the local concentration of PTEN 
molecules in the area of PTEN lipid substrate, PI3,4,5P2.  Therefore MAGI-2 may aid the 
ability of PTEN to decrease Akt signalling by increasing the number of PTEN molecules at 
appropriate sites for Akt deactivation. 
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 MAGI-2 PDZ2 and PDZ5 domains have been shown to bind to PTEN (Figure 4.8A).  A 
sequence alignment of PDZ2 and PDZ5 shows identities and similarities that are conserved 
between these two domains, not present in the non-PTEN binding PDZ domains (PDZ1, PDZ3 
and PDZ4) (Figure 5.1A, blue).  The PDZ2 and PDZ5 domains of MAGI-2 share 24% 
sequence identities and an additional 25% sequence similarities.  Conserved residues which are 
found in both PDZ2 and PDZ5, but not PDZ1, PDZ3 and PDZ4, of the MAGI proteins may be 
important in making contact with PTEN (Figure 5.1A, blue).  The Gly conserved residue is 
located in the carboxylate binding loop (Figure 5.1 and 5.2, blue).  The conserved negatively 
charged amino acids are found in both the β1 and the residue following the α1 strand (Figure 
5.1 and 5.2, blue).  The negatively charged residues are quite close to each other with respect to 
the folded PDZ domain however, they are outside the carboxylate binding loop that forms the 
binding pocket of the PDZ domain (Figure 5.2).  Therefore, these negatively charged residues 
may be important in making contact with the PTEN peptide and providing specificity for the 
PTEN protein.  These negatively charged residues are not part of the peptide binding pocket.  
Similar residues are also conserved in other PDZ domains known to bind PTEN (Figure 5.1B, 
blue).  These residues are conserved in PDZ domains that bind PTEN and therefore may confer 
specificity towards binding the PTEN protein. 
  
5.2.2 MAGI-2 association with p85 
 The p85 protein contains two Pro rich regions (Figure 1.4) that may allow it to bind to 
the WW domains of MAGI-2.  Previous studies have shown that p85 may be present in the 
PAC (Vazquez et al., 2001) and that p85 has the ability to bind to PTEN and increase its lipid 
phosphatase activity (Chagpar, 2004; Pastor, 2008).  Therefore, MAGI-2 may have the ability 
to bind to p85 and place it in close proximity of PTEN to increase the efficiency of PTEN 
attenuation of Akt signalling.  In a pull-down experiment, we found that p85 can bind to both 
WW domains of MAGI-2 (Figure 4.8B).  MAGI-2 association with p85 could be interpreted in 
two ways, both of which are not mutually exclusive.  p85 has been shown to positively regulate 
PTEN (Chagpar, 2004; Pastor, 2008) and the function of MAGI-2 may be to bind p85 and place 
it in close proximity to PTEN.  The other interpretation is that MAGI-2 may bind to the PI3K 
complex bound to the RTK in order to place the MAGI-2/PTEN complex at a specific location 
of the plasma membrane, near PI3K generated lipid products.  An immunoprecipitation  
Figure 5.1:  Comparison of CUSTLAW sequence alignments of PDZ domain sequences
that bind to PTEN with those that do not to identify residues that may confer
specificity towards PTEN.  A, Comparison of the MAGI PDZ domains that bind PTEN
(PDZ2 and PDZ5) with other MAGI PDZ domains that do not bind PTEN (PDZ1, PDZ3
and PDZ4).  The blue boxes represent amino acids that are conserved in the PDZ2 and
PDZ5 domain of MAGI-1 (MG1), MAGI-2 (MG2) and MAGI-3 (MG3).  The amino acids
representing the carboxylate binding loop are highlighted in red. B, PDZ domains from
NHERF, MAST205 and DLG that have been shown to bind to PTEN PDZ binding motif.
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experiment was performed to determine whether or not p85 could immunoprecipitate with 
MAGI-2, which showed negative results (Figure 4.12A and C).  This experiment was only done 
once and therefore, additional experiments are required to make conclusive remarks.  p85 has 
been shown to be present in many complexes such as PTEN/p85 (Chagpar, 2004), p85/p110 
that constitutes PI3K (reviewed in Zhao and Vogt, 2008) and associated with RTKs (Figure 
5.2) (Besset et al., 2000; Claesson-Welsh 1994; Fry and Waterfield, 1993; Zhang and 
Broxmeyer, 2000).  Therefore only a small percentage of p85 may be available for binding to 
MAGI-2.  p85 does have the ability to bind to the WW domains of MAGI-2 and future work is 
needed and determine if this interaction can also take place in cells.  We could optimize the 
expression of p85 and MAGI-2 levels in cells by transfecting cells with more cDNA encoding 
these proteins.  We could also try stimulating cells with EGF with smaller times points (i.e. 0, 
10, 20, 30, 40, 50, 60 seconds as opposed to 0, 1 and 5 min).  We could also try a fluorescence 
resonance energy transfer approach, as mentioned above, to determine better growth factor 
stimulation time courses to use in our immunoprecipitation assays. 
 
5.2.3 MAGI-2 and does not associate with RTKs 
MAGI proteins have been shown to bind to the C-terminal PDZ binding motifs of 
several cell surface receptors (Figure 1.17).  We set out to test the ability of MAGI-2 to interact 
with the RTKs:  EGFR and PDGFR.  Both of these receptors have C-terminal PDZ binding 
motifs and have been shown to interact with PDZ domains (Buxbaum et al., 2008; Demoulin et 
al., 2003; Kaech et al., 1998; Lazar et al., 2004; Maudsley et al., 2000).  Pull-down assays with 
endogenously expressed EGFR and PDGFR and all of the PDZ domains of MAGI-2 did not 
reveal any association between these receptors and the individual PDZ domains (Figure 4.9 and 
4.11).  The use of endogenously expressed RTKs may not provide a high enough signal to 
detect minute interactions, if they are in fact taking place.  These endogenously expressed 
RTKs may be interacting with other PDZ containing proteins in the cells, thereby limiting the 
RTKs available for MAGI-2 interaction.  Also, we have assumed that the EGFR expressed in 
COS-1 cells has an identical or similar PDZ binding motif to that of the human EGFR, which 
may not be the case.  Therefore, we could use cell lysate of human origin that expresses EGFR 
(such as HEK-293 cells).  Or we may need to transiently transfect RTKs in cells in order to 
detect MAGI-2 and RTK binding.  One problem with our pull-down system is that more than  
Figure 5.2:  NMR solution structure of the PDZ2 domain of MAGI-2 highlighting
conserved residues that are hypothesized to make contact with the PTEN protein (PTB
ID: 1UJV, Nameki et al., 2003).  The conserved residues that may bind PTEN are
highlighted in blue.  The carboxylate binding loop is highlighted in red, and the His at
position α2-1 is highlighted in purple.
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one PDZ domain may be required to bind to the dimerized RTK receptor, as it has previously 
been shown that tandem PDZ domains are required for stronger binding/or higher affinity 
binding (Mortier et al., 2005; Sugi et al., 2008; Zimmermann et al., 2002, 2005).  Since we had 
problems expressing GST-MAGI-2 FL, it may be beneficial to clone the two halves of the 
MAGI-2 protein mentioned earlier, in particular, a MAGI-2 protein containing PDZ1-PDZ5 
may allow for increased binding opportunities.  One last experimental method to detect MAGI-
2 PDZ binding to the C-terminal sequence of the EGFR or PDGFR would be to create short 
peptide sequences that are identical to the EGFR and PDGFR PDZ binding motifs, and test 
their ability to bind to each of the MAGI-2 PDZ domains.  This way we do not need to worry 
about competitive binding of the purified peptide and PDZ domains.  Therefore, we need to 
continue these experiments in order to confirm MAGI-2 PDZ domain binding, or the lack 
thereof, to the PDGFR or EGFR. 
 
5.3 The PAC and Akt attenuation 
The goal of this project was to determine whether MAGI-2 can act as a scaffolding 
protein towards PTEN, p85 and RTKs, in order to antagonize PI3K/Akt signalling.  This study 
provides insight into how the PTEN tumor suppressor protein functions in attenuating 
PI3K/Akt signalling.   PTEN is one of the most commonly mutated tumor suppressors in 
human cancers (Keniry and Parsons, 2008) and therefore it is important to understand its role in 
PI3K/Akt attenuation.  Because MAGI proteins share high sequence similarity and they possess 
many similar binding partners, understanding the scaffolding function of MAGI-2 may provide 
a model system for all three MAGI proteins. 
 MAGI-2 may be responsible for binding to PTEN and bringing it to the plasma 
membrane at the appropriate location for attenuation of Akt signalling (Figure 5.3).  We have 
shown that MAGI-2 PDZ2 and PDZ5 have the ability to bind to PTEN, thereby potentially 
increasing the local concentration of PTEN and its ability to attenuate Akt signalling.  MAGI-2 
WW domains also have the ability to bind to p85, a known positive regulator of PTEN lipid 
phosphatase activity (Chagpar, 2004; Pastor, 2008).  Therefore, MAGI-2 may increase the local 
concentration of PTEN and p85 at sites important for Akt activation and improve the ability of 
PTEN to attenuate Akt signalling.  MAGI-2 binding to p85 may also provide a mechanism  
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where MAGI-2 can bind to activated receptor through PI3K (Figure 5.3).  As a result, MAGI-2 
would be positioned next to PI3K lipid products, thereby making these accessible to PTEN.  
Therefore, it is currently hypothesized that MAGI-2 recruits PTEN and p85 to the PAC and 
increases the efficiency of Akt attenuation through PTEN regulation.   
 
5.4 MAGI-2 specific polyclonal antibody 
The MAGI group of MAGUK scaffolding proteins share high sequence similarity 
(Figure 1.6) (Wu et al., 2000b) however, MAGI-2 contains a unique C-terminal sequence 
(Figure 4.13A) that we termed the GARP C-terminal sequence.  We raised a rabbit polyclonal 
antibody that would recognize the GARP C-terminal sequence of MAGI-2.  Many of the 
published studies on MAGI proteins have used commercially available antibodies that do not 
distinguish between the MAGI group of scaffolding proteins (Hu et al., 2007; Subauste et al., 
2005; Wood et al., 1998; Wu et al., 2000a).  Additionally, much of the published work also 
generated N-terminally tagged MAGI proteins so that they could detect their protein of interest, 
much like we have done in this project (Figure 4.3).  However, N-terminally tagged proteins are 
transfected and expressed in cells and the overexpression of a protein in cells may show 
artificial results (Bendig 1988).  Therefore, generating a MAGI-2 specific antibody that has the 
potential to detect endogenous protein could be a useful reagent to provide physiological 
insights into MAGI-2 function. 
We have successfully generated a GARP antigen (Figure 4.13B) that was injected into a 
rabbit.  A dilution of the crude serum had the ability to detect Myc-MAGI-2 expressed in COS-
1 cell lysates (Figure 4.13C) and cell lysate control (Figure 4.13D).  The next steps we must 
take with this antibody is to purify it from the crude serum and test its ability to specifically 
detect endogenous MAGI-2 and not MAGI-1 or MAGI-3. 
 
5.5 Future studies 
 The goal of future studies is to continue to determine how MAGI-2 affects PTEN 
attenuation of PI3K/Akt signalling.  Now that we have determined that MAGI-2 has the ability 
to bind to PTEN and p85 in vitro, the next step would be to determine if these interactions are 
also found in cells and has physiological relevance.  We could continue studies on determining 
whether or not PTEN association is dependent on EGF stimulation.  Determining the   
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Figure 5.3:  The hypothesized role of the PAC in the attenuation of RTK activated Akt
signalling.  Upon growth factor (GF) stimulation, RTK subunits dimerize and
autophosphorylation occurs on the tyrosines.  Phosphorylated receptor recruits the PI3K
complex to the plasma membrane by binding to the RTK.  PI3K phosphorylates PI4,5P2 to
PI3,4,5P3 which recruits and activates the Ser/Thr kinase Akt, which in turn activates proteins
that promote anti-apoptotic signalling, cell cycle entry and cellular survival.  PTEN is present
in the cytosol of quiescent cells in its closed conformation.  Upon growth factor stimulation,
PTEN is believed to localize to the plasma membrane through electrostatic interactions with
the plasma membrane and through binding of the PDZ binding motif with PDZ2 and PDZ5 of
MAGI-2.  The ability of MAGI-2 to bind to two PTEN molecules may enable MAGI-2 to
increase the local concentration of PTEN and increase the attenuation efficiency of Akt.  The
binding of p85 to MAGI-2 may act two fold: to localize MAGI-2 to the appropriate site of
PI3K product and to bring together p85 with PTEN, to increase PTEN lipid phosphatase
activity towards PI3,4,5P2.  Therefore MAGI-2 may act as a scaffolding protein towards the
proteins involved in the attenuation of the Akt signalling pathway.
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transfection ratio of HA-PTEN and Myc-MAGI-2 that gives optimal expression of both 
proteins could aid in our immunoprecipitation experiments.  We could also determine whether 
the PDZ and PTEN association are direct by purifying GST-PDZ and His6-PTEN and 
performing a pull-down experiment with these purified proteins.  Similar transfections 
experiments could be performed to determine if the WW domains of MAGI-2 and p85 interact 
in cells and whether this interaction is dependent on EGF stimulation.  Similarly, we could 
purify GST-WW domains and used them in a pull-down assay with His6-p85 purified protein.  
We could also generate peptide sequences of the Pro rich sequences within the two Pro rich 
regions of p85 and perform pull-down assay with purified GST-WW domains to determine 
which Pro rich sequences have the potential to bind the WW domains of MAGI-2. 
To determine if MAGI-2 has the ability to bind to more than one PTEN molecule at a 
time would be worth pursuing.  PDZ domains can only interact with one peptide at a time 
because the binding pocket can only accommodate the C-terminal end of one peptide (Doyle et 
al., 1996; Morais Cabral et al., 1996).  Therefore, if two PTEN molecules can interact with the 
MAGI-2 protein, more than one PDZ domain would be involved.  To answer the question of 
whether or not MAGI-2 can bind to more than one PTEN molecule  at the same time, an in 
vitro assay could be used (Figure 5.3).  We could clone PTEN into a His6-PTEN expressing 
plasmid, isolate this fusion protein on a nickel column (Figure 5.4A), pour a purified truncated 
version of GST-MAGI-2 encoding the PDZ1-PDZ5 sequence (Figure 5.4B) followed by 
another incubation of a fused maltose binding protein (MBP)-PTEN protein (Figure 5.4C).  We 
would then elute the complex off of the column and resolve the mixture by SDS-PAGE and 
transfer to nitrocellulose membrane.  An immunoblot analysis could be used to detect for the 
presence of the MBP-PTEN with an MBP antibody.  If MAGI-2 can only interact with one 
PTEN molecule, there would be no detection of the MBP-PTEN (Figure 5.4C).  If however 
MAGI-2 can interact with two PTEN molecules simultaneously, MBP-PTEN will be present 
(Figure 5.4C).  An experiment in the absence of GST-MAGI-2 would be necessary to ensure 
that His6-PTEN and MBP-PTEN do not have the ability to associate.  If MAGI-2 can interact 
with two PTEN proteins simultaneously, the MAGI-2 scaffolding protein may be important in 
increasing the local concentration of PTEN, thereby amplifying the attenuation of Akt 
signalling. Because we have shown that p85 can associate with both WW domains of MAGI-2, 
we could test the similar hypothesis that two p85 proteins may bind MAGI-2 simultaneously. 
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 Currently, work is being done on the crystallization of MAGI-2 PDZ2 and PDZ5 
domains, and a C-terminal peptide of PTEN that encodes the PDZ binding motif.  Once this 
complex is crystallized, we can determine the important interacting residues between PTEN and 
the PDZ2 and PDZ5 domains of MAGI-2.  From here, we could make more informed decisions 
on the important contact points between the two proteins and generate mutants that abolish 
binding between the two.  These mutational analyses would be useful in determining important 
interactions between MAGI-2 and PTEN and its importance in the attenuation of the Akt 
signalling pathway. 
 Mutations that can abolish binding of the MAGI-2 scaffolding protein with its 
respective ligand are important in order to study the importance of the interaction between cell 
signalling intermediates in signal transduction pathways.  Although knockdown and knockout 
studies have proven to be very useful, small, discrete interruptions through mutational analysis 
may provide a more accurate picture of what is going on.  For example, if we were to knockout 
or knockdown MAGI proteins, we may see a disruption in the maintenance of cell junctions 
and the results seen may be a reflection of cell junction interruption and not specifically due to 
MAGI-2 effects in the attenuation of PI3K/Akt signalling.  Also, a knockdown in MAGI 
proteins may disrupt PTEN stability thereby decreasing PTEN expression in cells.  Therefore 
the reason why PTEN may not be attenuating Akt signalling would not be due to its association 
and localization with MAGI-2 however, but due to the lack of stability of the protein.  
Therefore, discrete mutational analysis that disrupts protein-protein interactions may provide 
useful information on providing a role for MAGI-2 and its binding partners in Akt signalling.   
Future work on this project would be to study the scaffolding effects of MAGI-2 and its 
role in the PTEN attenuation of PI3K/Akt signalling pathway.  We have shown that MAGI-2 
PDZ2 and PDZ5 have the ability to bind to PTEN and this may increase the local concentration 
of PTEN at areas of the plasma membrane that is high in PI3,4,5P2 in order to efficiently 
attenuate Akt signalling.  MAGI-2 may also have the ability to bind to p85 and this interaction 
may work twofold:  One, to increase the local concentration of p85, a positive PTEN regulator, 
in order to increase the ability of PTEN to attenuate Akt signalling, and two, to localize MAGI-
2 next to PI3K and its products, PI3,4,5P2, in order to bring PTEN to close proximity to its lipid 
products.  Future work is needed in order to confirm these findings and to test this model in 
cells and to determine if these interactions are dependent on EGF stimulation. 
Figure 5.4:  Hypothesized experiment to determine if MAGI-2 can bind to two PTEN
protein molecules simultaneously.  A, First, purified His6-PTEN will be immobilized onto
a Ni2+ column.  B, Purified GST-MAGI-2 will be poured into the column and allowed to
associate with His6-PTEN.  C, Purified MBP-PTEN will be poured on the column to allow
binding to MAGI-2.  These complexes will be eluted and the elutant will be resolved by
SDS-PAGE.  Proteins will be transferred to a nitrocellulose membrane and immunobloted
with an MBP antibody.  If MBP-PTEN is detected, MAGI-2 can interact with two PTEN
proteins simultaneously.  If MBP-PTEN is absent, MAGI-2 can interact with one PTEN
molecule at a time. GST tag is red, His6 tag is grey and MBP tag is green.
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